Anti-CD33 antibodies for cancer treatment
By developing antibodies with specific heavy and light chain variable domain sequences, the problem of insufficient binding affinity and stability of existing anti-CD33 agents is solved, and efficient specific binding to CD33 and longer half-life is achieved, which improves the Killing ability to cancer cells.
Patent Information
- Application Number
- CN202080059807.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-26
- Filing Date
- 2020-06-25
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-06-25
AI Technical Summary
When the existing anti-CD33 agents treat cancers such as acute myeloid leukemia, the tumor antigen binding affinity is poor and the in vivo half-life is short, making it difficult to effectively target and sustain effect.
An antibody or antigen-binding fragment thereof has been developed, including specific heavy and light chain variable domain sequences, capable of efficiently specifically binding to CD33 proteins, including chimeric antibodies and humanized antibodies, using specific amino acid sequences and structures. domain combination to enhance its binding affinity and stability.
It improves the binding affinity and in vivo stability of antibodies against CD33, extends the half-life, enhances the killing efficacy of cancer cells, and provides a more effective treatment plan.
Smart Images

Figure CN114401744B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 867,032, filed on June 26, 2019, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present technology generally relates to the preparation of immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) that specifically bind to CD33 protein and the use of the immunoglobulin-related compositions. Specifically, the present technology relates to the preparation of CD33-binding antibodies and the use of the antibodies in the detection and treatment of CD33-related cancers and Alzheimer's disease. Background Art
[0004] The following description of the background of the present technology is provided only to help understand the present technology and is not admitted to describe or constitute prior art of the present technology.
[0005] Acute myeloid leukemia (AML) accounts for 25% of pediatric leukemia, but accounts for more than half of the deaths from childhood leukemia. Compared with acute lymphoblastic leukemia, which is curable in >80% of children, the 5-year survival rate of pediatric AML is the worst among childhood cancers. In adults, in those patients diagnosed before the age of 60, AML is curable in 35%-40% of cases, while only 5%-15% of those patients who appear in late life can be cured (Dohner et al., NEngl J Med 373:1136-52 (2015)). Summary of the invention
[0006] In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ), wherein (a) V H comprising a V selected from SYYIH (SEQ ID NO: 14) and SYYMH (SEQ ID NO: 6 or 10) H - CDR1; a V selected from VIYPGNDDISYAQKFQG (SEQ ID NO: 7 or 15) and VIYPGNDDISYN QKFQG (SEQ ID NO: 11); H -CDR2 sequence; and V of EVRLRYFDV (SEQ ID NO: 8, 12 or 16) H -CDR3 sequence; and (b) the V Lcomprising a V selected from KSSQSVFFSSSQKNYLA (SEQ ID NO: 22, 26 or 30) L -CDR1 sequence, V of WASTRES (SEQ ID NO: 23, 27 or 31) L - CDR2 sequence and V of HQYLSSRT (SEQ ID NO: 24, 28 or 32) L -CDR3 sequence.
[0007] In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ), wherein: (a) said V H comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 13; and / or (b) V L Comprising an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29.
[0008] In any of the above embodiments, the antibody may further comprise an Fc domain of an isotype selected from IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgD, and IgE. In some embodiments, the antibody comprises an IgG1 constant region comprising one or more amino acid substitutions selected from N297A and K322A. Additionally or alternatively, in some embodiments, the antibody comprises an IgG4 constant region comprising an S228P mutation. In certain embodiments, the antigen binding fragment is selected from Fab, F(ab')2, Fab', scF v and F v In some embodiments, the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody. In certain embodiments, the antibody or antigen-binding fragment binds to the IgV domain of CD33.
[0009] In another aspect, the disclosure provides an antibody comprising a heavy chain (HC) amino acid sequence comprising SEQ ID NO:35, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, or a variant thereof having one or more conservative amino acid substitutions, and / or comprising SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70 The light chain (LC) amino acid sequence of NO:71 or a variant thereof having one or more conservative amino acid substitutions.
[0010] In certain embodiments, the antibody comprises a HC amino acid sequence and a LC amino acid sequence, respectively, selected from the group consisting of SEQ ID NO:35 and SEQ ID NO:33; SEQ ID NO:39 and SEQ ID NO:37; SEQ ID NO:43 and SEQ ID NO:41; SEQ ID NO:47 and SEQ ID NO:45; SEQ ID NO:51 and SEQ ID NO:49; SEQ ID NO:54 and SEQ ID NO:53; SEQ ID NO:56 and SEQ ID NO:55; SEQ ID NO:58 and SEQ ID NO:57; SEQ ID NO:60 and SEQ ID NO:59; SEQ ID NO:62 and SEQ ID NO:61; SEQ ID NO:64 and SEQ ID NO:63; SEQ ID NO:66 and SEQ ID NO:65; SEQ ID NO:68 and SEQ ID NO:67; SEQ ID NO:70 and SEQ ID NO:69; and SEQ ID NO:72 and SEQ ID NO:71.
[0011] In one aspect, the present disclosure provides an antibody comprising (a) a light chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to a light chain immunoglobulin variable domain sequence of any one of SEQ ID NOs: 21, 25 or 29; and / or (b) a heavy chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to a heavy chain immunoglobulin variable domain sequence of any one of SEQ ID NOs: 5, 9 or 13.
[0012] In another aspect, the disclosure provides an antibody comprising (a) an LC sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the LC sequence present in any of SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69 or SEQ ID NO:71; and / or (b) an LC sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the LC sequence present in any of SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69 or SEQ ID NO:71; The HC sequence present in any one of SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72 is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the HC sequence.
[0013] In any of the above embodiments, the antibody is a chimeric antibody, a humanized antibody, or a bispecific antibody. Additionally or alternatively, in some embodiments, the antibody comprises an IgG1 constant region comprising one or more amino acid substitutions selected from N297A and K322A. In certain embodiments, the antibody of the present technology comprises an IgG4 constant region comprising an S228P mutation. In any of the above embodiments, the antibody binds to the IgV domain of CD33. Additionally or alternatively, in some embodiments, the antibody of the present technology lacks α-1,6-fucose modification.
[0014] In one aspect, the present disclosure provides a bispecific antibody or antigen-binding fragment comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to an amino acid sequence selected from any one of SEQ ID NOs. 73-132. In certain embodiments, the bispecific antibody or antigen-binding fragment comprises an amino acid sequence selected from any one of SEQ ID NOs: 73-132.
[0015] In one aspect, the present disclosure provides a bispecific antigen-binding fragment, the bispecific antigen-binding fragment comprising a first polypeptide chain, wherein: the first polypeptide chain comprises, in the N-terminal to C-terminal direction: (i) a heavy chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; (ii) a flexible peptide linker comprising the amino acid sequence (GGGGS) 6; (iii) a light chain variable domain of the first immunoglobulin; (iv) a flexible peptide linker comprising the amino acid sequence (GGGGS) 4; (v) a heavy chain variable domain of a second immunoglobulin that is capable of specifically binding to a second epitope; (vi) a flexible peptide linker comprising the amino acid sequence (GGGGS) 6; (vii) a light chain variable domain of the second immunoglobulin; (viii) a flexible peptide linker sequence comprising the amino acid sequence TPLGDTTHT; and (ix) a self-assembly and decomposition (SADA) polypeptide, wherein the heavy chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 9, and SEQ ID NO: 13; and / or the light chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29.
[0016] In another aspect, the present disclosure provides a bispecific antigen-binding fragment, the bispecific antigen-binding fragment comprising a first polypeptide chain, wherein: the first polypeptide chain comprises, in the N-terminal to C-terminal direction: (i) a light chain variable domain of a first immunoglobulin capable of specifically binding to a first epitope, (ii) a flexible peptide linker comprising the amino acid sequence (GGGGS)6; (iii) a heavy chain variable domain of the first immunoglobulin; (iv) a flexible peptide linker comprising the amino acid sequence (GGGGS)4; (v) a heavy chain variable domain of a second immunoglobulin capable of specifically binding to a second epitope; (vi) a flexible peptide linker comprising the amino acid sequence (GGGGS)6; (vii) a light chain variable domain of the second immunoglobulin; (viii) a flexible peptide linker sequence comprising the amino acid sequence TPLGDTTHT; and (ix) a self-assembly and decomposition (SADA) polypeptide, wherein the heavy chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:9 and SEQ ID NO:13; and / or the light chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29. In certain embodiments of the bispecific antigen-binding fragments disclosed herein, the SADA polypeptide comprises a tetramerization, pentamerization or hexamerization domain. In some embodiments, the SADA polypeptide comprises a tetramerization domain of any one of p53, p63, p73, hnRNPC, SNA-23, Stefin B, KCNQ4 and CBFA2T1. Additionally or alternatively, in some embodiments, the bispecific antigen-binding fragment comprises an amino acid sequence selected from SEQ ID NO.73-132.
[0017] In one aspect, the present disclosure provides a bispecific antibody comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain, and a fourth polypeptide chain, wherein the first polypeptide chain and the second polypeptide chain are covalently bonded to each other, the second polypeptide chain and the third polypeptide chain are covalently bonded to each other, and the third polypeptide chain and the fourth polypeptide chain are covalently bonded to each other, and wherein: (a) each of the first polypeptide chain and the fourth polypeptide chain comprises, in the N-terminal to C-terminal direction: (i) a light chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; (ii) a light chain constant domain of the first immunoglobulin; (iii) a flexible peptide linker comprising the amino acid sequence (GGGGS)3; and (iv) a light chain constant domain of a second immunoglobulin that is capable of specifically binding to a first epitope. The invention relates to a light chain variable domain of a second immunoglobulin connected to a complementary heavy chain variable domain of the first immunoglobulin or a heavy chain variable domain of a second immunoglobulin connected to a complementary light chain variable domain of the second immunoglobulin, wherein the light chain variable domain and the heavy chain variable domain of the second immunoglobulin are capable of specifically binding to a second epitope and are connected together to form a single-chain variable fragment via a flexible peptide linker comprising the amino acid sequence (GGGGS) 6; and (b) each of the second polypeptide chain and the third polypeptide chain comprises in the N-terminal to C-terminal direction: (i) a heavy chain variable domain of the first immunoglobulin capable of specifically binding to the first epitope; and (ii) a heavy chain constant domain of the first immunoglobulin; and wherein the heavy chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 13; and / or the light chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO: 21, SEQ ID NO: 25 and SEQ ID NO: 29. In certain embodiments, the second immunoglobulin binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCRγ / δ, NKp46, KIR, or a small molecule DOTA hapten.
[0018] In one aspect, the disclosure provides a recombinant nucleic acid sequence encoding any of the antibodies or antigen-binding fragments described herein. In some embodiments, the recombinant nucleic acid sequence is selected from the group consisting of SEQ ID NO: 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52.
[0019] In another aspect, the disclosure provides a host cell or vector comprising any recombinant nucleic acid sequence disclosed herein.
[0020] In one aspect, the present disclosure provides a composition comprising an antibody or antigen-binding fragment of the present technology and a pharmaceutically acceptable carrier, wherein the antibody or antigen-binding fragment is optionally conjugated to an agent selected from the following: an isotope, a dye, a chromagen, a contrast agent, a drug, a toxin, a cytokine, an enzyme, an enzyme inhibitor, a hormone, a hormone antagonist, a growth factor, a radionuclide, a metal, a liposome, a nanoparticle, RNA, DNA or any combination thereof.
[0021] In some embodiments of the bispecific antibodies or antigen-binding fragments of the present technology, the bispecific antibodies bind to T cells, B cells, myeloid cells, plasma cells or mast cells. Additionally or alternatively, in some embodiments, the bispecific antibodies or antigen-binding fragments bind to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TC Rγ / δ, NKp46, KIR or small molecule DOTA hapten.The small molecule DOTA hapten can be selected from DOTA, DOTA-Bn, DOTA-deferoxamine, DOTA-Phe-Lys(HSG)-D-Tyr-Lys(HSG)-NH2, Ac-Lys(HSG)D-Tyr-Lys(HSG)-Lys(Tscg-Cys)-NH2, DOTA-D-Asp-D-Lys(HSG)-D-Asp-D-Lys(HSG)-NH2, DOTA-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2, DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2, DOTA-D-Ala-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2, DOTA-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-NH2, Ac-D-Phe-D-Lys(DOTA)-D-Tyr-D-Lys(DOTA)-NH2, Ac-D-Phe-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-NH2, Ac-D-Phe-D-Lys(Bz-DTPA)-D-Tyr-D-Lys(Bz-DTPA)-NH2, Ac-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(Tscg-Cys)-NH2, DOTA-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(Tscg-Cys)-NH2, (Tscg-Cys)-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(DOTA)-NH2, Tscg-D-Cys-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2, (Tscg-Cys)-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2, Ac-D-Cys-D-Lys(DOTA)-D-Tyr-D-Ala-D-Lys(DOTA)-D-Cys-NH2, Ac-D-Cys-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-NH2, Ac-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-D-Lys(Tscg-Cys)-NH2, and Ac-D-Lys(DOTA)-D-Tyr-D-Lys(DOTA)-D-Lys(Tscg-Cys)-NH2.
[0022] In another aspect, the present disclosure provides a method for treating CD33-related cancer or Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of any one of the antibodies or antigen-binding fragments disclosed herein. In certain embodiments, the antibody comprises a HC amino acid sequence and a LC amino acid sequence, respectively, selected from the group consisting of: SEQ ID NO:35 and SEQ ID NO:33; SEQ ID NO:39 and SEQ ID NO:37; SEQ ID NO:43 and SEQ ID NO:41; SEQ ID NO:47 and SEQ ID NO:45; SEQ ID NO:51 and SEQ ID NO:49; SEQ ID NO:54 and SEQ ID NO:53; SEQ ID NO:56 and SEQ ID NO:55; SEQ ID NO:58 and SEQ ID NO:57; SEQ ID NO:60 and SEQ ID NO:59; SEQ ID NO:62 and SEQ ID NO:61; SEQ ID NO:64 and SEQ ID NO:63; SEQ ID NO:66 and SEQ ID NO:65; SEQ ID NO:68 and SEQ ID NO:67; SEQ ID NO:70 and SEQ ID NO:69; and SEQ ID NO:72 and SEQ ID NO:71, wherein the antibody specifically binds to CD33. In some embodiments, the antibody or antigen-binding fragment comprises an amino acid sequence selected from any one of SEQ ID NOs. 73-132.
[0023] In some embodiments, the CD33-associated cancer is AML, biphenotypic leukemia, bi-lineage leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, or acute lymphoblastic leukemia.
[0024] Additionally or alternatively, in some embodiments of the method, the antibody or antigen-binding fragment is administered to the subject separately, sequentially or simultaneously with an additional therapeutic agent. Examples of additional therapeutic agents include one or more of the following: alkylating agents, platinum agents, taxanes, vinca agents, anti-estrogen drugs, aromatase inhibitors, ovarian inhibitors, VEGF / VEGFR inhibitors, EGF / EGFR inhibitors, PARP inhibitors, cytostatic alkaloids, cytotoxic antibiotics, antimetabolites, endocrine / hormonal agents, bisphosphonate therapeutics.
[0025] In another aspect, the present disclosure provides a method for detecting a tumor in a subject in vivo, the method comprising (a) administering to the subject an effective amount of an antibody or antigen-binding fragment of the present technology, wherein the antibody or antigen-binding fragment is configured to localize to a tumor expressing CD33 and is labeled with a radioactive isotope; and (b) detecting the presence of a tumor in the subject by detecting a level of radioactivity emitted by the antibody or antigen-binding fragment that is higher than a reference value. In some embodiments, the subject is diagnosed as having or suspected of having cancer. The level of radioactivity emitted by the antibody or antigen-binding fragment can be detected using positron emission tomography or single photon emission computed tomography.
[0026] Additionally or alternatively, in some embodiments, the method further comprises administering to the subject an effective amount of an immunoconjugate comprising an antibody or antigen-binding fragment of the present technology conjugated to a radionuclide. In some embodiments, the radionuclide is an alpha-emitting isotope, a beta-emitting isotope, an Auger emitter, or any combination thereof. Examples of beta-emitting isotopes include 86 Y. 90 Y. 89 Sr. 165 Dy, 186 Re, 188 Re, 177 Lu and 67 Cu. In some embodiments of the methods, non-specific FcR-dependent binding in normal tissues is eliminated or reduced (eg, via a N297A mutation in the Fc region, which results in deglycosylation).
[0027] Also disclosed herein is a kit for detecting and / or treating CD33-related cancer or Alzheimer's disease, the kit comprising at least one immunoglobulin-related composition of the present technology (e.g., any antibody or antigen-binding fragment described herein) or a functional variant thereof (e.g., a substitution variant) and instructions for use. In certain embodiments, the immunoglobulin-related composition is coupled to one or more detectable labels. In one embodiment, the one or more detectable labels include a radioactive label, a fluorescent label, or a chromogenic label.
[0028] Additionally or alternatively, in some embodiments, the kit further comprises a second antibody that specifically binds to the anti-CD33 immunoglobulin-related composition described herein. In some embodiments, the second antibody is coupled to at least one detectable label selected from a radioactive label, a fluorescent label, or a chromogenic label.
[0029] In another aspect, the present disclosure provides a method for selecting a subject for pretargeted radioimmunotherapy, the method comprising (a) administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and a bispecific antibody or antigen-binding fragment of the present technology that binds to the radiolabeled DOTA hapten and a CD33 antigen, wherein the complex is configured to localize to a tumor expressing the CD33 antigen recognized by the bispecific antibody or antigen-binding fragment of the complex; (b) detecting the level of radioactivity emitted by the complex; and (c) selecting the subject for pretargeted radioimmunotherapy when the level of radioactivity emitted by the complex is higher than a reference value.
[0030] In one aspect, the present disclosure provides a method for increasing the sensitivity of a tumor to radiotherapy in a subject diagnosed with a CD33-related cancer, the method comprising administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and a bispecific antibody or antigen-binding fragment of the present technology that recognizes and binds to the radiolabeled DOTA hapten and a CD33 antigen target, wherein the complex is configured to localize to a tumor expressing the CD33 antigen target recognized by the bispecific antibody or antigen-binding fragment of the complex.
[0031] In another aspect, the present disclosure provides a method for treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and a bispecific antibody or antigen-binding fragment of the present technology that recognizes and binds to the radiolabeled DOTA hapten and a CD33 antigen target, wherein the complex is configured to localize to a tumor expressing the CD33 antigen target recognized by the bispecific antibody or antigen-binding fragment of the complex.
[0032] In any of the above embodiments of the methods disclosed herein, the complex is administered intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intraorbitally, intradermally, intraperitoneally, transtracheally, subcutaneously, intraventricularly, orally, intratumorally, or intranasally. In some embodiments of the methods disclosed herein, the subject is a human. Additionally or alternatively, in any of the above embodiments of the methods disclosed herein, the radiolabeled DOTA hapten comprises 213 Bi, 211 At 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn, 215 Po, 211Bi, 221 Fr. 217 At 255 Fm, 86 Y. 90 Y. 89 Sr. 165 Dy, 186 Re, 188 Re, 177 Lu, 67 Cu, 111 In, 67 Ga, 51 Cr, 58 Co. 99m Tc, 103m Rh, 195m Pt, 119 Sb, 161 Ho, 189m Os, 192 Ir, 201 Tl, 203 Pb, 68 Ga, 227 Th or 64 Cu, and optionally contains an alpha-emitting isotope, a beta-emitting isotope, or an Auger emitter.
[0033] In one aspect, the present disclosure provides a method for increasing the sensitivity of a tumor to radiotherapy in a subject diagnosed with a CD33-related cancer, the method comprising (a) administering to the subject an effective amount of an anti-DOTA bispecific antibody or antigen-binding fragment of the present technology, wherein the anti-DOTA bispecific antibody or antigen-binding fragment is configured to localize to a tumor expressing a CD33 antigen target; and (b) administering to the subject an effective amount of a radiolabeled DOTA hapten, wherein the radiolabeled DOTA hapten is configured to bind to the anti-DOTA bispecific antibody or antigen-binding fragment. In another aspect, the present disclosure provides a method for treating cancer in a subject in need thereof, the method comprising (a) administering to the subject an effective amount of an anti-DOTA bispecific antibody or antigen-binding fragment of the present technology, wherein the anti-DOTA bispecific antibody or antigen-binding fragment is configured to localize to a tumor expressing a CD33 antigen target; and (b) administering to the subject an effective amount of a radiolabeled DOTA hapten, wherein the radiolabeled DOTA hapten is configured to bind to the anti-DOTA bispecific antibody or antigen-binding fragment. In some embodiments, the methods of the present technology further comprise administering to the subject an effective amount of a clearing agent prior to administering the radiolabeled DOTA hapten.
[0034] Additionally or alternatively, in any of the above embodiments of the methods disclosed herein, the radiolabeled DOTA hapten comprises 213 Bi, 211 At 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn, 215 Po, 211 Bi, 221 Fr. 217 At 255 Fm, 86 Y. 90 Y. 89 Sr. 165 Dy, 186 Re, 188 Re, 177 Lu, 67 Cu, 111 In, 67 Ga, 51 Cr, 58 Co. 99m Tc, 103m Rh, 195m Pt, 119 Sb, 161 Ho, 189m Os, 192 Ir, 201 Tl, 203 Pb, 68 Ga, 227 Th or 64 Cu, and optionally comprises an alpha particle emitting isotope, a beta particle emitting isotope, or an Auger emitter. In any of the above embodiments of the methods disclosed herein, the subject is a human. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1A Shown is a schematic diagram of a modular tetravalent IgG-scFv format comprising an IgG molecule with two binding sites covalently linked to two scFvs, providing two additional binding domains.
[0036] Figure 1B An exemplary analysis of the biochemical purity of the BC269 (hMy96 L1H3) BsAb of the present disclosure is shown. The upper figure shows a size exclusion chromatography-high performance liquid chromatography (SEC-HPLC) spectrum. The protein in the eluent is detected based on the absorbance of ultraviolet light at a wavelength of 280nm. The relative amount of protein in the SEC-HPLC peak from the chromatogram is shown in the figure below.
[0037] Figure 2 The stability of humanized My96 IgG antibodies at 40°C is shown. The indicated antibodies were incubated at 40°C and aliquots thereof were taken at the indicated times to assess purity using HPLC. The table in the lower figure shows the stability values as measured by the area under the curve of the HPLC peak corresponding to the antibody monomer. The upper figure shows a line graph plotting the stability values at 40°C as a function of incubation time.
[0038] Figure 3 The stability of the anti-CD33 BsAb of the present technology is shown. Figure 2 Stability was measured as described in and plotted as a function of incubation time at 40°C.
[0039] Figure 4 hMy96 CD33-BsAb redirects T cells to kill CD33(+) AML cells. 51 T cells were tested for cytotoxicity against CD33(+) AML cells in a Cr release assay. In the presence of humanized CD33-BsAb, extensive killing of AML cell lines was observed with EC50 in the femtomolar range (for MOLM13).
[0040] Figure 5A Shown are bioluminescence images illustrating the growth of MOLM13 AML tumors in different experimental groups. Figure 5B Shown in the Figure 5A Quantification of signals in different experimental groups of mice is shown. Figure 5C Shown is the growth quantification of MOLM13 AML tumors treated with BC119 (non-targeting control BsAb) or BC269.
[0041] Figure 6 The amino acid sequences of murine and humanized My96 heavy chain variable domains are shown (SEQ ID NOs: 1, 5, 9 and 13, respectively). My96_VH-1, My96_VH-2 and My96_VH-3 are three variants of humanized My96 heavy chain variable domains. H CDR1, V H CDR2 and V H The CDR3 sequence is indicated by underlined bold font.
[0042] Figure 7The amino acid sequences of the murine and humanized My96 light chain variable domains are shown (SEQ ID NOs: 17, 21, 25 and 29, respectively). My96_VL-1, My96_VL-2 and My96_VL-3 are three variants of the humanized My96 light chain variable domain. L CDR1, V L CDR2 and V L The CDR3 sequence is indicated by underlined bold font.
[0043] Fig. 8A and Figure 8B The amino acid sequence and nucleotide sequence of the light chain (SEQ ID NO: 33-34) and heavy chain (SEQ ID NO: 35-36) of the chMy96 BsAb are shown, respectively. The signal peptide is underlined, the variable domain of the chimeric anti-CD33 bispecific antibody is indicated in bold font, the My96 CDR sequence of the chimeric anti-CD33 antibody is indicated in underlined bold font, and the linker sequence is italicized and underlined.
[0044] Fig.9A and Fig. 9B The amino acid sequence and nucleotide sequence of the light chain (SEQ ID NO: 37-38) and heavy chain (SEQ ID NO: 39-40) of humanized My96 x CD3 BsAb BC248 (hMy96 L2H3) are shown, respectively. The signal peptide is underlined, the variable domain of the humanized anti-CD33 bispecific antibody is indicated in bold font, the My96 CDR sequence of the humanized My96 x CD3 BsAb is indicated in underlined bold font, and the linker sequence is italicized and underlined.
[0045] Fig. 10A and Fig. 10B The amino acid sequence and nucleotide sequence of the light chain (SEQ ID NO: 41-42) and heavy chain (SEQ ID NO: 43-44) of the humanized My96 x CD3 BsAb BC269 (hMy96 L1H3) are shown, respectively. The signal peptide is underlined, the variable domain of the humanized anti-CD33 antibody is indicated in bold font, and the linker sequence is italicized and underlined.
[0046] Fig.11A and Fig. 11BThe amino acid sequence and nucleotide sequence of the light chain (SEQ ID NO: 45-46) and heavy chain (SEQ ID NO: 47-48) of the humanized My96 x CD3 BsAb BC256 (hMy96 L1H1) are shown, respectively. The signal peptide is underlined, the variable domain of the humanized anti-CD33 antibody is indicated in bold font, and the linker sequence is italicized and underlined.
[0047] Fig. 12A and Fig. 12B The amino acid sequence and nucleotide sequence of the light chain (SEQ ID NO: 49-50) and heavy chain (SEQ ID NO: 51-52) of humanized My96 x CD3 BsAb BC257 (hMy96 L1H2) are shown, respectively. The signal peptide is underlined, the variable domain of the humanized anti-CD33 antibody is indicated in bold font, and the linker sequence is italicized and underlined.
[0048] Figure 13A-13J The amino acid sequences of the light and heavy chains of the murine My96 x C825 (anti-DOTA) BsAb in IgG-scFv format are shown. The light chain amino acid sequences are shown in SEQ ID NOs: 53, 55, 57, 59, 61, 63, 65, 67, 69, and 71; and the heavy chain amino acid sequences are shown in SEQ ID NOs: 54, 56, 58, 60, 62, 64, 66, 68, 70, and 72. The signal peptide is underlined, the variable domains of the humanized anti-CD33 antibody are indicated in bold font, and the linker sequence is italicized and underlined.
[0049] Figure 14A-14HHH The amino acid sequence of humanized My96x C825 (anti-DOTA) BsAb in single-chain bispecific tandem fragment variable (scBsTaFv) format (SEQ ID NO: 73-132) is shown. The signal peptide is underlined, the variable domain of the humanized anti-CD33 antibody is indicated in bold font, the linker and spacer sequences are italic and underlined, the p53, p63 or p73 tetramerization domains are underlined, and the histidine 6 tag is indicated in italic font. DETAILED DESCRIPTION
[0050] It should be appreciated that certain aspects, modes, embodiments, variations and features of the methods of the present invention are described below in varying levels of detail in order to provide a substantial understanding of the present technology.
[0051] The present disclosure generally provides immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) that can specifically bind to a CD33 polypeptide. The immunoglobulin-related compositions of the present technology can be used in methods for detecting or treating CD33-related cancers or Alzheimer's disease in subjects in need thereof. Therefore, various aspects of the methods of the present invention relate to the preparation, characterization and manipulation of anti-CD33 antibodies. The immunoglobulin-related compositions of the present technology can be used alone or in combination with additional therapeutic agents for treating cancer. In some embodiments, the immunoglobulin-related compositions are humanized antibodies, chimeric antibodies, or bispecific antibodies.
[0052] In practicing the methods of the present invention, many conventional techniques in molecular biology, protein biochemistry, cell biology, immunology, microbiology, and recombinant DNA are used. See, for example, Sambrook and Russell, eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; Ausubel et al., eds. (2007) Current Protocols in Molecular Biology series; Methods in Enzymology (Academic Press, Inc., New York) series; MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach; Harlow and Lane, eds. (1999) Antibodies, A Laboratory Manual; Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th edition; Gait, ed. (1984) Oligonucleotide Synthesis; U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos, eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides, ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker, ed. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al., ed. (1996) Weir's Handbook of Experimental Immunology. Methods for detecting and measuring the level of polypeptide gene expression products (i.e., gene translation levels) are well known in the art and include the use of polypeptide detection methods, such as antibody detection and quantification techniques. (See also, Strachan and Read, Human Molecular Genetics, 2nd ed. (John Wiley and Sons, Inc., New York, 1999)). .
[0053] definition
[0054] Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by those of ordinary skill in the art to which the technology belongs. As used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural designators unless the context clearly dictates otherwise. For example, reference to "a cell" includes combinations of two or more cells, and so on. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, analytical chemistry, and nucleic acid chemistry and hybridization described below are those well known and commonly used in the art.
[0055] As used herein, the term "about" with respect to a number is generally deemed to include numbers that fall within 1%, 5%, or 10% in either direction (greater than or less than) of the stated number, unless the context indicates otherwise or it is otherwise obvious (except where such a number is below 0% or above 100% of the possible value).
[0056] As used herein, "administering" an agent or drug to a subject includes any route of introducing or delivering a compound to a subject to perform its intended function. Administration can be by any suitable route, including, but not limited to, oral, intranasal, parenteral (intravenous, intramuscular, intraperitoneal, or subcutaneous), rectal, intrathecal, intratumoral, or topical. Administration includes self-administration and administration by another person.
[0057] "Adjuvant" refers to one or more substances that cause immune system stimulation. In this case, the adjuvant is used to enhance the immune response to one or more vaccine antigens or antibodies. The adjuvant can be administered to the subject before, in combination with, or after the administration of the vaccine. Examples of chemical compounds used as adjuvants include aluminum compounds, oils, block polymers, immunostimulatory complexes, vitamins and minerals (e.g., vitamin E, vitamin A, selenium, and vitamin B12), Quil A (saponin), bacterial and fungal cell wall components (e.g., lipopolysaccharides, lipoproteins, and glycoproteins), hormones, cytokines, and co-stimulatory factors.
[0058] As used herein, the term "antibody" collectively refers to immunoglobulins or immunoglobulin-like molecules, including, for example, but not limited to, IgA, IgD, IgE, IgG, and IgM, combinations thereof, and similar molecules produced during an immune response in any vertebrate, such as mammals (such as humans, goats, rabbits, and mice), as well as non-mammalian species (such as shark immunoglobulins). As used herein, "antibodies" (including complete immunoglobulins) and "antigen-binding fragments" specifically bind to a target molecule (or a group of highly similar target molecules) while substantially excluding binding to other molecules (e.g., a binding constant for the target molecule is at least 10 greater than a binding constant for other molecules in a biological sample). 3 M -1 , at least 10 4 M -1 or at least 10 5 M -1 The term "antibody" also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies). See also Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL); Kuby, J., Immunology, 3rd ed., WH Freeman & Co., New York, 1997.
[0059] More specifically, an antibody refers to a polypeptide ligand that specifically recognizes and binds to an antigen epitope and contains at least a light chain immunoglobulin variable region or a heavy chain immunoglobulin variable region. Antibodies are composed of heavy chains and light chains, each of which has a variable region, called a heavy chain variable region (V H ) region and light chain variable (V L ) area. H Area and V LThe regions are jointly responsible for binding to the antigen recognized by the antibody. Typically, immunoglobulins have heavy (H) chains and light (L) chains interconnected by disulfide bonds. There are two types of light chains, namely λ (lambda) and κ (kappa). There are five main heavy chain categories (or isotypes): IgM, IgD, IgG, IgA and IgE, which determine the functional activity of the antibody molecule. Each heavy chain and light chain contains a constant region and a variable region (the region is also referred to as a "domain"). Combined, the heavy chain variable region and the light chain variable region specifically bind to the antigen. The light chain variable region and the heavy chain variable region contain a "framework" region interrupted by three hypervariable regions (also referred to as "complementarity determining regions" or "CDRs"). The scope of the framework region and CDR has been defined (see Kabat et al., Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, 1991, which is hereby incorporated by reference). The Kabat database is currently maintained online. The sequences of the framework regions of different light or heavy chains are relatively conserved within species. The framework region of an antibody (i.e., the combined framework region of the constituent light and heavy chains) predominantly adopts a β-sheet conformation, and the CDR forms a loop connecting the β-sheet structure, and in some cases the loop forms a part of the β-sheet structure. Therefore, the framework region plays a role in forming a scaffold that positions the CDR in the correct orientation through interchain non-covalent interactions.
[0060] The CDRs are primarily responsible for binding to the antigenic epitope. The CDRs of each chain are usually referred to as CDR1, CDR2, and CDR3, are numbered sequentially starting from the N-terminus, and are usually also identified according to the chain in which a particular CDR is located. H CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, while V L CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found. An antibody that binds to the CD33 protein will have a specific V H Area and V L Region sequence, thus having a specific CDR sequence. Antibodies with different specificities (i.e., different binding sites for different antigens) have different CDRs. Although CDRs are different between different antibodies, only a limited number of amino acid positions in the CDR are directly involved in antigen binding. These positions in the CDR are called specificity determining residues (SDRs). As used herein, "immunoglobulin-related compositions" refer to antibodies (including monoclonal antibodies, polyclonal antibodies, humanized antibodies, chimeric antibodies, recombinant antibodies, multispecific antibodies, bispecific antibodies, etc.) and antibody fragments. Antibodies or their antigen-binding fragments specifically bind to antigens.
[0061] As used herein, the term "antibody-related polypeptide" means an antigen-binding antibody fragment including a single-chain antibody, which may contain one or more variable regions alone or in combination with all or part of the following polypeptide elements: the hinge region, CH1, CH2, and CH3 domains of an antibody molecule. The technology also includes any combination of one or more variable regions and hinge regions, CH1, CH2, and CH3 domains. Antibody-related molecules that can be used in the method of the present invention are, for example, but not limited to, Fab, Fab' and F(ab')2, Fd, single-chain Fv (scFv), single-chain antibodies, disulfide-linked Fv (sdFv), and V L or V H Examples include: (i) Fab fragments, i.e., fragments of V L 、V H , C L and CH1 domains; (ii) F(ab')2 fragments, i.e. bivalent fragments comprising two Fab fragments connected by a disulfide bridge in the hinge region; (iii) H and CH1 domains; (iv) a V fragment consisting of a single arm of the antibody L and V H (v) dAb fragment (Ward et al., Nature 341:544-546, 1989), which consists of V H domain composition; and (vi) isolated complementarity determining regions (CDRs). Thus, an "antibody fragment" or "antigen binding fragment" may comprise a portion of a full-length antibody, typically its antigen binding or variable region. Examples of antibody fragments or antigen binding fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
[0062] As used herein, "bispecific antibody" or "BsAb" refers to an antibody that can simultaneously bind to two targets with different structures (e.g., two different target antigens, two different epitopes on the same target antigen, or a hapten and a target antigen or an epitope on a target antigen). A variety of different bispecific antibody structures are known in the art. In some embodiments, each antigen-binding portion in a bispecific antibody includes a V H and / or V L region; in some such embodiments, V H and / or V L The V regions are those found in a particular monoclonal antibody. In some embodiments, the bispecific antibody contains two antigen-binding portions, each of which includes a V region from a different monoclonal antibody. H and / or V LIn some embodiments, the bispecific antibody contains two antigen-binding moieties, wherein one of the two antigen-binding moieties comprises a V H and / or V L region of the immunoglobulin molecule, the V H and / or V L The second antigen binding portion comprises a CDR region from the first monoclonal antibody; and the second antigen binding portion comprises a CDR region from the first monoclonal antibody; H and / or V L The antibody fragment of the V region (e.g., Fab, F(ab'), F(ab')2, Fd, Fv, dAB, scFv, etc.), H and / or V L The region contains the CDRs from the second monoclonal antibody.
[0063] As used herein, a "scavenger" is an agent that binds to excess bispecific antibodies present in the blood compartment of a subject to promote rapid clearance via the kidneys. The use of a scavenger prior to hapten administration (e.g., DOTA) helps to achieve a better tumor to background ratio in a pretargeted radioimmunotherapy (PRIT) system. Examples of scavengers include 500kD-dextran-DOTA-Bn(Y) (Orcutt et al., Mol Cancer Ther. 11(6): 1365–1372 (2012)), 500kD aminodextran-DOTA conjugates, antibodies against pretargeted antibodies, and the like.
[0064] As used herein, the term "conjugated" refers to the association of two molecules by any method known to those skilled in the art. Suitable types of association include chemical bonds and physical bonds. Chemical bonds include, for example, covalent bonds and coordination bonds. Physical bonds include, for example, hydrogen bonds, dipole interactions, van der Waals forces, electrostatic interactions, hydrophobic interactions, and aromatic stacking.
[0065] As used herein, the term "diabodies" refers to small antibody fragments with two antigen-binding sites contained in the same polypeptide chain in conjunction with a light chain variable domain (V L ) connected to the heavy chain variable domain (V H )(V H V L ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are more fully described in, for example, EP 404,097; WO 93 / 11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
[0066] As used herein, the term "single-chain antibody" or "single-chain Fv (scFv)" refers to the two domains V and Fv fragments. L and V H The single-chain antibody molecule may contain a polymer having multiple individual molecules, such as a dimer, trimer or other polymer. v The two domains of the fragment V L and V H They are encoded by separate genes, but they can be joined by synthetic linkers using recombinant methods so that they can become a single protein chain, in which V L and V H The domains pair to form a monovalent molecule (called a single-chain F v (scF v )). Bird et al. (1988) Science 242:423-426 and Huston et al. (1988) Proc. Natl. Acad Sci. USA 85:5879-5883. Such single-chain antibodies can be prepared by recombinant techniques or by enzymatic or chemical cleavage of intact antibodies.
[0067] Fragments of any of the foregoing antibodies are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for binding specificity and neutralization activity in the same manner as are intact antibodies.
[0068] As used herein, "antigen" refers to a molecule to which an antibody (or its antigen-binding fragment) can selectively bind. The target antigen can be a protein, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. In some embodiments, the target antigen can be a polypeptide (e.g., a CD33 polypeptide). The antigen can also be administered to an animal to generate an immune response in the animal.
[0069] The term "antigen binding fragment" refers to a fragment of a complete immunoglobulin structure having a polypeptide portion responsible for binding to an antigen. Examples of antigen binding fragments that can be used in the present technology include, but are not limited to, scFv, (scFv)2, scFvFc, Fab, Fab' and F(ab')2.
[0070] "Binding affinity" refers to the strength of the total non-covalent interaction between a single binding site of a molecule (e.g., an antibody) and the molecule's binding partner (e.g., an antigen or antigenic peptide). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (K D ) is represented by. Affinity can be measured by standard methods known in the art (including those described herein). Low affinity complexes contain antibodies that generally tend to dissociate easily from the antigen, while high affinity complexes contain antibodies that generally tend to remain bound to the antigen for a longer period of time.
[0071] As used herein, the term "biological sample" means a sample material derived from living cells. Biological samples can include tissues, cells, proteins or membrane extracts of cells separated from a subject and biological fluids (e.g., ascites or cerebrospinal fluid (CSF)), as well as tissues, cells and fluids present in a subject. The biological samples of this technology include but are not limited to samples taken from: breast tissue, kidney tissue, cervix, endometrium, head or neck, gallbladder, parotid tissue, prostate, brain, pituitary gland, kidney tissue, muscle, esophagus, stomach, small intestine, colon, liver, spleen, pancreas, thyroid tissue, heart tissue, lung tissue, bladder, adipose tissue, lymph node tissue, uterus, ovarian tissue, adrenal tissue, testicular tissue, tonsil, thymus, blood, hair, cheek, skin, serum, plasma, CSF, sperm, prostatic fluid, semen, urine, feces, sweat, saliva, sputum, mucus, bone marrow, lymph and tears. Biological samples can also be obtained from the biopsy of internal organs or from cancer. Biological samples can be obtained from subjects for diagnosis or research; or can be obtained from individuals who have not been ill, as controls or for basic research. Samples can be obtained by standard methods, including, for example, venipuncture and surgical biopsy. In certain embodiments, the biological sample is a tissue sample obtained by needle biopsy.
[0072] As used herein, the term "CDR-grafted antibody" means an antibody in which at least one CDR of a "recipient" antibody is replaced by a CDR "graft" having the desired antigen specificity from a "donor" antibody.
[0073] As used herein, the term "chimeric antibody" refers to an antibody in which the Fc constant region of a monoclonal antibody from one species (e.g., a mouse Fc constant region) is replaced with the Fc constant region of an antibody from another species (e.g., a human Fc constant region) using recombinant DNA technology. See generally, Robinson et al., PCT / US86 / 02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., WO 86 / 01533; Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 0125,023; Better et al., Science 240:1041-1043, 1988; Liu et al., Proc. Natl. Acad. Sci. USA 84:3439-3443, 1987; Liu et al., J. Immunol 139:3521-3526, 1987; Sun et al., Proc. Natl. Acad. Sci. USA 84:214-218, 1987; Nishimura et al., Cancer Res 47:999-1005, 1987; Wood et al., Nature 314:446-449, 1885; and Shaw et al., J. Natl. Cancer Inst. 80:1553-1559, 1988.
[0074] As used herein, the term "consensus FR" means the framework (FR) antibody region in the consensus immunoglobulin sequence. The FR region of an antibody does not contact the antigen.
[0075] As used herein, a "control" is an alternative sample used in an experiment for comparison purposes. A control can be "positive" or "negative." For example, where the purpose of an experiment is to determine the relevance of the efficacy of a therapeutic agent for the treatment of a particular type of disease, a positive control (a compound or composition known to exhibit the desired therapeutic effect) and a negative control (a subject or sample that does not receive treatment or receives a placebo) are typically used.
[0076] As used herein, the term "effective amount" refers to an amount sufficient to achieve the desired therapeutic and / or preventive effect, such as an amount that results in the prevention or reduction of a disease or condition described herein or one or more signs or symptoms associated with a disease or condition described herein. In the case of therapeutic or preventive applications, the amount of the composition applied to the subject will vary according to the composition, the extent, type and severity of the disease, and according to individual characteristics (such as general health, age, sex, body weight and drug tolerance). The technician will be able to determine the appropriate dosage based on these and other factors. The composition may also be administered in combination with one or more additional therapeutic compounds. In the methods described herein, the therapeutic composition may be administered to a subject having one or more signs or symptoms of a disease or condition described herein. As used herein, a "therapeutically effective amount" of a composition refers to a composition level in which the physiological effects of a disease or condition are improved or eliminated. The therapeutically effective amount may be administered in one or more administrations.
[0077] As used herein, the term "effector cell" means an immune cell that participates in the effector phase of an immune response, which is opposite to the cognitive phase and activation phase of an immune response. Exemplary immune cells include cells of bone marrow or lymphoid origin, such as lymphocytes (e.g., B cells and T cells, including cytolytic T cells (CTL)), killer cells, natural killer cells, macrophages, monocytes, eosinophils, neutrophils, polymorphonuclear cells, granulocytes, mast cells, and basophils. Effector cells express specific Fc receptors and perform specific immune functions. Effector cells can induce antibody-dependent cell-mediated cytotoxicity (ADCC), such as neutrophils that can induce ADCC. For example, monocytes, macrophages, neutrophils, eosinophils, and lymphocytes expressing FcαR participate in the specific killing of target cells and present antigens to other components of the immune system, or bind to cells presenting antigens.
[0078] As used herein, the term "epitope" means a protein determinant that can specifically bind to an antibody. An epitope is usually composed of chemically active surface groups of a molecule (such as amino acids or sugar side chains) and usually has specific three-dimensional structural characteristics, as well as specific charge characteristics. The difference between a conformational epitope and a non-conformational epitope is that in the presence of a denaturing solvent, the binding to a conformational epitope rather than a non-conformational epitope is lost. In some embodiments, the "epitope" of a CD33 protein is a region of the protein that specifically binds to an anti-CD33 antibody of the present technology. In some embodiments, the epitope is a conformational epitope or a non-conformational epitope. In order to screen for anti-CD33 antibodies that bind to an epitope, a conventional cross-blocking assay can be performed, such as the assay described in the following document: Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Harlow and David Lane, eds. (1988). This assay can be used to determine whether an anti-CD33 antibody binds to the same site or epitope as an anti-CD33 antibody of the present technology. Alternatively or additionally, epitope mapping can be performed by methods known in the art. For example, the antibody sequence can be mutagenized, such as by alanine scanning, to identify contact residues. In a different approach, peptides corresponding to different regions of the CD33 protein can be used in competition assays with multiple test antibodies, or with a test antibody and an antibody with a characterized or known epitope.
[0079] As used herein, "expression" includes one or more of the following: transcription of a gene into a precursor mRNA; splicing and other processing of the precursor mRNA to produce a mature mRNA; mRNA stability; translation of the mature mRNA into protein (including codon usage and tRNA availability); and glycosylation and / or other modifications of the translation product (if required for proper expression and function).
[0080] As used herein, the term "gene" means a segment of DNA that contains all the information for regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.
[0081] "Homology" or "identity" or "similarity" refers to the sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing the positions in each sequence, which can be aligned for comparison purposes. When the position in the compared sequence is occupied by the same base or amino acid, the molecules are homologous at that position. The degree of homology between sequences varies with the number of matching or homologous positions shared by the sequences. A polynucleotide or polynucleotide region (or polypeptide or polypeptide region) has a certain percentage (e.g., at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of "sequence identity" with another sequence, which means that, when aligned, the bases (or amino acids) of that percentage are the same in comparing the two sequences. This alignment and homology or sequence identity percentage can be determined using software programs known in the art. In some embodiments, default parameters are used for alignment. One alignment program is BLAST, using default parameters. Specifically, the programs are BLASTN and BLASTP, using the following default parameters: genetic code = standard; filter = none; chain = two; cutoff = 60; expectation = 10; matrix = BLOSUM62; description = 50 sequences; sorting mode = high score (HIGH SCORE); database = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translation + SwissProtein + SPupdate + PIR. Detailed information on these programs can be found at the National Center for Biotechnology Information. Biologically equivalent polynucleotides are those polynucleotides with a specified homology percentage and encoding polypeptides with the same or similar biological activity. If two sequences share less than 40% identity or less than 25% identity with each other, the sequences are considered "unrelated" or "non-homologous".
[0082] As used herein, the "humanized" form of a non-human (e.g., mouse) antibody is a chimeric antibody containing a minimal sequence derived from a non-human immunoglobulin. For the most part, a humanized antibody is a human immunoglobulin, in which the hypervariable region residues of the receptor are replaced by the hypervariable region residues (donor antibody) with the desired specificity, affinity and ability from a non-human species (e.g., mouse, rat, rabbit or non-human primate). In some embodiments, the Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. In addition, a humanized antibody may be included in residues not found in the receptor antibody or the donor antibody. These modifications are carried out to further improve antibody performance such as binding affinity. Typically, a humanized antibody will comprise substantially all of at least one, usually two variable domains (e.g., Fab, Fab', F(ab')2, or Fv), wherein all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the FR regions are those of the consensus FR sequences of human immunoglobulins, but the FR regions may include one or more amino acid substitutions that improve binding affinity. The number of these amino acid substitutions in the FR is typically no more than 6 in the H chain and no more than 3 in the L chain. The humanized antibody may optionally also comprise at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a human immunoglobulin constant region. For further details, see Jones et al., Nature 321:522-525 (1986); Reichmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See, e.g., Ahmed and Cheung, FEBS Letters 588(2):288-297 (2014).
[0083] As used herein, the term "hypervariable region" refers to the amino acid residues in an antibody that are responsible for antigen binding. A hypervariable region generally includes amino acid residues from a "complementarity determining region" or "CDR" (e.g., V L before and after residues 24-34 (L1), 50-56 (L2), and 89-97 (L3), and V H 31-35B (H1), 50-65 (H2), and 95-102 (H3) in the sequence of the 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)) and / or those residues from the "hypervariable loops" (e.g., V LResidues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in V H 26-32 (H1), 52A-55 (H2) and 96-101 (H3) (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
[0084] As used herein, when used in the context of two or more nucleic acid or polypeptide sequences, the term "identical" or "identity" percentage refers to when compared and aligned for maximum correspondence over a comparison window or a specific region, as measured using the BLAST or BLAST 2.0 sequence comparison algorithm with the default parameters described below or by manual alignment and visual inspection (e.g., NCBI website), two or more sequences or subsequences are identical or have a specified percentage of identical amino acid residues or nucleotides (i.e., about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity over a specified region (e.g., a nucleotide sequence encoding an antibody described herein or an amino acid sequence of an antibody described herein). Such sequences are referred to as "substantially identical". This term also refers to or can be applied to the complement of a test sequence. The term also includes sequences with deletions and / or additions, as well as those with substitutions. In some embodiments, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or that is 50-100 amino acids or nucleotides in length.
[0085] As used herein, the term "intact antibody" or "intact immunoglobulin" means an antibody having at least two heavy (H) chain polypeptides and two light (L) chain polypeptides interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as HCVR or V H ) and a heavy chain constant region. The heavy chain constant region is composed of three domains: CH1, CH2, and CH3. Each light chain consists of a light chain variable region (abbreviated herein as LCVR or V L ) and the light chain constant region. The light chain constant region consists of a domain C L Composition. H and V L The regions can be further subdivided into regions of high variability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). H and V LIt is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
[0086] As used herein, the term "individual", "patient" or "subject" can be a single organism, a vertebrate, a mammal or a human. In some embodiments, the individual, patient or subject is a human.
[0087] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, that is, except for a possible naturally occurring mutation that may be present in a small amount, the individual antibodies constituting the population are identical. For example, a monoclonal antibody may be an antibody derived from a single clone (including any eukaryotic, prokaryotic or phage clone) rather than a method for producing it. A monoclonal antibody composition exhibits a single binding specificity and affinity to a specific epitope. Monoclonal antibodies are highly specific for a single antigenic site. In addition, compared to conventional (polyclonal) antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody is for a single determinant on an antigen. The modifier "monoclonal" indicates that the antibody is characterized by being obtained from a substantially homogeneous antibody population, and should not be construed as requiring the antibody to be produced by any ad hoc method. Monoclonal antibodies can be prepared using a variety of techniques known in the art, including, for example, but not limited to, hybridoma, recombinant and phage display techniques. For example, the monoclonal antibody to be used according to the method of the invention can be prepared by the hybridoma method originally described by Kohler et al., Nature 256:495 (1975), or can be prepared by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). For example, "monoclonal antibodies" can also be separated from phage antibody libraries using the techniques described by Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991).
[0088] As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal compounds, isotonic and absorption delaying compounds, etc., that are compatible with pharmaceutical administration. Pharmaceutically acceptable carriers and their formulations are known to those skilled in the art and are described, for example, in Remington's Pharmaceutical Sciences (20th edition, A. Gennaro, ed., 2000, Lippincott, Williams & Wilkins, Philadelphia, Pennsylvania).
[0089] As used herein, the term "polyclonal antibody" means a preparation of antibodies derived from at least two (2) different antibody-producing cell lines. The use of this term includes preparations of at least two (2) antibodies containing antibodies that specifically bind to different epitopes or regions of an antigen.
[0090] As used herein, the term "polynucleotide" or "nucleic acid" means any RNA or DNA, which can be unmodified or modified RNA or DNA. Polynucleotides include, but are not limited to, single-stranded and double-stranded DNA, DNA as a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, RNA as a mixture of single-stranded and double-stranded regions, and hybrid molecules comprising DNA and RNA, which can be single-stranded or more generally double-stranded or a mixture of single-stranded and double-stranded regions. In addition, polynucleotides refer to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNA or RNA containing one or more modified bases, and DNA or RNA to which the backbone is modified for stability or other reasons.
[0091] As used herein, the terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer comprising two or more amino acids linked to each other by peptide bonds or modified peptide bonds (i.e., peptide isosteres). Polypeptides refer to both short chains, commonly referred to as peptides, glycopeptides or oligomers, and longer chains, commonly referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified by natural processes (such as post-translational processing) or by chemical modification techniques well known in the art. Such modifications are fully described in basic textbooks and more detailed monographs as well as lengthy research literature.
[0092] As used herein, "PRIT" or "Pretargeted Radioimmunotherapy" refers to a multi-step process that addresses the slow blood clearance of tumor-targeting antibodies, which leads to undesirable toxicity to normal tissues such as the bone marrow. In pretargeting, a radionuclide or other diagnostic or therapeutic agent is attached to a small hapten. A pretargeting bispecific antibody with binding sites for the hapten as well as the target antigen is first administered. Unbound antibody is then allowed to clear from the circulation, and the hapten is subsequently administered.
[0093] As used herein, the term "recombinant" when used with respect to, for example, a cell or a nucleic acid, protein or vector, indicates that the cell, nucleic acid, protein or vector has been modified by the introduction of a heterologous nucleic acid or protein or by the alteration of a native nucleic acid or protein, or that the material is derived from a cell so modified. Thus, for example, a recombinant cell expresses genes not found in the native (non-recombinant) form of the cell, or expresses native genes that are otherwise abnormally expressed, under-expressed, or not expressed at all.
[0094] As used herein, the term "separate" therapeutic use refers to the simultaneous or substantially simultaneous administration of at least two active ingredients by different routes.
[0095] As used herein, the term "sequential" therapeutic use refers to the administration of at least two active ingredients at different times, with the same or different routes of administration. More specifically, sequential use refers to the entire administration of one active ingredient before the administration of the other one or more active ingredients begins. Thus, one active ingredient can be administered a few minutes, hours, or days before the administration of the other one or more active ingredients. In this case, there is no simultaneous treatment.
[0096] As used herein, "specific binding" refers to a molecule (e.g., an antibody or antigen-binding fragment thereof) that recognizes and binds to another molecule (e.g., an antigen) but does not substantially recognize and bind to other molecules. As used herein, the terms "specifically bind," "specifically binds to," or "specific for" a particular molecule (e.g., a polypeptide or an epitope on a polypeptide) can be defined, for example, by a molecule having about 10 -4 M, 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M or 10 - 12 M of K DThe term "specifically binds" may also refer to binding in which a molecule (e.g., an antibody or antigen-binding fragment thereof) binds to a specific polypeptide (e.g., a CD33 polypeptide) or an epitope on a specific polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
[0097] As used herein, the term "simultaneous" therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or substantially at the same time.
[0098] As used herein, the term "therapeutic agent" is intended to mean a compound that, when present in an effective amount, produces a desired therapeutic effect on a subject in need thereof.
[0099] As used herein, "treating" or "treatment" encompasses treating a disease or disorder described herein in a subject, such as a human, and includes: (i) inhibiting the disease or disorder, i.e., preventing its development; (ii) alleviating the disease or disorder, i.e., causing regression of the disorder; (iii) slowing the progression of the disorder; and / or (iv) inhibiting, alleviating, or slowing the progression of one or more symptoms of the disease or disorder. In some embodiments, treatment means that symptoms associated with the disease are, for example, alleviated, reduced, cured, or in a state of remission.
[0100] It is also understood that the various treatment modalities for disorders as described herein are intended to mean "substantially," which includes complete treatment but also less than complete treatment, and in which some biologically or medically relevant result is achieved. The treatment can be continuous, extended treatment for chronic diseases, or a single or several administrations for acute condition treatment.
[0101] One or more amino acid sequence modifications of the anti-CD33 antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of anti-CD33 antibodies are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the antibody amino acid sequence. As long as the antibody obtained has the desired properties, any combination of deletions, insertions and substitutions may be performed to obtain the desired antibody. Modifications also include changes in the glycosylation pattern of the protein. The sites of greatest interest for substitution mutagenesis include the hypervariable regions, but FR changes are also contemplated. "Conservative substitutions" are shown in the table below.
[0102]
[0103]
[0104] One type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody. A convenient method for generating such substitution variants involves affinity maturation using phage display. In particular, several hypervariable region sites (e.g., 6-7 sites) are mutated to produce all possible amino acid substitutions at each site. The antibody variants thus produced are displayed as fusions of the gene III product of M13 packaged in each particle in a monovalent manner from filamentous phage particles. The variants displayed by phage display are then screened for their biological activity (e.g., binding affinity), as disclosed herein. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues that contribute significantly to antigen binding. Alternatively or additionally, analyzing the crystal structure of the antigen-antibody complex may be beneficial to identify the contact points between the antibody and the antigen. According to the technology described in detail herein, such contact residues and adjacent residues are candidates for substitution. Once such variants are produced, this group of variants is screened as described herein, and antibodies with similar or better properties in one or more related assays can be selected for further development.
[0105] CD33
[0106] CD33 (also known as Siglec-3, SIGLEC3, gp67, p67) is a 67kDa plasma membrane protein that binds to sialic acid and is a member of the sialic acid-binding Ig-associated lectin (SIGLEC) protein family. Siglec proteins are believed to be involved in a variety of biological processes, such as hematopoiesis, neuronal development, and immunity (Vinson et al., J. Biol. Chem. 271: 9267-9272 (1996)). Studies have also shown that Siglec proteins mediate cell adhesion / cell signaling by recognizing sialylated cell surface glycans (Kelm et al., Glycoconj. J. 13: 913-926 (1996); Kelm et al., Eur. J. Biochem. 255: 663-672 (1998); Vinson et al., J. Biol. Chem. 271: 9267-9272 (1996)). The extracellular portion of CD33 contains two immunoglobulin domains (an IgV domain and an IgC2 domain). The IgV domain is far from the membrane, while the IgC2 domain is close to the membrane. The intracellular portion of CD33 contains an immunoreceptor tyrosine inhibitory motif (ITIM). In an immune response, CD33 can act as an inhibitory receptor by recruiting one or more cytoplasmic phosphatases upon ligand-induced tyrosine phosphorylation, which block signal transduction by dephosphorylating signal transduction molecules.
[0107] CD33 is known to be expressed on myeloid cells. CD33 expression has also been reported on many malignant cells. Anti-CD33 agents are generally divided into four groups: naked antibodies, antibody-toxin conjugates, radionuclide conjugates, and bispecific antibodies. Although CD33 has been targeted for the treatment of cancers such as acute myeloid leukemia, there is currently no effective CD33-targeted therapy on the market. Existing anti-CD33 agents have, among other things, poor tumor antigen binding affinity and short in vivo half-life.
[0108] Immunoglobulin-related compositions of the present technology
[0109] The present technology describes methods and compositions for producing and using anti-CD33 immunoglobulin-related compositions (e.g., anti-CD33 antibodies or antigen-binding fragments thereof). The anti-CD33 immunoglobulin-related compositions of the present disclosure can be used to diagnose or treat CD33-related cancers or Alzheimer's disease. Anti-CD33 immunoglobulin-related compositions within the scope of the present technology include, for example, but not limited to, monoclonal antibodies, chimeric antibodies, humanized antibodies, bispecific antibodies, and diabodies that specifically bind to a target polypeptide, its homologs, derivatives, or fragments. The present disclosure also provides an antigen-binding fragment of any anti-CD33 antibody disclosed herein, wherein the antigen-binding fragment is selected from Fab, F(ab)'2, Fab', scF v and F v The present technology discloses an anti-CD33 bispecific antibody format that solves the existing problems of poor tumor antigen binding affinity and short in vivo half-life.
[0110] In one aspect, the present technology provides chimeric and humanized variants of My96, including multispecific immunoglobulin-related compositions (eg, bispecific antibody agents).
[0111]
[0112] In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ), wherein (a) V H comprising a V selected from SYYIH (SEQ ID NO: 14) and SYYMH (SEQ ID NO: 6 or 10) H - CDR1; a V selected from VIYPGNDDISYAQKFQG (SEQ ID NO: 7 or 15) and VIYPGNDDISYN QKFQG (SEQ ID NO: 11); H -CDR2 sequence; and V of EVRLRYFDV (SEQ ID NO: 8, 12 or 16)H -CDR3 sequence; and (b) the V L comprising a V selected from KSSQSVFFSSSQKNYLA (SEQ ID NO: 22, 26 or 30) L -CDR1 sequence, V of WASTRES (SEQ ID NO: 23, 27 or 31) L - CDR2 sequence and V of HQYLSSRT (SEQ ID NO: 24, 28 or 32) L -CDR3 sequence.
[0113] In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof comprising a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ), wherein: (a) said V H comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 13; and / or (b) V L Comprising an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29.
[0114] In any of the above embodiments, the antibody further comprises an Fc domain of any isotype, such as, but not limited to, IgG (including IgG1, IgG2, IgG3, and IgG4), IgA (including IgA1 and IgA2), IgD, IgE, or IgM and IgY. Non-limiting examples of constant region sequences include:
[0115] Human IgD constant region, Uniprot: P01880 (SEQ ID NO: 133)
[0116] APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTWYMGTQSQPQRTFPEIQRRDSYYMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDHGPMK
[0117] Human IgG1 constant region, Uniprot: P01857 (SEQ ID NO:134)
[0118] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0119] Human IgG2 constant region, Uniprot: P01859 (SEQ ID NO:135)
[0120] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0121] Human IgG3 constant region, Uniprot: P01860 (SEQ ID NO:136)
[0122] ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK
[0123] Human IgM constant region, Uniprot: P01871 (SEQ ID NO:137)
[0124] GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITLSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLGQSMFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVAHEALPNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY
[0125] Human IgG4 constant region, Uniprot: P01861 (SEQ ID NO:138)
[0126] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
[0127] Human IgA1 constant region, Uniprot: P01876 (SEQ ID NO:139)
[0128] ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY
[0129] Human IgA2 constant region, Uniprot: P01877 (SEQ ID NO:140)
[0130] ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRMAGKPTHVNVSVVMAEVDGTCY
[0131] Human Igκ constant region, Uniprot: P01834 (SEQ ID NO:141)
[0132] TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
[0133] In some embodiments, the immunoglobulin-related compositions of the present technology comprise a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or 100% identical to SEQ ID NO: 133-140. Additionally or alternatively, in some embodiments, the immunoglobulin-related compositions of the present technology comprise a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or 100% identical to SEQ ID NO: 141. In some embodiments, the immunoglobulin-related compositions of the present technology bind to the IgV domain of CD33. In some embodiments, the epitope is a conformational epitope or a non-conformational epitope.
[0134] In another aspect, the present disclosure provides an isolated immunoglobulin-related composition (e.g., an antibody or an antigen-binding fragment thereof), which comprises a heavy chain (HC) amino acid sequence of SEQ ID NO:35, SEQ ID NO:39, SEQ ID NO:43, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, or a variant thereof having one or more conservative amino acid substitutions.
[0135] Additionally or alternatively, in some embodiments, the immunoglobulin-related compositions of the present technology comprise a light chain (LC) amino acid sequence comprising SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, or variants thereof having one or more conservative amino acid substitutions.
[0136] In some embodiments, the immunoglobulin-related compositions of the present technology comprise HC amino acid sequences and LC amino acid sequences selected from the following: SEQ ID NO:35 and SEQ ID NO:33; SEQ ID NO:39 and SEQ ID NO:37; SEQ ID NO:43 and SEQ ID NO:41; SEQ ID NO:47 and SEQ ID NO:45; SEQ ID NO:51 and SEQ ID NO:49; SEQ ID NO:54 and SEQ ID NO:53; SEQ ID NO:56 and SEQ ID NO:55; SEQ ID NO:58 and SEQID NO:57; SEQ ID NO:60 and SEQ ID NO:59; SEQ ID NO:62 and SEQ ID NO:61; SEQ ID NO:64 and SEQ ID NO:63; SEQ ID NO:66 and SEQ ID NO:65; SEQ ID NO:68 and SEQ ID NO:67; SEQ ID NO:70 and SEQ ID NO:69; and SEQ ID NO:72 and SEQ ID NO:71.
[0137] In any of the above embodiments of the immunoglobulin-related compositions, the HC and LC immunoglobulin variable domain sequences form an antigen binding site that binds to the IgV domain of CD33. In some embodiments, the epitope is a conformational epitope or a non-conformational epitope.
[0138] In some embodiments, the HC and LC immunoglobulin variable domain sequences are components of the same polypeptide chain. In other embodiments, the HC and LC immunoglobulin variable domain sequences are components of different polypeptide chains. In certain embodiments, the antibody is a full-length antibody.
[0139] In some embodiments, the immunoglobulin-related compositions of the present technology specifically bind to at least one CD33 polypeptide. In some embodiments, the immunoglobulin-related compositions of the present technology are present in an amount of about 10 -3 M, 10 -4 M, 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 The dissociation constant (K D) binds to at least one CD33 polypeptide. In certain embodiments, the immunoglobulin-related composition is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody. In some embodiments, the antibody comprises a human antibody framework region.
[0140] In certain embodiments, the immunoglobulin-related compositions include one or more of the following features: (a) a light chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a light chain immunoglobulin variable domain sequence present in any one of SEQ ID NOs: 21, 25, or 29; and / or (b) a heavy chain immunoglobulin variable domain sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to a heavy chain immunoglobulin variable domain sequence present in any one of SEQ ID NOs: 5, 9, or 13. In another aspect, one or more amino acid residues in the immunoglobulin-related compositions provided herein are substituted with another amino acid. The substitution may be a "conservative substitution" as defined herein.
[0141] In one aspect, the disclosure provides an immunoglobulin-related composition comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to an amino acid sequence selected from SEQ ID NO. 73-132.
[0142] In another aspect, the disclosure provides an antibody comprising (a) an LC sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the LC sequence present in any of SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69 or SEQ ID NO:71; and / or (b) an LC sequence that is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the LC sequence present in any of SEQ ID NO:33, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69 or SEQ ID NO:71; The HC sequence present in any one of SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72 is at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the HC sequence.
[0143] In one aspect, the present disclosure provides a bispecific antigen-binding fragment, the bispecific antigen-binding fragment comprising a first polypeptide chain, wherein: the first polypeptide chain comprises, in the N-terminal to C-terminal direction: (i) a heavy chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; (ii) a flexible peptide linker comprising the amino acid sequence (GGGGS)6; (iii) a light chain variable domain of the first immunoglobulin; (iv) a flexible peptide linker comprising the amino acid sequence (GGGGS)4; (v) a heavy chain variable domain of a second immunoglobulin that is capable of specifically binding to a second epitope; (vi) a flexible peptide linker comprising the amino acid sequence (GGGGS)6; (vii) a light chain variable domain of the second immunoglobulin; (viii) a flexible peptide linker sequence comprising the amino acid sequence TPLGDTTHT; and (ix) a self-assembly and decomposition (SADA) polypeptide, wherein the heavy chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:9 and SEQ ID NO:13; and / or the light chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29.
[0144] In another aspect, the present disclosure provides a bispecific antigen-binding fragment, the bispecific antigen-binding fragment comprising a first polypeptide chain, wherein: the first polypeptide chain comprises, in the N-terminal to C-terminal direction: (i) a light chain variable domain of a first immunoglobulin capable of specifically binding to a first epitope, (ii) a flexible peptide linker comprising the amino acid sequence (GGGGS)6; (iii) a heavy chain variable domain of the first immunoglobulin; (iv) a flexible peptide linker comprising the amino acid sequence (GGGGS)4; (v) a heavy chain variable domain of a second immunoglobulin capable of specifically binding to a second epitope; (vi) a flexible peptide linker comprising the amino acid sequence (GGGGS)6; (vii) a light chain variable domain of the second immunoglobulin; (viii) a flexible peptide linker sequence comprising the amino acid sequence TPLGDTTHT; and (ix) a self-assembly and decomposition (SADA) polypeptide, wherein the heavy chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:9 and SEQ ID NO:13; and / or the light chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29.
[0145] In certain embodiments of the bispecific antigen-binding fragment disclosed herein, the SADA polypeptide comprises a tetramerization, pentamerization or hexamerization domain. In some embodiments, the SADA polypeptide comprises a tetramerization domain of any one of p53, p63, p73, hnRNPC, SNA-23, Stefin B, KCNQ4 and CBFA2T1. Additionally or alternatively, in some embodiments, the bispecific antigen-binding fragment comprises an amino acid sequence selected from SEQ ID NO.73-132.
[0146] In one aspect, the present disclosure provides a bispecific antibody comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain, and a fourth polypeptide chain, wherein the first polypeptide chain and the second polypeptide chain are covalently bonded to each other, the second polypeptide chain and the third polypeptide chain are covalently bonded to each other, and the third polypeptide chain and the fourth polypeptide chain are covalently bonded to each other, and wherein: (a) each of the first polypeptide chain and the fourth polypeptide chain comprises, in the N-terminal to C-terminal direction: (i) a light chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; (ii) a light chain constant domain of the first immunoglobulin; (iii) a flexible peptide linker comprising the amino acid sequence (GGGGS)3; and (iv) a light chain constant domain of a second immunoglobulin that binds to a first epitope. The invention relates to a single-chain variable fragment of the present invention, wherein the light chain variable domain of the first immunoglobulin is connected to the complementary heavy chain variable domain of the first immunoglobulin or the heavy chain variable domain of the second immunoglobulin is connected to the complementary light chain variable domain of the second immunoglobulin, wherein the light chain variable domain and the heavy chain variable domain of the second immunoglobulin are capable of specifically binding to a second epitope and are connected together to form a single-chain variable fragment via a flexible peptide linker comprising the amino acid sequence (GGGGS)6; and (b) each of the second polypeptide chain and the third polypeptide chain comprises in the N-terminal to C-terminal direction: (i) a heavy chain variable domain of the first immunoglobulin capable of specifically binding to the first epitope; and (ii) a heavy chain constant domain of the first immunoglobulin; and wherein the heavy chain variable domain of the first immunoglobulin comprises a sequence selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:9 and SEQ ID NO:13; and / or the light chain variable domain of the first immunoglobulin comprises a sequence selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:29. In certain embodiments, the second immunoglobulin binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCRγ / δ, NKp46, KIR, or a small molecule DOTA hapten.
[0147] In certain embodiments, the immunoglobulin-related composition comprises an IgG1 constant region comprising one or more amino acid substitutions selected from N297A and K322A. Additionally or alternatively, in some embodiments, the immunoglobulin-related composition comprises an IgG4 constant region comprising an S228P mutation.
[0148] In some aspects, the anti-CD33 immunoglobulin-related compositions described herein contain structural modifications to promote rapid binding and cellular uptake and / or slow release. In some aspects, the anti-CD33 immunoglobulin-related compositions (e.g., antibodies) of the present technology may contain deletions in the CH2 constant heavy chain region to promote rapid binding and cellular uptake and / or slow release. In some aspects, Fab fragments are used to promote rapid binding and cellular uptake and / or slow release. In some aspects, F(ab)'2 fragments are used to promote rapid binding and cellular uptake and / or slow release.
[0149] In one aspect, the present technology provides a nucleic acid sequence encoding any immunoglobulin-related composition described herein. Also disclosed herein is a recombinant nucleic acid sequence encoding any antibody described herein. In some embodiments, the nucleic acid sequence is selected from SEQ ID NO: 34, 36, 38, 40, 42, 44, 46, 48, 50 and 52.
[0150] In another aspect, the present technology provides host cells that express any nucleic acid sequence encoding any of the immunoglobulin-related compositions described herein.
[0151] The immunoglobulin-related compositions (e.g., anti-CD33 antibodies) of the present technology can be monospecific, bispecific, trispecific, or have greater multispecificity. Multispecific antibodies can be specific for different epitopes of one or more CD33 polypeptides, or can be specific for both one or more CD33 polypeptides and a heterologous composition (e.g., a heterologous polypeptide or a solid support material). See, e.g., WO 93 / 17715; WO 92 / 08802; WO 91 / 00360; WO 92 / 05793; Tutt et al., J. Immunol. 147: 60-69 (1991); U.S. Pat. Nos. 5,573,920, 4,474,893, 5,601,819, 4,714,681, 4,925,648, 6,106,835; Kostelny et al., J. Immunol. 148: 1547-1553 (1992). In some embodiments, the immunoglobulin-related composition is chimeric. In certain embodiments, the immunoglobulin-related composition is humanized.
[0152] The immunoglobulin-related compositions of the present technology can be further recombinantly fused to a heterologous polypeptide at the N-terminus or C-terminus, or chemically conjugated (including covalent and non-covalent conjugation) to a polypeptide or other composition. For example, the immunoglobulin-related compositions of the present technology can be recombinantly fused or conjugated to molecules and effector molecules (such as heterologous polypeptides, drugs or toxins) that can be used as markers in detection assays. See, for example, WO 92 / 08495; WO 91 / 14438; WO 89 / 12624; U.S. Patent No. 5,314,995; and EP 0 396 387.
[0153] In any of the above embodiments of the immunoglobulin-related compositions of the present technology, the antibody or antigen-binding fragment can be optionally conjugated to an agent selected from the following: an isotope, a dye, a chromogen, a contrast agent, a drug, a toxin, a cytokine, an enzyme, an enzyme inhibitor, a hormone, a hormone antagonist, a growth factor, a radionuclide, a metal, a liposome, a nanoparticle, RNA, DNA, or any combination thereof. For chemical or physical bonds, the functional groups on the immunoglobulin-related compositions are typically associated with the functional groups on the agent. Alternatively, the functional groups on the agent are associated with the functional groups on the immunoglobulin-related compositions.
[0154] Functional groups on the medicament and functional groups on the immunoglobulin-related composition can be directly associated. For example, functional groups on the medicament (e.g., sulfhydryl) can be associated with functional groups on the immunoglobulin-related composition (e.g., sulfhydryl) to form disulfide bonds. Alternatively, the functional groups can be associated through a cross-linking agent (i.e., a linker). Some examples of cross-linking agents are described below. The cross-linking agent can be attached to the medicament or the immunoglobulin-related composition. The number of medicaments or immunoglobulin-related compositions in the conjugate is also limited by the number of functional groups present on the other party. For example, the maximum number of medicaments associated with the conjugate depends on the number of functional groups present on the immunoglobulin-related composition. Alternatively, the maximum number of immunoglobulin-related compositions associated with the medicament depends on the number of functional groups present on the medicament.
[0155] In another embodiment, the conjugate comprises an immunoglobulin-related composition associated with an agent. In one embodiment, the conjugate comprises at least one agent chemically bonded (e.g., conjugated) to at least one immunoglobulin-related composition. The agent can be chemically bonded to the immunoglobulin-related composition by any method known to those skilled in the art. For example, the functional group on the agent can be directly attached to the functional group on the immunoglobulin-related composition. Some examples of suitable functional groups include, for example, amino, carboxyl, sulfhydryl, maleimide, isocyanate, isothiocyanate and hydroxyl.
[0156] The agent may also be chemically bonded to the immunoglobulin-related composition by a cross-linking agent such as a dialdehyde, carbodiimide, dimaleimide, etc. Cross-linking agents may be obtained, for example, from Pierce Biotechnology, Inc. of Rockford, IL. The Pierce Biotechnology, Inc. website may provide assistance. Additional cross-linking agents include the platinum cross-linking agents described in the following patents: U.S. Pat. Nos. 5,580,990; 5,985,566; and 6,133,038 to Kreatech Biotechnology, BV of Amsterdam, The Netherlands.
[0157] Alternatively, the functional groups on the agent and the immunoglobulin-related composition can be the same. Homobifunctional crosslinkers are generally used to crosslink the same functional groups. Examples of homobifunctional crosslinkers include EGS (ie, ethylene glycol bis [succinimidyl succinate]), DSS (ie, disuccinimidyl suberate), DMA (ie, dimethyl adipimidate. 2HCl), DTSSP (ie, 3,3'-dithiobis [sulfosuccinimidyl propionate]), DPDPB (ie, 1,4-bis-[3'-(2'-pyridyldithio)-propionamido] butane) and BMH (ie, bismaleimidohexane). Such homobifunctional crosslinkers can also be obtained from Pierce Biotechnology, Inc.
[0158] In other cases, it may be beneficial to cleave the agent from the immunoglobulin-related composition. The website of Pierce Biotechnology, Inc. can also provide assistance to those skilled in the art in selecting a suitable cross-linking agent, which can be cleaved by, for example, an enzyme in the cell. Thus, the agent can be separated from the immunoglobulin-related composition. Examples of cleavable linkers include SMPT (i.e., 4-succinimidyloxycarbonyl-methyl-a-[2-pyridyldithio]toluene), sulfo-LC-SPDP (i.e., sulfosuccinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), LC-SPDP (i.e., succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), sulfo-LC-SPDP (i.e., sulfosuccinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate), SPDP (i.e., N-succinimidyl 3-[2-pyridyldithio]-propionamidohexanoate), and AEDP (i.e., 3-[(2-aminoethyl)dithio]propionic acid HCl).
[0159] In another embodiment, the conjugate comprises at least one agent physically bound to at least one immunoglobulin-related composition. The agent can be physically bound to the immunoglobulin-related composition by any method known to those skilled in the art. For example, the immunoglobulin-related composition and the agent can be mixed by any method known to those skilled in the art. The order of mixing is not important. For example, the agent can be physically mixed with the immunoglobulin-related composition by any method known to those skilled in the art. For example, the immunoglobulin-related composition and the agent can be placed in a container and stirred by, for example, shaking the container to mix the immunoglobulin-related composition and the agent.
[0160] The immunoglobulin-related compositions can be modified by any method known to those skilled in the art. For example, as described above, the immunoglobulin-related compositions can be modified by cross-linking agents or functional groups.
[0161] A. Methods for preparing anti-CD33 antibodies of the present technology
[0162] Overview. First, a target polypeptide is selected, and antibodies of the present technology against the target polypeptide can be generated. For example, antibodies can be generated against the full-length CD33 protein, the CD33 protein lacking the IgC2 domain, or against a portion of the extracellular domain of the CD33 protein (e.g., the IgV domain). The techniques for generating antibodies against such target polypeptides are well known to those skilled in the art. Examples of such techniques include, but are not limited to, those involving display libraries, heterologous or human mice, hybridomas, and the like. Target polypeptides within the scope of the present technology include any polypeptide derived from the CD33 protein, any polypeptide containing an extracellular domain (e.g., an IgV domain) capable of eliciting an immune response.
[0163] It will be appreciated that recombinantly engineered antibodies and antibody fragments (eg, antibody-related polypeptides) directed against CD33 protein and fragments thereof are suitable for use in accordance with the present disclosure.
[0164] Anti-CD33 antibodies that can be subjected to the techniques described herein include monoclonal antibodies and polyclonal antibodies, as well as antibody fragments, such as Fab, Fab', F(ab')2, Fd, scFv, diabodies, antibody light chains, antibody heavy chains and / or antibody fragments. Methods that can be used to produce high yields of antibody Fv-containing polypeptides such as Fab' and F(ab')2 antibody fragments have been described. See U.S. Patent No. 5,648,237.
[0165] Typically, antibodies are obtained from a species of origin. More specifically, nucleic acid or amino acid sequences of the light chain, heavy chain, or variable portions of both of an antibody of the species of origin that is specific to a target polypeptide antigen are obtained. The species of origin is any species that can be used to generate antibodies or antibody libraries of the present technology, such as rats, mice, rabbits, chickens, monkeys, humans, etc.
[0166] Phage or phagemid display technology is a technology that can be used to derive antibodies of the present technology. The technology used to produce and clone monoclonal antibodies is well known to those skilled in the art. The expression of sequences encoding antibodies of the present technology can be carried out in Escherichia coli.
[0167] Due to the degeneracy of nucleic acid coding sequences, other sequences encoding amino acid sequences that are substantially identical to those of naturally occurring proteins can be used in the practice of the present technology. These sequences include, but are not limited to, nucleic acid sequences including all or part of the nucleic acid sequences encoding the above-mentioned polypeptides, which are altered by substitution of different codons for functionally equivalent amino acid residues within the coding sequence, thereby producing silent changes. It should be understood that the nucleotide sequences of immunoglobulins according to the present technology tolerate up to 25% sequence homology variation as calculated by standard methods ("Current Methods in Sequence Comparison and Analysis," Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp. 127-149, 1998, Alan R. Liss, Inc.), as long as such variants form effective antibodies that recognize CD33 proteins. For example, one or more amino acid residues within a polypeptide sequence can be substituted by another amino acid of similar polarity, which acts as a functional equivalent, thereby resulting in silent changes. Substitutes for amino acids within the sequence can be selected from other members of the class to which the amino acids belong. For example, non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. Positively charged (basic) amino acids include arginine, lysine and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Also included within the scope of the present technology are proteins or fragments or derivatives thereof, which are differentially modified during or after translation, such as by glycosylation, proteolytic cleavage, connection to antibody molecules or other cellular ligands, etc. In addition, the nucleic acid sequence encoding the immunoglobulin can be mutated in vitro or in vivo to generate and / or destroy the translation, initiation and / or termination of the sequence, or to produce variations in the coding region and / or form new restriction endonuclease sites or destroy pre-existing sites to facilitate further in vitro modification. Any mutagenesis technique known in the art may be used, including but not limited to in vitro site-directed mutagenesis (J. Biol. Chem. 253:6551), use of Tab linkers (Pharmacia), and the like.
[0168] Preparation of polyclonal antisera and immunogens. The method of producing antibodies or antibody fragments of the present technology generally comprises immunizing a subject (usually a non-human subject, such as a mouse or rabbit) with a purified CD33 protein or a fragment thereof or with a cell expressing a CD33 protein or a fragment thereof. A suitable immunogenic preparation may contain, for example, a recombinantly expressed CD33 protein or a chemically synthesized CD33 peptide. Using standard techniques for polyclonal and monoclonal antibody preparation, the extracellular domain of the CD33 protein or a portion or fragment thereof (e.g., an IgV domain) can be used as an immunogen to produce anti-CD33 antibodies that bind to the CD33 protein or a portion or fragment thereof.
[0169] The full-length CD33 protein or a fragment thereof can be used as an immunogen as a fragment. In some embodiments, the CD33 fragment comprises the IgV domain of CD33, so that antibodies generated against the peptide form specific immune complexes with CD33 proteins, including CD33 splice variants lacking the IgC2 domain.
[0170] The IgV domain of CD33 is encoded by the second exon of CD33 and is 116 amino acids in length, spanning amino acids 19-135 of the full-length CD33 protein. In some embodiments, the antigenic CD33 peptide comprises at least 5, 8, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100 or 110 amino acid residues. Depending on the use and according to methods well known to those skilled in the art, longer antigenic peptides are sometimes required rather than shorter antigenic peptides. Multimers of a given epitope are sometimes more effective than monomers.
[0171] If desired, the immunogenicity of the CD33 protein (or its fragment) can be increased by fusion or conjugation with a carrier protein, such as keyhole limpet hemocyanin (KLH) or ovalbumin (OVA). Many such carrier proteins are known in the art. The CD33 protein can also be combined with a conventional adjuvant, such as Freund's complete or incomplete adjuvant, to enhance the subject's immune response to the polypeptide. Various adjuvants used to enhance the immune response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surfactants (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants (such as Bacille Calmette-Guerin and Corynebacterium parvum), or similar immunostimulatory compounds. These techniques are standard in the art.
[0172] When describing the present technology, immune responses may be described as "primary" or "secondary" immune responses. A primary immune response (also referred to as a "protective" immune response) refers to an immune response generated in an individual as a result of initial exposure (e.g., initial "immunization") to a specific antigen (e.g., a CD33 protein). In some embodiments, immunization can be performed by vaccinating an individual with a vaccine containing the antigen. For example, the vaccine can be a CD33 vaccine comprising one or more antigens derived from CD33 proteins. Over time, the primary immune response may weaken or diminish, and may even disappear or at least become so diminished that it cannot be detected. Therefore, the present technology also relates to a "secondary" immune response, also referred to herein as a "memory immune response." The term secondary immune response refers to an immune response elicited in an individual after a primary immune response has been generated.
[0173] Thus, a secondary immune response may be elicited, for example, to enhance an existing immune response that has been weakened or attenuated, or to regenerate a previous immune response that has disappeared or can no longer be detected. A secondary or memory immune response may be a humoral (antibody) response or a cellular response. A secondary or memory humoral response occurs following stimulation of memory B cells generated upon initial presentation of an antigen. A delayed type hypersensitivity (DTH) reaction is a CD4 + A type of cellular secondary or memory immune response mediated by T cells. The first exposure to an antigen primes the immune system, and one or more additional exposures result in DTH.
[0174] After appropriate immunization, anti-CD33 antibodies can be prepared from the subject's serum. If necessary, antibody molecules against CD33 protein can be isolated from mammals (eg, from blood) and further purified by well-known techniques such as polypeptide A chromatography to obtain IgG fractions.
[0175] Monoclonal antibodies. In one embodiment of the present technology, the antibody is an anti-CD33 monoclonal antibody. For example, in some embodiments, the anti-CD33 monoclonal antibody can be a human or mouse anti-CD33 monoclonal antibody. In order to prepare monoclonal antibodies against CD33 protein or its derivatives, fragments, analogs or homologs, any technique for producing antibody molecules by continuous cell line culture can be used. Such techniques include, but are not limited to, hybridoma technology (see, for example, Kohler and Milstein, 1975. Nature 256: 495-497); tri-source hybridoma technology; human B cell hybridoma technology (see, for example, Kozbor et al., 1983. Immunol. Today 4: 72) and EBV hybridoma technology to produce human monoclonal antibodies (see, for example, Cole et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pages 77-96). Human monoclonal antibodies can be used in the practice of the present technology, and can be obtained by using human hybridomas (see, for example, Cote et al., 1983. Proc. Natl. Acad. Sci. USA 80: 2026-2030) or by transforming human B cells in vitro with Epstein Barr virus (see, for example, Cole et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). For example, a nucleic acid population encoding an antibody region can be isolated. PCR using primers derived from sequences encoding antibody conserved regions is used to amplify sequences encoding antibody portions from the population, and then DNA encoding antibodies or fragments thereof (such as variable domains) is reconstructed from the amplified sequences. Such amplified sequences can also be fused to DNA encoding other proteins, such as phage coats or bacterial cell surface proteins, to express and display fusion polypeptides on phages or bacteria. The amplified sequence can then be expressed and further selected or isolated based on, for example, the affinity of the expressed antibody or fragment thereof for an antigen or epitope present on the CD33 protein. Alternatively, hybridomas expressing anti-CD33 monoclonal antibodies can be prepared by immunizing a subject and then isolating the hybridoma from the subject's spleen using conventional methods. See, for example, Milstein et al., (Galfre and Milstein, Methods Enzymol (1981) 73: 3-46). Screening of hybridomas using standard methods will produce monoclonal antibodies with different specificities (i.e., to different epitopes) and affinities.The selected monoclonal antibody with the desired properties (e.g., CD33 binding) can be used as expressed by a hybridoma, can be conjugated to molecules such as polyethylene glycol (PEG) to alter its properties, or the cDNA encoding the monoclonal antibody can be isolated, sequenced, and manipulated in various ways. Synthetic dendromeric trees can be added to reactive amino acid side chains such as lysine to enhance the immunogenic properties of the CD33 protein. In addition, CPG-dinucleotide technology can be used to enhance the immunogenic properties of the CD33 protein. Other manipulations include substitution or deletion of specific aminoacyl residues that promote instability of the antibody during storage or after administration to a subject, and affinity maturation techniques to improve the affinity of the antibody for the CD33 protein.
[0176] Hybridoma technology. In some embodiments, the antibody of the present technology is an anti-CD33 monoclonal antibody produced by a hybridoma, wherein the hybridoma includes a B cell obtained from a transgenic non-human animal (e.g., a transgenic mouse) having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell. Hybridoma technology includes those known in the art and taught in the following documents: Harlow et al., Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 349 (1988); Hammerling et al., Monoclonal Antibodies And T-Cell Hybridomas, 563-681 (1981). Other methods for producing hybridomas and monoclonal antibodies are well known to those skilled in the art.
[0177] Phage display technology. As noted above, antibodies of the present technology can be produced by applying recombinant DNA technology and phage display technology. For example, various phage display methods known in the art can be used to prepare anti-CD33 antibodies. In the phage display method, functional antibody domains are displayed on the surface of phage particles, which carry polynucleotide sequences encoding the functional antibody domains. By directly selecting with antigens (usually antigens bound or captured to a solid surface or beads), phages with desired binding properties are selected from a library or combinatorial antibody library (e.g., human or mouse). The phage used in these methods is typically a filamentous phage, including fd and M13 with Fab, Fv or disulfide-stabilized Fv antibody domains, which are recombinantly fused to phage gene III or gene VIII proteins. In addition, the method is suitable for the construction of Fab expression libraries (see, e.g., Huse et al., Science 246: 1275-1281, 1989) to quickly and efficiently identify monoclonal Fab fragments with the desired specificity for a CD33 polypeptide, e.g., a polypeptide or a derivative, fragment, analog or homolog thereof.Other examples of phage display methods that can be used to make antibodies of the present technology include those disclosed in the following references: Huston et al., Proc. Natl. Acad. Sci USA, 85:5879-5883, 1988; Chaudhary et al., Proc. Natl. Acad. Sci USA, 87:1066-1070, 1990; Brinkman et al., J. Immunol. Methods 182:41-50, 1995; Ames et al., J. Immunol. Methods 184:177-186, 1995; Kettleborough et al., Eur. J. Immunol. 24:952-958, 1994; Persic et al., Gene 187:9-18, 1997; Burton et al., Advances in Immunology 57:191-280,1994; PCT / GB91 / 01134; WO 90 / 02809; WO 91 / 10737; WO 92 / 01047; WO 92 / 18619; WO 93 / 11236; WO 95 / 15982; WO 95 / 20401; WO 96 / 06213; WO 92 / 01047 (Medical Research Council et al.); WO 97 / 08320 (Morphosys); WO 92 / 01047 (CAT / MRC); WO 91 / 17271 (Affymax); and U.S. Patent Nos. 5,698,426, 5,223,409, 5,403,484, 5,580,717, 5,427,908, 5,750,753, 5,821,047, 5,571,698, 5,427,908, 5,516,637, 5,780,225, 5,658,727 and 5,733,743. U.S. Patent No. 6,753,136 to Lohning has described a method for displaying polypeptides on the surface of phage particles by attaching the polypeptides via disulfide bonds. As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to produce whole antibodies (including human antibodies) or any other desired antigen-binding fragments and expressed in any desired host (including mammalian cells, insect cells, plant cells, yeast and bacteria).For example, techniques for recombinantly producing Fab, Fab' and F(ab')2 fragments can also be utilized using methods known in the art, such as those disclosed in WO 92 / 22324; Mullinax et al., BioTechniques 12:864-869, 1992; and Sawai et al., AJRI 34:26-34, 1995; and Better et al., Science 240:1041-1043, 1988.
[0178] Typically, hybrid antibodies or hybrid antibody fragments cloned into display vectors can be selected for the appropriate antigen to identify variants that retain good binding activity because the antibody or antibody fragment will be present on the surface of the phage or phagemid particle. See, e.g., Barbas III et al., Phage Display, A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001). However, other vector formats can be used for this process, such as cloning antibody fragment libraries into lytic phage vectors (modified T7 or Lambda Zap systems) for selection and / or screening.
[0179] Expression of recombinant anti-CD33 antibodies. As described above, antibodies of the present technology can be produced by applying recombinant DNA technology. The recombinant polynucleotide construct encoding the anti-CD33 antibodies of the present technology generally includes an expression control sequence operably linked to the coding sequence of the anti-CD33 antibody chain, and the expression control sequence includes a naturally associated or heterologous promoter region. Therefore, another aspect of the present technology includes a vector containing one or more nucleic acid sequences encoding the anti-CD33 antibodies of the present technology. For the recombinant expression of one or more polypeptides of the present technology, a nucleic acid containing all or part of the nucleotide sequence encoding the anti-CD33 antibody is inserted into a suitable cloning vector or expression vector (i.e., a vector containing the necessary elements for transcription and translation of the inserted polypeptide coding sequence) by recombinant DNA technology well known in the art and described in detail below. U.S. Patent Nos. 6,291,160 and 6,680,192 to Lerner et al. have described methods for producing a variety of vector populations.
[0180] In general, expression vectors that can be used in recombinant DNA technology are usually in the form of plasmids. In this disclosure, "plasmid" and "vector" are used interchangeably because plasmids are the most commonly used vector forms. However, the present technology is intended to include such other forms of expression vectors that are not technically plasmids and perform equivalent functions, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses, and adeno-associated viruses). Such viral vectors allow infection of a subject and expression of a construct in the subject. In some embodiments, the expression control sequence is a eukaryotic promoter system in a vector capable of transforming or transfecting a eukaryotic host cell. Once the vector is incorporated into a suitable host, the host is maintained under conditions suitable for high-level expression of nucleotide sequences encoding anti-CD33 antibodies and collection and purification of anti-CD33 antibodies (e.g., cross-reactive anti-CD33 antibodies). See generally US2002 / 0199213. These expression vectors can generally be replicated in a host organism as an episome or as a component of the host chromosomal DNA. Typically, the expression vector contains a selection marker, such as ampicillin resistance or hygromycin resistance, to allow detection of cells transformed with the desired DNA sequence. The vector may also encode a signal peptide that can be used to direct secretion of the extracellular antibody fragment, such as pectin lyase. See U.S. Patent No. 5,576,195.
[0181] The recombinant expression vector of the present technology comprises a nucleic acid encoding a protein having CD33 binding properties, and the recombinant expression vector is in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences selected according to the host cell for expression, and the one or more regulatory sequences are operably connected to the nucleic acid sequence to be expressed. In the recombinant expression vector, "operably connected" is intended to mean that the target nucleotide sequence is connected to one or more regulatory sequences in a manner that allows the nucleotide sequence to be expressed (for example, in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (for example, polyadenylation signals). Such regulatory sequences are described in, for example, the following documents: Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, California (1990). Regulatory sequences include those regulatory sequences that direct constitutive expression of nucleotide sequences in many types of host cells and those regulatory sequences that direct expression of nucleotide sequences only in certain host cells (for example, tissue-specific regulatory sequences). Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the expression level of the desired polypeptide, etc. Typical regulatory sequences that can be used as promoters for expression of recombinant polypeptides (e.g., anti-CD33 antibodies) include, for example, but not limited to, promoters of 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, in particular, promoters from: alcohol dehydrogenase, isocytochrome C, and enzymes responsible for maltose and galactose utilization. In one embodiment, the polynucleotide encoding the anti-CD33 antibody of the present technology is operably linked to the ara B promoter and is expressible in the host cell. See U.S. Patent No. 5,028,530. The expression vector of the present technology can be introduced into a host cell to produce a polypeptide or peptide encoded by the nucleic acid described herein, including a fusion polypeptide (e.g., anti-CD33 antibody, etc.).
[0182] Another aspect of the present technology relates to host cells expressing anti-CD33 antibodies, the host cells containing nucleic acids encoding one or more anti-CD33 antibodies. The recombinant expression vectors of the present technology can be designed to express anti-CD33 antibodies in prokaryotic or eukaryotic cells. For example, anti-CD33 antibodies can be expressed in bacterial cells (such as Escherichia coli), insect cells (using baculovirus expression vectors), fungal cells (e.g., yeast, yeast cells) or mammalian cells. Suitable host cells are further discussed in the following literature: Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, California (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase. Methods that can be used to prepare and screen polypeptides (e.g., anti-CD33 antibodies) with predetermined properties via expression of randomly generated polynucleotide sequences have been previously described. See U.S. Patent Nos. 5,763,192; 5,723,323; 5,814,476; 5,817,483; 5,824,514; 5,976,862; 6,492,107; 6,569,641.
[0183] The expression of polypeptides in prokaryotes is most often carried out in Escherichia coli using vectors containing constitutive or inducible promoters that direct the expression of fusion or non-fusion polypeptides. Fusion vectors add many amino acids to the polypeptide encoded therein, usually to the amino terminus of the recombinant polypeptide. Such fusion vectors usually have three purposes: (i) increase the expression of the recombinant polypeptide; (ii) increase the solubility of the recombinant polypeptide; and (iii) assist in the purification of the recombinant polypeptide by acting as a ligand in affinity purification. Typically, in a fusion expression vector, a proteolytic cleavage site is introduced at the junction of the fusion part and the recombinant polypeptide so that the recombinant polypeptide can be separated from the fusion part after the fusion polypeptide is purified. Such enzymes and their homologous recognition sequences include factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67:31-40), pMAL (New England Biolabs, Beverly, Massachusetts) and pRIT5 (Pharmacia, Piscataway, New Jersey), which fuse glutathione S-transferase (GST), maltose E binding polypeptide or polypeptide A to the target recombinant polypeptide, respectively.
[0184] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS INENZYMOLOGY 185, Academic Press, San Diego, CA (1990) 60-89). Pack et al., U.S. Pat. Nos. 6,294,353; 6,692,935, have described methods for targeted assembly of different active peptides or protein domains via polypeptide fusion to produce multifunctional polypeptides. One strategy for maximizing expression of recombinant polypeptides (e.g., anti-CD33 antibodies) in E. coli is to express the polypeptide in a host bacterium that has an impaired ability to proteolytically cleave the recombinant polypeptide. See, for example, Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, California (1990) 119-128. Another strategy is to change the nucleic acid sequence of the nucleic acid to be inserted into the expression vector so that the individual codons for each amino acid are those codons that are preferentially used in the expression host (e.g., E. coli) (see, for example, Wada et al., 1992. Nucl. Acids Res. 20: 2111-2118). This change in the nucleic acid sequence of the present technology can be performed by standard DNA synthesis techniques.
[0185] In another embodiment, the anti-CD33 antibody expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerevisiae include pYepSec1 (Baldari et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, Cell 30: 933-943, 1982), pJRY88 (Schultz et al., Gene 54: 113-123, 1987), pYES2 (Invitrogen Corporation, San Diego, California) and picZ (Invitrogen Corp, San Diego, California). Alternatively, baculovirus expression vectors can be used to express anti-CD33 antibodies in insect cells. Baculovirus vectors that can be used to express polypeptides (eg, anti-CD33 antibodies) in cultured insect cells (eg, SF9 cells) include the pAc series (Smith et al., Mol. Cell. Biol. 3:2156-2165, 1983) and the pVL series (Lucklow and Summers, 1989. Virology 170:31-39).
[0186] In yet another embodiment, a nucleic acid encoding an anti-CD33 antibody of the present technology is expressed in a mammalian cell using a mammalian expression vector. Examples of mammalian expression vectors include, for example, but not limited to, pCDM8 (Seed, Nature 329: 840, 1987) and pMT2PC (Kaufman et al., EMBO J. 6: 187-195, 1987). When used in mammalian cells, the control function of the expression vector is usually provided by a viral regulatory element. For example, commonly used promoters are derived from polyoma virus, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells that can be used to express the anti-CD33 antibodies of the present technology, see, for example, Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, Chapters 16 and 17.
[0187] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid in a specific cell type (e.g., tissue-specific regulatory elements). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al., Genes Dev. 1: 268-277, 1987), lymphoid-specific promoters (Calame and Eaton, Adv. Immunol. 43: 235-275, 1988), promoters of T cell receptors (Winoto and Baltimore, EMBO J. 8: 729-733, 1989) and immunoglobulins (Banerji et al., 1983. Cell 33: 729-740; Queen and Baltimore, Cell 33: 741-748, 1983.), neuron-specific promoters (e.g., neurofilament promoter; Byrne and Ruddle, Proc. Natl. Acad. Sci. USA 86:5473-5477, 1989), pancreas-specific promoters (Edlund et al., 1985. Science 230:912-916) and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally regulated promoters are also contemplated, such as the mouse hox promoter (Kessel and Gruss, Science 249:374-379, 1990) and the alpha-fetoprotein promoter (Campes and Tilghman, Genes Dev. 3:537-546, 1989).
[0188] Another aspect of the inventive method relates to a host cell into which a recombinant expression vector of the present technology has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It should be understood that such terms refer not only to a specific subject cell, but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in the offspring due to mutations or environmental influences, such progeny may in fact be different from the parental cell, but are still included in the scope of the term as used herein.
[0189] The host cell can be any prokaryotic or eukaryotic cell. For example, anti-CD33 antibodies can be expressed in bacterial cells (such as Escherichia coli), insect cells, yeast or mammalian cells. Mammalian cells are hosts suitable for expressing nucleotide segments encoding immunoglobulins or fragments thereof. See Winnacker, From Genes To Clones, (VCH Publishers, New York, 1987). Many suitable host cell lines capable of secreting complete heterologous proteins have been developed in the art, and the suitable host cell lines include Chinese hamster ovary (CHO) cell lines, various COS cell lines, HeLa cells, L cells and myeloma cell lines. In some embodiments, the cells are non-human. The expression vectors of these cells can include expression control sequences, such as replication origins, promoters, enhancers, and necessary processing information sites, such as ribosome binding sites, RNA splicing sites, polyadenylation sites and transcription terminator sequences. Queen et al., Immunol. Rev. 89: 49, 1986. Illustrative expression control sequences are promoters derived from endogenous genes, cytomegalovirus, SV40, adenovirus, bovine papilloma virus, etc. Co et al., J Immunol. 148: 1149, 1992. Other suitable host cells are known to those skilled in the art.
[0190] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional conversion or transfection techniques. As used herein, the terms "conversion" and "transfection" are intended to refer to various art-recognized techniques for introducing exogenous nucleic acids (e.g., DNA) into host cells, including calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofection, electroporation, gene guns, or transfection based on viruses. Other methods for transforming mammalian cells include using polybrene, protoplast fusion, liposomes, electroporation, and microinjection (generally referring to Sambrook et al., Molecular Cloning). Suitable methods for transforming or transfecting host cells can be found in the following documents: Sambrook et al. (MOLECULAR CLONING: ALABORATORY MANUAL. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989) and other laboratory manuals. Depending on the type of cell host, the vector containing the target DNA segment can be transferred to the host cell by a well-known method.
[0191] For stable transfection of mammalian cells, it is known that only a small portion of cells can integrate foreign DNA into their genomes, depending on the expression vector and transfection technique used. In order to identify and select these integrants, genes encoding selectable markers (e.g., resistance to antibiotics) are usually introduced into host cells together with the target gene. Various selectable markers include those that confer resistance to drugs (such as G418, hygromycin and methotrexate). Nucleic acids encoding selectable markers can be introduced into host cells on the same vector as the vector encoding the anti-CD33 antibody, or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells incorporating the selectable marker gene will survive, while other cells die).
[0192] Host cells (such as prokaryotic or eukaryotic host cells in culture) comprising anti-CD33 antibodies of the present technology can be used to produce (i.e., express) recombinant anti-CD33 antibodies. In one embodiment, the method includes culturing host cells (into which a recombinant expression vector encoding an anti-CD33 antibody has been introduced) in a suitable culture medium, thereby producing anti-CD33 antibodies. In another embodiment, the method also includes the step of isolating the anti-CD33 antibody from the culture medium or the host cell. Once expressed, the anti-CD33 antibody, such as a collection of anti-CD33 antibodies or anti-CD33 antibody-related polypeptides, is purified from the culture medium and the host cell. Anti-CD33 antibodies can be purified according to standard procedures in the art (including HPLC purification, column chromatography, gel electrophoresis, etc.). In one embodiment, anti-CD33 antibodies are produced in a host organism by the method of U.S. Patent No. 4,816,397 of Boss et al. Typically, anti-CD33 antibody chains are expressed together with signal sequences and are thereby released into the culture medium. However, if the anti-CD33 antibody chains are not naturally secreted by the host cells, the anti-CD33 antibody chains can be released by treating with a mild detergent. Purification of recombinant polypeptides is well known in the art and includes ammonium sulfate precipitation, affinity chromatography purification techniques, column chromatography, ion exchange purification techniques, gel electrophoresis, and the like (see generally Scopes, Protein Purification (Springer-Verlag, New York, 1982)).
[0193] Polynucleotides encoding anti-CD33 antibodies, such as the coding sequence of anti-CD33 antibodies, can be incorporated into a transgene for introduction into the genome of a transgenic animal and subsequently expressed in the milk of the transgenic animal. See, for example, U.S. Patent Nos. 5,741,957, 5,304,489, and 5,849,992. Suitable transgenes include light chain and / or heavy chain coding sequences operably linked to promoters and enhancers from mammary gland-specific genes, such as casein or beta-lactoglobulin. For the production of transgenic animals, the transgene can be microinjected into fertilized oocytes, or the transgene can be incorporated into the genome of embryonic stem cells and the nuclei of such cells transferred into enucleated oocytes.
[0194] Single-chain antibody. In one embodiment, the anti-CD33 antibody of the present technology is a single-chain anti-CD33 antibody. According to the present technology, the technology can be suitable for producing single-chain antibodies specific for CD33 protein (see, for example, U.S. Patent No. 4,946,778). Examples of technologies that can be used to produce single-chain Fvs and antibodies of the present technology include those described in the following documents: U.S. Patent Nos. 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology, 203: 46-88, 1991; Shu, L. et al., Proc. Natl. Acad. Sci. USA, 90: 7995-7999, 1993; and Skerra et al., Science 240: 1038-1040, 1988.
[0195] Chimeric and humanized antibodies. In one embodiment, the anti-CD33 antibody of the present technology is a chimeric anti-CD33 antibody. In one embodiment, the anti-CD33 antibody of the present technology is a humanized anti-CD33 antibody. In one embodiment of the present technology, the donor antibody and the recipient antibody are monoclonal antibodies from different species. For example, the recipient antibody is a human antibody (to minimize its antigenicity in humans), in which case the resulting CDR-grafted antibody is referred to as a "humanized" antibody.
[0196] Recombinant anti-CD33 antibodies (such as chimeric monoclonal antibodies and humanized monoclonal antibodies) comprising human and non-human portions can be prepared using standard recombinant DNA techniques and are within the scope of the present technology. For certain uses, including in vivo uses of the anti-CD33 antibodies of the present technology in humans and uses of these agents in in vitro detection assays, chimeric or humanized anti-CD33 antibodies can be used. Such chimeric monoclonal antibodies and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art. Such useful methods include, for example, but are not limited to, those described in International Application No. PCT / US86 / 02269; U.S. Pat. No. 5,225,539; European Patent No. 184187; European Patent No. 171496; European Patent No. 173494; PCT International Publication No. WO 86 / 01533; U.S. Pat. Nos. 4,816,567; 5,225,539; European Patent No. 125023; Better et al., 1988. Science 240:1041-1043; Liu et al., 1987. Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al., 1987. J. Immunol. 139:3521-3526; Sun et al., 1987. Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al., 1987. Cancer Res. 47:999-1005; Wood et al., 1985. Nature 314:446-449; Shaw et al., 1988. J. Natl. Cancer Inst. 80:1553-1559; Morrison (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214; Jones et al., 1986. Nature 321:552-525; Verhoeyan et al., 1988. Science 239:1534; Morrison, Science 229:1202, 1985; Oi et al., BioTechniques 4:214, 1986; Gillies et al., J. Immunol. Methods, 125:191-202, 1989; U.S. Patent No. 5,807,715; and Beidler et al., 1988. J. Immunol. 141:4053-4060.For example, antibodies can be humanized using a variety of techniques including CDR grafting (EP 0 239 400; WO 91 / 09967; U.S. Pat. Nos. 5,530,101; 5,585,089; 5,859,205; 6,248,516; EP 460 167), veneering or resurfacing (EP 0 592 106; EP 0 519 596; Padlan EA, Molecular Immunology, 28:489-498, 1991; Studnicka et al., Protein Engineering 7:805-814, 1994; Roguska et al., PNAS 91:969-973, 1994), and chain shuffling (U.S. Pat. No. 5,565,332). In one embodiment, the cDNA encoding the murine anti-CD33 monoclonal antibody is digested with a specifically selected restriction endonuclease to remove the sequence encoding the Fc constant region and replace it with the equivalent portion of the cDNA encoding the human Fc constant region (see Robinson et al., PCT / US86 / 02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., WO 86 / 01533; Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J Immunol 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Cancer Res 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559; U.S. Pat. No. 6,180,370; U.S. Pat. Nos. 6,300,064; 6,696,248; 6,706,484; 6,828,422.
[0197] In one embodiment, the present technology provides the construction of humanized anti-CD33 antibodies that are less likely to induce a human anti-mouse antibody (hereinafter referred to as "HAMA") response while still having effective antibody effector function. As used herein, the terms "human" and "humanized" with respect to antibodies refer to any antibody that is expected to elicit a weak immunogenic response that is therapeutically tolerable in a human subject. In one embodiment, the present technology provides humanized anti-CD33 antibodies, heavy chain and light chain immunoglobulins.
[0198] CDR antibodies. In some embodiments, the anti-CD33 antibodies of the present technology are anti-CD33 CDR antibodies. Typically, the donor and recipient antibodies used to generate anti-CD33 CDR antibodies are monoclonal antibodies from different species; typically, the recipient antibody is a human antibody (to minimize its antigenicity in humans), in which case the resulting CDR-grafted antibody is called a "humanized" antibody. The graft may have a single V of the recipient antibody. H or V L A single CDR (or even a portion of a single CDR) within a H and V L In general, all three CDRs in all variable domains of the recipient antibody will be replaced by the corresponding donor CDRs, but only the required number needs to be replaced so that the resulting CDR-grafted antibody fully binds to the CD33 protein. Methods for producing CDR-grafted and humanized antibodies are taught in the following patents: U.S. Pat. No. 5,585,089 to Queen et al.; U.S. Pat. No. 5,693,761; U.S. Pat. No. 5,693,762; and U.S. Pat. No. 5,225,539 to Winter; and EP 0682040. It can be used to prepare V H and V L Polypeptide methods are taught in the following patents: Winter et al., US Patent Nos. 4,816,397; 6,291,158; 6,291,159; 6,291,161; 6,545,142; EP0368684; EP0451216; and EP0120694.
[0199] After selecting suitable framework region candidates from the same family and / or same family member, one or both of the heavy chain and light chain variable regions are produced by transplanting the CDR from the species of origin into the hybrid framework region. Conventional methods known to those skilled in the art can be used to complete the assembly of hybrid antibodies or hybrid antibody fragments with hybrid variable chain regions in any of the above aspects. For example, DNA sequences encoding hybrid variable domains as described herein (i.e., frameworks based on target species and CDRs from species of origin) can be produced by oligonucleotide synthesis and / or PCR. Suitable restriction enzymes can also be used to separate the nucleic acids encoding CDR regions from species of origin antibodies, and connected to the target species framework by connecting with suitable ligases. Alternatively, the framework regions of the variable chains of species of origin antibodies can be changed by site-directed mutagenesis.
[0200] Since hybrids are constructed from selections between multiple candidates corresponding to each framework region, there are many sequence combinations suitable for construction according to the principles described herein. Thus, libraries of hybrids can be assembled whose members have different combinations of individual framework regions. Such libraries can be electronic database collections of sequences or physical collections of hybrids.
[0201] This process does not usually change the FRs of the recipient antibody flanking the transplanted CDRs. However, one skilled in the art can sometimes improve the antigen binding affinity of the resulting anti-CD33 CDR-grafted antibody by replacing certain residues of a given FR to make the FR more similar to the corresponding FR of the donor antibody. Suitable substitution positions include amino acid residues adjacent to the CDR, or amino acid residues that can interact with the CDR (see, e.g., US 5,585,089, especially columns 12-16). Alternatively, one skilled in the art can start with the donor FR and modify it to make it more similar to the recipient FR or human consensus FR. Techniques for making these modifications are known in the art. In particular, if the resulting FR conforms to the human consensus FR at that position or is at least 90% or more identical to such a consensus FR, doing so may not significantly increase the antigenicity of the resulting modified anti-CD33 CDR-grafted antibody compared to the same antibody with fully human FRs.
[0202] Bispecific antibodies (BsAb). Bispecific antibodies are antibodies that can simultaneously bind to two targets with different structures (e.g., two different target antigens, two different epitopes on the same target antigen, or a hapten and a target antigen or an epitope on a target antigen). BsAb can be prepared, for example, by combining heavy chains and / or light chains that recognize different epitopes of the same or different antigens. In some embodiments, through molecular function, a bispecific binder binds to one antigen (or epitope) on one of its two binding arms (a VH / VL pair) and binds to a different antigen (or epitope) on its second arm (a different VH / VL pair). According to this definition, a bispecific binder has two different antigen binding arms (both specificity and CDR sequences are different) and is monovalent for each antigen it binds.
[0203] The bispecific antibodies (BsAb) and bispecific antibody fragments (BsFab) of the present technology have at least one arm specifically bound to, for example, CD33 and at least one other arm specifically bound to a second target antigen. In some embodiments, the second target antigen is an antigen or epitope of a B cell, a T cell, a myeloid cell, a plasma cell, or a mast cell. Additionally or alternatively, in certain embodiments, the second target antigen is selected from CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCRγ / δ, NKp46, and KIR. In certain embodiments, BsAb can bind to tumor cells expressing CD33 antigens on the cell surface. In some embodiments, BsAb has been engineered to promote killing of tumor cells by guiding (or recruiting) cytotoxic T cells to the tumor site. Other exemplary BsAbs include those having a first antigen binding site specific for CD33 and a second antigen binding site specific for a small molecule hapten (e.g., DTP A, IMP288, DOTA, DOTA-Bn, DOTA-deferoxamine, other DOTA chelates described herein, biotin, fluorescein, or those disclosed in Goodwin, D A. et al., 1994, Cancer Res. 54(22):5937-5946).
[0204] A variety of bispecific fusion proteins can be produced using molecular engineering. For example, BsAb utilizing complete immunoglobulin framework (e.g., IgG), single-chain variable fragment (scFv) or its combination has been constructed. In some embodiments, bispecific fusion protein is bivalent, and it includes, for example, scFv with a single binding site for a kind of antigen and a Fab fragment with a single binding site for a second antigen. In some embodiments, bispecific fusion protein is bivalent, and it includes, for example, scFv with a single binding site for a kind of antigen and another scFv fragment with a single binding site for a second antigen. In other embodiments, bispecific fusion protein is tetravalent, and it includes, for example, an immunoglobulin (e.g., IgG) with two binding sites for a kind of antigen and two identical scFv for a second antigen. It has been shown that the BsAb consisting of two scFv units in series is a clinically successful bispecific antibody form. In some embodiments, the BsAb comprises two single-chain variable fragments (scFv) in series, which are designed so that the scFv that binds to a tumor antigen (e.g., CD33) is connected to the scFv that engages T cells (e.g., by binding to CD3). In this way, T cells are recruited to the tumor site so that they can mediate cytotoxic killing of tumor cells. See, for example, Dreier et al., J. Immunol. 170: 4397-4402 (2003); Bargou et al., Science 321: 974-977 (2008). In some embodiments, the BsAb of the present technology comprises two single-chain variable fragments (scFv) in series, which are designed so that the scFv that binds to a tumor antigen (e.g., CD33) is connected to the scFv that engages the small molecule DOTA hapten.
[0205] The latest methods for producing BsAbs include engineered recombinant monoclonal antibodies with additional cysteine residues that make them more firmly cross-linked than more common immunoglobulin isotypes. See, for example, FitzGerald et al., Protein Eng. 10 (10): 1221-1225 (1997). Another method is an engineered recombinant fusion protein that connects two or more different single-chain antibodies or antibody fragment segments with the desired dual specificity. See, for example, Coloma et al., Nature Biotech. 15: 159-163 (1997). A variety of bispecific fusion proteins can be produced using molecular engineering.
[0206] Bispecific fusion proteins connecting two or more different single-chain antibodies or antibody fragments are produced in a similar manner. Recombinant methods can be used to produce a variety of fusion proteins. In some specific embodiments, the BsAb according to the present technology comprises an immunoglobulin containing a heavy chain and a light chain and an scFv. In some specific embodiments, the scFv is connected to the C-terminus of the heavy chain of any CD33 immunoglobulin disclosed herein. In some specific embodiments, the scFv is connected to the C-terminus of the light chain of any CD33 immunoglobulin disclosed herein. In various embodiments, the scFv is connected to the heavy chain or light chain via a linker sequence. By PCR reaction, the appropriate linker sequence necessary for in-frame connection of the heavy chain Fd with the scFv is introduced into the V L and V κ The DNA fragment encoding the scFv was then ligated into a staging vector containing a DNA sequence encoding the CH1 domain. The resulting scFv-CH1 construct was excised and ligated to a V vector containing a DNA sequence encoding the CD33 antibody. H The obtained vector can be used to transfect appropriate host cells, such as mammalian cells, to express the bispecific fusion protein.
[0207] In some embodiments, the linker length is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids. In some embodiments, the linker is characterized in that it tends not to adopt a rigid three-dimensional structure, but to provide flexibility (e.g., the first and / or second antigen binding site) for the polypeptide. In some embodiments, based on the specific characteristics conferred on the BsAb, such as increased stability, a linker is used in the BsAb described herein. In some embodiments, the BsAb of the present technology comprises a G4S linker. In some specific embodiments, the BsAb of the present technology comprises (G4S) n A linker wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more.
[0208] Self-assembly decomposition (SADA) conjugate. In some embodiments, the anti-CD33 antibody of the present technology includes one or more SADA domains. The SADA domain can be designed and / or customized to achieve environmentally dependent multimerization with beneficial kinetics, thermodynamics and / or pharmacological properties. For example, it should be recognized that the SADA domain can be a part of the conjugate, which allows the effective delivery of the payload to the target site of interest while minimizing the risk of off-target interactions. The anti-CD33 antibody of the present technology may include a SADA domain connected to one or more binding domains. In some embodiments, such conjugates are characterized in that they are under relevant conditions (e.g., in a solution present in the case where the conjugate is higher than a threshold concentration or pH and / or when present at a target site characterized by the relevant level or density of the receptor of the payload) multimerize to form a complex of desired size, and decompose into smaller forms under other conditions (e.g., in the absence of relevant environmental multimerization triggers).
[0209] Compared with the conjugate without SADA domain, SADA conjugate can have improved characteristics. In some embodiments, the improved properties of polymer conjugates include: increased affinity / combination to target, increased specificity to target cells or tissues and / or extended initial serum half-life. In some embodiments, improved properties include becoming a smaller state (e.g., dimer or monomer) by dissociation, and SADA conjugates show reduced non-specific binding, reduced toxicity and / or improved renal clearance. In some embodiments, SADA conjugates include SADA polypeptides, and the SADA polypeptides have an amino acid sequence with a homologous multimerized polypeptide of the human body showing at least 75% identity and characterized by one or more polymer dissociation constants (K D )'s amino acid sequence.
[0210] In some embodiments, the SADA conjugate is constructed and arranged so that it adopts a first multimerization state and one or more higher-order multimerization states. In some embodiments, the size of the first multimerization state is less than about 70kDa. In some embodiments, the first multimerization state is a non-multimerization state (e.g., a monomer or dimer). In some embodiments, the first multimerization state is a monomer. In some embodiments, the first multimerization state is a dimer. In some embodiments, the first multimerization state is a multimerization state (e.g., a trimer or a tetramer). In some embodiments, a high-order multimerization state is a homotetramer or a higher-order homomultimer having a size greater than 150kDa. In some embodiments, when the conjugate is at a size higher than the SADA polypeptide K D In some embodiments, when the concentration of the conjugate is lower than the concentration of the SADA polypeptide K DWhen the SADA conjugate is activated, it switches from one or more higher-order multimerization states to the first multimerization state under physiological conditions.
[0211] In some embodiments, the SADA polypeptide is covalently linked to the binding domain via a joint. Any suitable joint known in the art can be used. In some embodiments, the SADA polypeptide is connected to the binding domain via a polypeptide joint. In some embodiments, the polypeptide joint is a Gly-Ser joint. In some embodiments, the polypeptide joint is or comprises a sequence of (GGGGS)n, wherein n represents the number of repeated GGGGS units and is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more. In some embodiments, the binding domain is directly fused to the SADA polypeptide.
[0212] In some embodiments, the SADA domain is a human polypeptide or a fragment and / or derivative thereof. In some embodiments, the SADA domain is substantially non-immunogenic in humans. In some embodiments, the SADA polypeptide is stable as a polymer. In some embodiments, the SADA polypeptide lacks unpaired cysteine residues. In some embodiments, the SADA polypeptide does not have a large exposed hydrophobic surface. In some embodiments, the SADA domain has or is predicted to have a structure comprising a helical bundle, which can be associated in a parallel or antiparallel orientation. In some embodiments, the SADA polypeptide can reverse multimerization. In some embodiments, the SADA domain is a tetramerization domain, a heptamerization domain, a hexamerization domain or an octamerization domain. In certain embodiments, the SADA domain is a tetramerization domain. In some embodiments, the SADA domain is composed of a multimerization domain, each of which is composed of a helical bundle associated in a parallel or antiparallel orientation. In some embodiments, the SADA domain is selected from one of the following human proteins: p53, p63, p73, heterogeneous nuclear ribonucleoprotein C (hnRNPC), N-terminal domain of synaptosome-associated protein 23 (SNAP-23), Stefin B (cystatin B), potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) or cyclin D-associated protein (CBFA2T1). Examples of suitable SADA domains are described in PCT / US2018 / 031235, which is incorporated herein by reference in its entirety. The polypeptide sequences of exemplary SADA domains are provided below.
[0213] Human p53 tetramerization domain amino acid sequence (321-359)
[0214] KPLDGEYFTLQIRGRERRFEMFRELNEALELKDAQAGKEP(SEQ ID NO:142)
[0215] Human p63 tetramerization domain amino acid sequence (396-450)
[0216] RSPDDELLYLPVRGRETYEMLLKIKESLELMQYLPQHTIETYRQQQQQQHQHLLQKQ(SEQ ID NO:143)
[0217] Human p73 tetramerization domain amino acid sequence (348-399)
[0218] RHGDEDTYYLQVRGRENFEILMKLKESLELMELVPQPLVDSYRQQQQLLQRP (SEQ ID NO: 144).
[0219] Human HNRNPC tetramerization domain amino acid sequence (194-220)
[0220] QAIKKELTQIKQKVDSLLENLEKIEKE(SEQ ID NO:145)
[0221] Human SNAP-23 tetramerization domain amino acid sequence (23-76)
[0222] STRRILGLAIESQDAGIKTITMLDEQKEQLNRIEEGLDQINKDMRETEKTLTEL(SEQ ID NO:146)
[0223] Human Stefin B tetramerization domain amino acid sequence (2-98)
[0224] MCGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAGTNYFIKVH VGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF(SEQ ID NO:147)
[0225] KCNQ4 tetramerization domain amino acid sequence (611-640)
[0226] DEISMMGRVVKVEKQVQSIEHKLDLLLGFY(SEQ ID NO:148)
[0227] CBFA2T1 tetramerization domain amino acid sequence (462-521)
[0228] TVAEAKRQAAEDALAVINQQEDSSESCWNCGRKASETCSGCNTARYCGSFCQHKDW EKHH(SEQ IDNO:149)
[0229] In some embodiments, the SADA polypeptide is or comprises the tetramerization domain of p53, p63, p73, heterogeneous ribonucleoprotein C (hnRNPC), N-terminal domain of synaptosome-associated protein 23 (SNAP-23), Stefin B (cystatin B), voltage-gated potassium channel subfamily KQT member 4 (KCNQ4) or cyclin D-associated protein (CBFA2T1). In some embodiments, the SADA polypeptide is or comprises a sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in any one of SEQ ID NOs: 142-149.
[0230] Fc modification. In some embodiments, the anti-CD33 antibody of the present technology comprises a variant Fc region, wherein the variant Fc region comprises at least one amino acid modification relative to the wild-type Fc region (or parent Fc region), such that the affinity of the molecule for an Fc receptor (e.g., FcγR) is altered, provided that the variant Fc region is not substituted at a position that directly contacts the Fc receptor based on crystallographic and structural analyses of Fc-Fc receptor interactions (such as those disclosed by Sondermann et al., Nature, 406:267-273 (2000)). Examples of positions in the Fc region that directly contact an Fc receptor (such as FcγR) include amino acids 234-239 (hinge region), amino acids 265-269 (B / C loop), amino acids 297-299 (C7E loop), and amino acids 327-332 (F / G) loop.
[0231] In some embodiments, the anti-CD33 antibodies of the present technology have altered affinity for activating and / or inhibitory receptors, wherein the variant Fc region has one or more amino acid modifications, wherein the one or more amino acid modifications are substitution of N297 to alanine or substitution of K322 to alanine.
[0232] Glycosylation modification. In some embodiments, the anti-CD33 antibodies of the present technology have an Fc region that contains variant glycosylation compared to a parent Fc region. In some embodiments, the variant glycosylation includes the absence of fucose; in some embodiments, the variant glycosylation is due to expression in GnT1-deficient CHO cells.
[0233] In some embodiments, the antibodies of the present technology may have modified glycosylation sites relative to an appropriate reference antibody that binds to an antigen of interest (e.g., CD33) without altering the functionality of the antibody, such as binding activity to the antigen. As used herein, "glycosylation site" includes any specific amino acid sequence in an antibody to which an oligosaccharide (i.e., a carbohydrate containing two or more monosaccharides linked together) will be specifically and covalently attached.
[0234] Oligosaccharide side chains are usually connected to the backbone of the antibody via N-linked or O-linked. N-linked glycosylation refers to the attachment of the oligosaccharide moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of the oligosaccharide moiety to a hydroxyamino acid, such as serine, threonine. For example, an Fc-glycoform (hCD33-IgGln) lacking certain oligosaccharides (including fucose) and terminal N-acetylglucosamine can be produced in special CHO cells and exhibits enhanced ADCC effector function.
[0235] In some embodiments, the carbohydrate content of the immunoglobulin-related compositions disclosed herein is modified by adding or deleting glycosylation sites. Methods for modifying the carbohydrate content of antibodies are well known in the art and are included in the present technology, see, for example, U.S. Patent No. 6,218,149; EP 0359096B1; U.S. Patent Publication No. US 2002 / 0028486; International Patent Application Publication WO 03 / 035835; U.S. Patent Publication No. 2003 / 0115614; U.S. Patent No. 6,218,149; U.S. Patent No. 6,472,511; The above patents are all incorporated herein by reference in their entirety. In some embodiments, the carbohydrate content of an antibody (or its related part or component) is modified by deleting one or more endogenous carbohydrate parts of the antibody. In some specific embodiments, the present technology includes deleting the glycosylation site of the Fc region of the antibody by modifying the asparagine at position 297 to alanine.
[0236] Engineered glycoforms can be used for a variety of purposes, including but not limited to enhancing or reducing effector function. Engineered glycoforms can be produced by any method known to those skilled in the art, such as by using engineered or variant expression strains, by co-expression with one or more enzymes (e.g., N-acetylglucosamine transferase III (GnTIII)), by expressing molecules comprising Fc regions in various organisms or cell lines from various organisms, or by modifying one or more carbohydrates after molecules comprising Fc regions have been expressed. Methods for generating engineered glycoforms are known in the art and include, but are not limited to, those described in Umana et al., 1999, Nat. Biotechnol. 17:176-180; Davies et al., 2001, Biotechnol. Bioeng. 74:288-294; Shields et al., 2002, J. Biol. Chem. 277:26733-26740; Shinkawa et al., 2003, J. Biol. Chem. 278:3466-3473; U.S. Patent No. 6,602,684; U.S. Patent Application Serial No. 10 / 277,370; U.S. Patent Application Serial No. 10 / 113,929; International Patent Application Publication Nos. WO 00 / 61739A1; WO 01 / 292246A1; WO 02 / 311140A1; WO 02 / 30954A1; POTILLEGENT TM Technology (Biowa, Inc., Princeton, NJ); GLYCOMAB TM Glycosylation engineering technology (GLYCART biotechnology AG, Zurich, Switzerland); each of which is incorporated herein by reference in its entirety. See, e.g., International Patent Application Publication No. WO 00 / 061739; U.S. Patent Application Publication No. 2003 / 0115614; Okazaki et al., 2004, JMB, 336: 1239-49.
[0237] Fusion protein. In one embodiment, the anti-CD33 antibody of the present technology is a fusion protein. When fused with a second protein, the anti-CD33 antibody of the present technology can be used as an antigen tag. Examples of domains that can be fused to a polypeptide include not only heterologous signal sequences, but also other heterologous functional regions. Fusion is not necessarily direct, but can be performed through a linker sequence. Moreover, the fusion protein of the present technology can also be engineered to improve the characteristics of the anti-CD33 antibody. For example, a region of additional amino acids (particularly charged amino acids) can be added to the N-terminus of the anti-CD33 antibody to improve stability and durability during purification from host cells or subsequent processing and storage. In addition, a peptide portion can be added to the anti-CD33 antibody to facilitate purification. Such regions can be removed before the final preparation of the anti-CD33 antibody. Adding a peptide portion to facilitate the processing of a polypeptide is a conventional technique well known in the art. The anti-CD33 antibody of the present technology can be fused with a marker sequence (such as a peptide that promotes the purification of a fusion polypeptide). In selected embodiments, the marker amino acid sequence is a hexa-histidine peptide, particularly as provided in the pQE vector (QIAGEN, Inc., Chatsworth, Calif.), many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824, 1989, for example, hexa-histidine allows for convenient purification of the fusion protein. Another peptide tag that can be used for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. Wilson et al., Cell 37:767, 1984.
[0238] Thus, any of these above-described fusion proteins can be engineered using the polynucleotides or polypeptides of the present technology.Additionally, in some embodiments, the fusion proteins described herein exhibit increased half-life in vivo.
[0239] Fusion proteins with a disulfide-linked dimeric structure (due to IgG) can bind and neutralize other molecules more efficiently than individual monomeric secreted proteins or protein fragments. Fountoulakis et al., J. Biochem. 270:3958-3964, 1995.
[0240] Similarly, EP-AO 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various parts of the constant region of an immunoglobulin molecule and another human protein or a fragment thereof. In many cases, the Fc portion in the fusion protein is beneficial in therapy and diagnosis, and can therefore lead to, for example, improved pharmacokinetic properties. See EP-A 0232262. Alternatively, it may be necessary to delete or modify the Fc portion after expression, detection and purification of the fusion protein. For example, if the fusion protein is used as an antigen for immunization, the Fc portion may hinder therapy and diagnosis. In drug discovery, for example, human proteins (such as hIL-5) have been fused to the Fc portion for the purpose of high-throughput screening assays to identify antagonists of hIL-5. Bennett et al., J.Molecular Recognition 8:52-58, 1995; Johanson et al., J.Biol.Chem., 270:9459-9471, 1995.
[0241] Labeled anti-CD33 antibodies. In one embodiment, the anti-CD33 antibodies of the present technology are coupled to a labeling moiety, i.e., a detectable group. The specific label or detectable group conjugated to the anti-CD33 antibody is not a key aspect of the present technology, as long as it does not significantly interfere with the specific binding of the anti-CD33 antibody of the present technology to the CD33 protein. The detectable group can be any material with detectable physical or chemical properties. Such detectable labels have been well developed in the fields of immunoassays and imaging. In general, almost any label that can be used in such methods can be applied to the present technology. Therefore, a label is any composition that can be detected by spectral, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the practice of the present technology include magnetic beads (e.g., Dynabeads TM ), fluorescent dyes (e.g., fluorescein isothiocyanate, Texas Red, rhodamine, etc.), radioactive labels (e.g., 3 H. 14 C. 35 S. 125 I. 121 I. 131 I. 112 In, 99 mTc), other imaging agents such as microbubbles (for ultrasound imaging), 18 F. 11 C. 15 O (for positron emission tomography), 99m TC, 111In (for single photon emission tomography), enzymes (e.g., horseradish peroxidase, alkaline phosphatase, and other enzymes commonly used in ELISA), and calorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. Patents describing the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241, each of which is incorporated herein by reference in its entirety and for all purposes. See also Handbook of Fluorescent Probes and Research Chemicals (6th Edition, Molecular Probes, Inc., Eugene, Oregon).
[0242] The label can be coupled directly or indirectly to the desired component of the assay according to methods well known in the art. As described above, a variety of labels can be used, and the choice of label depends on factors such as the sensitivity required, ease of conjugation to the compound, stability requirements, available instrumentation, and disposal regulations.
[0243] Non-radioactive labels are usually attached by indirect means. Typically, a ligand molecule (e.g., biotin) is covalently bound to a molecule. The ligand is then bound to an anti-ligand (e.g., streptavidin) molecule, which is inherently detectable or covalently bound to a signaling system such as a detectable enzyme, fluorescent compound, or chemiluminescent compound. Many ligands and anti-ligands can be used. In the case where a ligand (e.g., biotin, thyroxine, and cortisol) has a natural anti-ligand, the ligand can be used in combination with a labeled naturally occurring anti-ligand. Alternatively, any hapten or antigenic compound can be used in combination with an antibody such as an anti-CD33 antibody.
[0244] The molecule can also be directly conjugated to the compound that produces the signal, for example, by conjugating with an enzyme or a fluorophore. The target enzyme as a label will mainly be a hydrolase, particularly a phosphatase, an esterase and a glycosidase, or an oxidoreductase, particularly a peroxidase. Fluorescent compounds that can be used as labeling parts include, but are not limited to, for example, fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, etc. Chemiluminescent compounds that can be used as labeling parts include, but are not limited to, for example, fluorescein and 2,3-dihydrophthalazinediones, such as luminol. For a review of various labels or signal generating systems that can be used, see U.S. Patent No. 4,391,904.
[0245] The means of detecting the label is well known to those skilled in the art. Therefore, for example, when the label is a radioactive label, the detection means includes a scintillation counter or film, such as in autoradiography. When the label is a fluorescent label, it can be detected by exciting the fluorescent dye with the light of the appropriate wavelength and detecting the fluorescence produced. Fluorescence can be detected in a visual form, by film, by using an electronic detector such as a charge coupled device (CCD) or a photomultiplier tube, etc. Similarly, enzyme labels can be detected by providing a suitable substrate for the enzyme and detecting the resulting reaction product. Finally, simple colorimetric labels can be detected simply by observing the color associated with the label. Therefore, in various dip-dye rod assays, the conjugated gold is often pink, and the various conjugated beads present the color of beads.
[0246] Some assay formats do not require the use of labeled components. For example, an agglutination assay can be used to detect the presence of a target antibody, such as an anti-CD33 antibody. In this case, antigen-coated particles are agglutinated by a sample containing the target antibody. In this format, no components need to be labeled, and the presence of the target antibody is detected by simple visual inspection.
[0247] B. Identification and Characterization of Anti-CD33 Antibodies of the Present Technology
[0248] Methods for identifying and / or screening anti-CD33 antibodies of the present technology. Methods for identifying and screening antibodies against CD33 polypeptides for those antibodies with the desired specificity for CD33 protein (e.g., those antibodies that bind to the IgV domain of CD33) include any immune-mediated techniques known in the art. Components of the immune response can be detected in vitro by various methods well known to those of ordinary skill in the art. For example, (1) cytotoxic T lymphocytes can be incubated with radiolabeled target cells and the lysis of these target cells detected by the release of radioactivity; (2) helper T lymphocytes can be incubated with antigen and antigen-presenting cells, and cytokine synthesis and secretion measured by standard methods (Windhagen A et al., Immunity, 2:373-80, 1995); (3) antigen-presenting cells can be incubated with whole protein antigen and the presentation of the antigen on MHC detected by T lymphocyte activation assay or biophysical methods (Harding et al., Proc. Natl. Acad. Sci., 86:4230-4, 1989); (4) mast cells can be incubated with agents that cross-link their Fc-ε receptors and histamine release measured by enzyme immunoassay (Siraganian et al., TIPS, 4:432-437, 1983); and (5) enzyme-linked immunosorbent assay (ELISA).
[0249] Similarly, the products of immune responses in model organisms (e.g., mice) or human subjects can also be detected by various methods well known to those of ordinary skill in the art. For example, (1) the production of antibodies in response to vaccination can be easily detected by standard methods currently used in clinical laboratories, such as ELISA; (2) the migration of immune cells to the site of inflammation can be detected by scratching the skin surface and placing a sterile container to capture the migrating cells at the scratch site (Peters et al., Blood, 72:1310-5, 1988); (3) the use of 3 H-thymidine measures the proliferation of peripheral blood mononuclear cells (PBMCs) in response to mitogens or mixed lymphocyte reactions; (4) the phagocytic capacity of granulocytes, macrophages, and other phagocytes in PBMCs can be measured by placing PBMCs in wells with labeled particles (Peters et al., Blood, 72:1310-5, 1988); and (5) the differentiation of immune system cells can be measured by labeling PBMCs with antibodies to CD molecules (such as CD4 and CD8) and measuring the fraction of PBMCs expressing these markers.
[0250] In one embodiment, the display of CD33 peptides on the surface of replicable genetic packages is used to select anti-CD33 antibodies of the present technology. See, e.g., U.S. Patent Nos. 5,514,548; 5,837,500; 5,871,907; 5,885,793; 5,969,108; 6,225,447; 6,291,650; 6,492,160; EP 585 287; EP 605522; EP 616640; EP1024191; EP 589 877; EP 774 511; EP 844 306. Methods useful for producing / selecting filamentous phage particles containing a phagemid genome encoding a binding molecule with a desired specificity have been described. See, for example, EP 774 511; US 5871907; US 5969108; US 6225447; US 6291650; US 6492160.
[0251] In some embodiments, anti-CD33 antibodies of the present technology are selected using display of CD33 peptides on the surface of yeast host cells. Methods that can be used to isolate scFv polypeptides by display on the surface of yeast have been described by Kieke et al., Protein Eng. 1997 Nov; 10(11): 1303-10.
[0252] In some embodiments, anti-CD33 antibodies of the present technology are selected using ribosome display. Methods that can be used to identify ligands in peptide libraries using ribosome display have been described by Mattheakis et al., Proc. Natl. Acad. Sci. USA 91:9022-26, 1994; and Hanes et al., Proc. Natl. Acad. Sci. USA 94:4937-42, 1997.
[0253] In certain embodiments, tRNA display of CD33 peptides is used to select anti-CD33 antibodies of the present technology. Methods that can be used for in vitro selection of ligands using tRNA display have been described by Merryman et al., Chem. Biol., 9:741-46, 2002.
[0254] In one embodiment, anti-CD33 antibodies of the present technology are selected using RNA display. Methods that can be used to select peptides and proteins using RNA display libraries have been described by Roberts et al., Proc. Natl. Acad. Sci. USA, 94: 12297-302, 1997; and Nemoto et al., FEBS Lett., 414: 405-8, 1997. Methods that can be used to select peptides and proteins using non-natural RNA display libraries have been described by Frankel et al., Curr. Opin. Struct. Biol., 13: 506-12, 2003.
[0255] In some embodiments, the anti-CD33 antibodies of the present technology are expressed in the periplasm of Gram-negative bacteria and mixed with labeled CD33 protein. See WO 02 / 34886. In clones expressing recombinant polypeptides with affinity for CD33 protein, the concentration of labeled CD33 protein bound to the anti-CD33 antibody is increased, and the cells are allowed to separate from the rest of the library, as described in Harvey et al., Proc. Natl. Acad. Sci. 22: 9193-98 2004 and U.S. Patent Publication No. 2004 / 0058403.
[0256] After selecting the desired anti-CD33 antibody, it is expected that the antibody can be produced in large quantities by any technique known to those skilled in the art (e.g., prokaryotic or eukaryotic cell expression, etc.). Anti-CD33 antibodies (which are, for example, but not limited to, anti-CD33 hybrid antibodies or fragments) can be produced by constructing an expression vector encoding an antibody heavy chain using conventional techniques, in which the CDRs and (if necessary) the minimum portion of the variable region framework required to retain the binding specificity of the origin species antibody (engineered according to the techniques described herein) are derived from the origin species antibody, and the remainder of the antibody is derived from the target species immunoglobulin that can be manipulated as described herein, thereby generating a vector for expressing the hybrid antibody heavy chain.
[0257] Measurement of CD33 binding. In some embodiments, the CD33 binding assay refers to an assay format in which a CD33 protein and an anti-CD33 antibody are mixed under conditions suitable for binding between the CD33 protein and the anti-CD33 antibody and assessing the amount of binding between the CD33 protein and the anti-CD33 antibody. The amount of binding is compared with a suitable control, which may be the amount of binding in the absence of the CD33 protein, the amount of binding in the presence of a non-specific immunoglobulin composition, or both. The amount of binding may be assessed by any suitable method. Binding assays include, for example, ELISA, radioimmunoassays, proximity scintillation assays, fluorescence energy transfer assays, liquid chromatography, membrane filtration assays, and the like. Biophysical assays for directly measuring CD33 proteins bound to anti-CD33 antibodies are, for example, nuclear magnetic resonance, fluorescence, fluorescence polarization, surface plasmon resonance (BIACORE chip), and the like. Specific binding is determined by standard assays known in the art, such as radioligand binding assays, ELISA, FRET, immunoprecipitation, SPR, NMR (2D-NMR), mass spectrometry, and the like. If the specific binding of a candidate anti-CD33 antibody is at least 1% greater than the binding observed in the absence of the candidate anti-CD33 antibody, the candidate anti-CD33 antibody can be used as an anti-CD33 antibody according to the present technology.
[0258] Uses of anti-CD33 antibodies of the present technology
[0259] Overview. The anti-CD33 antibodies of the present technology can be used in methods known in the art related to the localization and / or quantification of CD33 proteins (e.g., for measuring the level of CD33 proteins in appropriate physiological samples, for diagnostic methods, for polypeptide imaging, etc.). The antibodies of the present technology can be used to separate CD33 proteins by standard techniques such as affinity chromatography or immunoprecipitation. The anti-CD33 antibodies of the present technology can facilitate the purification of natural immunoreactive CD33 proteins from biological samples such as mammalian serum or cells, as well as the purification of recombinantly produced immunoreactive CD33 proteins expressed in host systems. In addition, anti-CD33 antibodies can be used to detect immunoreactive CD33 proteins (e.g., in plasma, cell lysates, or cell supernatants) to evaluate the expression abundance and pattern of immunoreactive polypeptides. The anti-CD33 antibodies of the present technology can be used to diagnostically monitor the level of immunoreactive CD33 proteins in tissues as part of a clinical testing program, for example, to determine the efficacy of a given treatment regimen. As described above, detection can be facilitated by coupling (i.e., physically connecting) the anti-CD33 antibodies of the present technology to a detectable substance.
[0260] Detection of CD33 protein. An exemplary method for detecting the presence of an immunoreactive CD33 protein in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with an anti-CD33 antibody of the present technology capable of detecting an immunoreactive CD33 protein, thereby detecting the presence of an immunoreactive CD33 protein in the biological sample. Detection can be accomplished by a detectable label attached to the antibody.
[0261] The term "labeled" with respect to anti-CD33 antibodies is intended to encompass direct labeling of the antibody by coupling (i.e., physically linking) a detectable substance to the antibody, as well as indirect labeling of the antibody by reactivity with another compound (e.g., a secondary antibody) that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin so that it can be detected with fluorescently labeled streptavidin.
[0262] In some embodiments, the anti-CD33 antibodies disclosed herein are conjugated to one or more detectable labels. For such uses, the anti-CD33 antibodies can be detectably labeled by covalent or non-covalent attachment of chromogenic agents, enzymatic agents, radioisotopic agents, isotopic agents, fluorescent agents, toxic agents, chemiluminescent agents, nuclear magnetic resonance contrast agents, or other labels.
[0263] Examples of suitable chromogenic labels include diaminobenzidine and 4-hydroxyazo-benzene-2-carboxylic acid. Examples of suitable enzyme labels include malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triosephosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
[0264] Examples of suitable radioisotope labels include 3 H. 111 In, 125 I. 131 I. 32 P. 35 S. 14 C. 51 Cr, 57 To, 58 Co. 59 Fe, 75 Se, 152 Eu, 90 Y. 67 Cu, 217 Ci, 211 At 212 Pb, 47 Sc, 109 Pd etc. 111 In is an exemplary isotope when using in vivo imaging because it avoids 125 I or 131 The problem of CD33 binding antibodies labeled with I being dehalogenated by the liver is solved. In addition, this isotope has a gamma emission energy that is more favorable for imaging (Perkins et al., Eur. J. Nucl. Med. 70:296-301 (1985); Carasquillo et al., J. Nucl. Med. 25:281-287 (1987)). For example, a monoclonal antibody conjugated with 1-(P-isothiocyanatobenzyl)-DPTA 111 In exhibits little uptake in non-tumor tissues (particularly the liver) and enhances the specificity of tumor localization (Esteban et al., J. Nucl. Med. 28:861-870 (1987)). Examples of suitable non-radioactive isotope labels include 157 Gd, 55 Mn, 162 Dy, 52 Tr and 56 Fe.
[0265] Examples of suitable fluorescent labels include 152Eu labeling, fluorescein labeling, isothiocyanate labeling, rhodamine labeling, phycoerythrin labeling, phycocyanin labeling, allophycocyanin labeling, green fluorescent protein (GFP) labeling, o-phthalaldehyde labeling and fluorescamine labeling.Examples of suitable toxin labels include diphtheria toxin, ricin toxin and cholera toxin.
[0266] Examples of chemiluminescent labels include luminol labels, isoluminol labels, aromatic acridinium ester labels, imidazole labels, acridinium salt labels, oxalate labels, luciferin labels, luciferase labels, and aequorin labels. Examples of nuclear magnetic resonance contrast agents include heavy metal nuclei such as Gd, Mn, and iron.
[0267] The detection methods of the present technology can be used to detect immunoreactive CD33 proteins in biological samples in vitro and in vivo. In vitro techniques for detecting immunoreactive CD33 proteins include enzyme-linked immunosorbent assay (ELISA), western blot, immunoprecipitation, radioimmunoassay and immunofluorescence. In addition, in vivo techniques for detecting immunoreactive CD33 proteins include introducing labeled anti-CD33 antibodies into a subject. For example, the anti-CD33 antibodies can be labeled with a radioactive marker, the presence and location of which in the subject can be detected by standard imaging techniques. In one embodiment, the biological sample contains CD33 protein molecules from a test subject.
[0268] Immunoassays and imaging. The anti-CD33 antibodies of the present technology can be used to determine the level of immunoreactive CD33 protein in a biological sample (e.g., human plasma) using antibody-based techniques. For example, protein expression in tissues can be studied using classical immunohistological methods. Jalkanen, M. et al., J. Cell. Biol. 101:976-985, 1985; Jalkanen, M. et al., J. Cell. Biol. 105:3087-3096, 1987. Other antibody-based methods that can be used to detect protein gene expression include immunoassays such as enzyme-linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA). Suitable antibody assay labels are known in the art and include enzyme labels (such as glucose oxidase) and radioisotopes or other radioactive agents (such as iodine ( 125 I. 121 I. 131 I), carbon ( 14 C) Sulfur ( 35 S), tritium ( 3 H), Indium ( 112 In) and technetium ( 99 mTc)) and fluorescent labels such as fluorescein, rhodamine, and green fluorescent protein (GFP), as well as biotin.
[0269] In addition to determining the level of immunoreactive CD33 protein in a biological sample, the anti-CD33 antibodies of the present technology can also be used for in vivo imaging of CD33. Antibodies that can be used in this method include those that can be detected by X-ray radiography, NMR or ESR. For X-ray radiography, suitable labels include radioisotopes, such as barium or cesium, which emit detectable radiation but are not significantly harmful to the subject. Labels suitable for NMR and ESR include those with detectable characteristic spins, such as deuterium, which can be incorporated into the anti-CD33 antibody by labeling nutrients for the relevant scFv clone.
[0270] The cells have been treated with an appropriate detectable imaging moiety such as a radioisotope (e.g., 131 I. 112 In, 99 An anti-CD33 antibody labeled with mTc, a radiopaque substance, or a material detectable by nuclear magnetic resonance (NMR) is introduced (e.g., parenterally, subcutaneously, or intraperitoneally) into a subject. It is understood in the art that the size of the subject and the imaging system used will determine the amount of imaging moiety required to produce a diagnostic image. In the case of a radioisotope moiety, for a human subject, the amount of radioactivity injected is generally between about 5 and 20 millicuries. 99 The labeled anti-CD33 antibody will then accumulate in the cell location containing the specific target polypeptide. For example, the labeled anti-CD33 antibody of the present technology will accumulate in cells and tissues in the subject where the CD33 protein has been located.
[0271] Thus, the present technology provides a method for diagnosing a medical condition, the method involving: (a) determining the expression of an immunoreactive CD33 protein by measuring the binding of an anti-CD33 antibody of the present technology in cells or body fluids of an individual; (b) comparing the amount of immunoreactive CD33 protein present in the sample with a standard reference, wherein an increase or decrease in the level of the immunoreactive CD33 protein compared to the standard indicates a medical condition.
[0272] Affinity purification. The anti-CD33 antibodies of the present technology can be used to purify immunoreactive CD33 proteins from a sample. In some embodiments, the antibody is immobilized on a solid support. Examples of such solid supports include plastics (such as polycarbonates), complex carbohydrates (such as agarose and sepharose), acrylic resins, and beads such as polyacrylamide and latex. The techniques for coupling antibodies to such solid supports are well known in the art (Weir et al., "Handbook of Experimental Immunology" 4th edition, Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby et al., Meth. Enzym. 34 Academic Press, New York (1974)).
[0273] The simplest method of combining antigen with antibody-support matrix is to collect beads in a column and pass the antigen solution downward through the column. The efficiency of this method depends on the contact time between the immobilized antibody and the antigen, and the contact time can be extended by using a low flow rate. The immobilized antibody captures the antigen when the antigen flows through. Alternatively, the antigen can be contacted with the antibody support matrix in the following manner: the antigen solution is mixed with a support (e.g., beads) and rotated or shaken to achieve maximum contact between the antigen and the immobilized antibody. After the binding reaction is completed, the slurry is passed into the column to collect beads. The beads are washed with a suitable washing buffer solution, and then the pure or substantially pure antigen is eluted.
[0274] The antibody or polypeptide of interest can be conjugated to a solid support such as a bead. In addition, if desired, a first solid support such as a bead can also be conjugated to a second solid support (which can be a second bead or other support) by any suitable means, including those disclosed herein for conjugating a polypeptide to a support. Therefore, any conjugation methods and means disclosed herein for conjugating a polypeptide to a solid support can also be used to conjugate a first support to a second support, wherein the first and second solid supports can be the same or different.
[0275] Suitable linkers (which may be crosslinkers) for conjugating polypeptides to solid supports include a variety of agents that can react with functional groups present on the support surface or with the polypeptide or both. Reagents that can be used as crosslinkers include homobifunctional agents and particularly heterobifunctional agents. Useful bifunctional crosslinkers include, but are not limited to, N-SIAB, dimaleimide, DTNB, N-SATA, N-SPDP, SMCC, and 6-HYNIC. The crosslinker can be selected to provide a selectively cleavable bond between the polypeptide and the solid support. For example, a photolabile crosslinker such as 3-amino-(2-nitrophenyl) propionic acid can be used as a means of cleaving the polypeptide from the solid support. (Brown et al., Mol. Divers, pp. 4-12 (1995); Rothschild et al., Nucl. Acids Res., 24: 351-66 (1996); and U.S. Pat. No. 5,643,722). Other crosslinking agents are well known in the art. (See, e.g., Wong (1991), supra; and Hermanson (1996), supra).
[0276] The antibody or polypeptide can be fixed on a solid support (such as beads) by a covalent amide bond formed between the carboxyl-functionalized beads and the amino terminus of the polypeptide, or conversely by a covalent amide bond formed between the amino-functionalized beads and the carboxyl terminus of the polypeptide. In addition, a difunctional trityl linker can be attached to the support via an amino resin by an amino group or a carboxyl group on the resin, such as a 4-nitrophenyl active ester attached to a resin (such as Wang resin). When using the difunctional trityl method, the solid support may need to be treated with a volatile acid (such as formic acid or trifluoroacetic acid) to ensure that the polypeptide is cut and can be removed. In this case, the polypeptide can be deposited on the bottom of the hole of the solid support or on the flat surface of the solid support as a plaque without beads. After adding the matrix solution, the polypeptide can be desorbed into the MS.
[0277] Hydrophobic trityl linkers can also be used as acid-labile linkers by cleaving the amino-linked trityl group from the polypeptide using a volatile acid or an appropriate matrix solution (e.g., a matrix solution containing 3-HPA). Acid instability can also be altered. For example, a trityl, monomethoxytrityl, dimethoxytrityl, or trimethoxytrityl group can be changed to a suitable para-substituted or more acid-labile tritylamine derivative of the polypeptide, i.e., a trityl ether bond and a tritylamine bond can be formed with the polypeptide. Thus, the polypeptide can be removed from the hydrophobic linker, for example, by destroying the hydrophobic attraction under acidic conditions or by cleaving the trityl ether bond or the tritylamine bond, including (if necessary) under typical MS conditions, where a matrix such as 3-HPA is used as an acid.
[0278] Orthogonal cleavable linkers can also be used to bind a first solid support (e.g., beads) to a second solid support, or can be used to bind a polypeptide of interest to a solid support. Using such linkers, a first solid support (e.g., beads) can be selectively cleaved from a second solid support without cleaving the polypeptide from the support; the polypeptide can then be cleaved from the beads at a later time. For example, a disulfide linker that can be cleaved using a reducing agent such as DTT can be used to bind the beads to a second solid support, and an acid-cleavable bifunctional trityl group can be used to fix the polypeptide to the support. As needed, the connection between the polypeptide and the solid support can be cleaved first, for example, to keep the connection between the first and second supports intact. The trityl linker can provide covalent or hydrophobic conjugation, and regardless of the nature of the conjugation, the trityl group is easily cleaved under acidic conditions.
[0279] For example, beads can be combined with a second support through a linking group, and a linking group with the following length and chemical properties can be selected, which promotes high-density binding of beads to solid supports or high-density binding of polypeptides to beads. Such linking groups can have, for example, a "tree-like" structure, thereby providing multiple functional groups for each attachment site on the solid support. Examples of such linking groups include polylysine, polyglutamic acid, penta-erythrole, and trihydroxyaminomethane.
[0280] Non-covalent binding association. Through non-covalent interactions, antibodies or polypeptides can be conjugated to a solid support, or a first solid support can also be conjugated to a second solid support. For example, magnetic beads made of ferromagnetic materials that can be magnetized can be attracted to a magnetic solid support and can be released from the support by removing the magnetic field. Alternatively, the solid support can have ionic or hydrophobic moieties, which can allow the ionic or hydrophobic moieties to interact with a polypeptide (e.g., a polypeptide containing an attached trityl group) or with a second solid support having a hydrophobic character, respectively.
[0281] The solid support may also have members of a specific binding pair and thus may be conjugated to a polypeptide containing a complementary binding moiety or to a second solid support. For example, beads coated with avidin or with streptavidin may be bound to a polypeptide in which a biotin moiety is incorporated, or to a second solid support coated with biotin or a biotin derivative such as iminobiotin.
[0282] It should be appreciated that any binding member disclosed herein or otherwise known in the art can be reversed. Thus, for example, biotin can be incorporated into a polypeptide or solid support, and conversely, avidin or other biotin binding moiety can be incorporated into a support or polypeptide, respectively. Other specific binding pairs contemplated for use herein include, but are not limited to, hormones and their receptors, enzymes and their substrates, nucleotide sequences and their complementary sequences, antibodies and their specifically interacting antigens, and other such pairs known to those skilled in the art.
[0283] A. Diagnostic Uses of Anti-CD33 Antibodies of the Present Technology
[0284] Overview. The anti-CD33 antibodies of the present technology can be used in diagnostic methods. Thus, the present technology provides methods of diagnosing CD33 activity in a subject using the antibodies. The anti-CD33 antibodies of the present technology can be selected so that they have any level of epitope binding specificity and very high binding affinity to the CD33 protein. Generally speaking, the higher the binding affinity of the antibody, the more stringent washing conditions can be performed in the immunoassay to remove non-specifically bound material without removing the target polypeptide. Thus, the anti-CD33 antibodies of the present technology used in diagnostic assays typically have about 10 8 M -1 , 10 9 M -1 , 10 10 M -1 , 10 11 M -1 or 10 12 M -1 In addition, it is desirable that anti-CD33 antibodies for use as diagnostic reagents have sufficient kinetic association rates to reach equilibrium under standard conditions within at least 12 h, at least five (5) h, or at least one (1) hour.
[0285] Anti-CD33 antibodies can be used to detect immunoreactive CD33 proteins in a variety of standard assay formats. Such formats include immunoprecipitation, Western blot, ELISA, radioimmunoassay, and immunometric assays. See Harlow and Lane, Antibodies, A Laboratory Manual (Cold Spring Harbor Publications, New York, 1988); U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,879,262; 4,034,074; 3,791,932; 3,817,837; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876. A biological sample can be obtained from any tissue or fluid of a subject. In certain embodiments, the subject is in an early stage of cancer. In one embodiment, the early stage of cancer is determined by the level or expression pattern of CD33 protein in a sample obtained from the subject. In certain embodiments, the sample is selected from urine, blood, serum, plasma, saliva, amniotic fluid, cerebrospinal fluid (CSF), and biopsy body tissue.
[0286] Immunoassay or sandwich assay is a form of the present technology diagnostic method. See U.S. Patent Nos. 4,376,110, 4,486,530, 5,914,241 and 5,965,375. Such assays use an antibody (e.g., an anti-CD33 antibody or anti-CD33 antibody population) fixed to a solid phase and another anti-CD33 antibody or anti-CD33 antibody population in a solution. Typically, a solution anti-CD33 antibody or anti-CD33 antibody population is labeled. If an antibody population is used, the population may contain antibodies specifically bound to different epitopes within a target polypeptide. Therefore, the same population may be used for both solid phase and solution antibodies. If anti-CD33 monoclonal antibodies are used, the first and second CD33 monoclonal antibodies with different binding specificities are used for solid phase and solution phase. Solid phase (also referred to as "capture") and solution (also referred to as "detection") antibodies may be contacted with the target antigen in any order or simultaneously. If a solid phase antibody is contacted first, the assay is referred to as a forward assay. In contrast, if the solution antibody is contacted first, the assay is called a reverse assay. If the target is contacted with both antibodies at the same time, the assay is called a simultaneous assay. After contacting the CD33 protein with the anti-CD33 antibody, the sample is incubated for a period of time, which is generally from about 10 minutes to about 24 hours, and is generally about 1 hour. A washing step is then performed to remove components in the sample that are not specifically bound to the anti-CD33 antibody used as a diagnostic reagent. When the solid phase antibody and the solution antibody are combined in a separate step, washing can be performed after either or both of the binding steps. After washing, the binding is quantified, usually by detecting the label attached to the solid phase through the binding of the labeled solution antibody. Usually for a given antibody pair or antibody population and a given reaction condition, a calibration curve is prepared from a sample containing a known concentration of the target antigen. The concentration of the immunoreactive CD33 protein in the sample being tested is then read by interpolation from the calibration curve (i.e., standard curve). The analyte can be measured from the amount of the labeled solution antibody bound at equilibrium or by kinetic measurements of the bound labeled solution antibody at a series of time points before reaching equilibrium. The slope of this curve is a measure of the CD33 protein concentration in the sample.
[0287] Suitable supports for use in the above methods include, for example, nitrocellulose membranes, nylon membranes and derivatized nylon membranes, and also particles such as agarose, dextran-based gels, dipsticks, microparticles, microspheres, magnetic particles, test tubes, microtiter wells, SEPHADEX TM (Amersham Pharmacia Biotech, Piscataway, NJ) etc. Immobilization can be achieved by absorption or by covalent attachment. Optionally, the anti-CD33 antibody can be linked to a linker molecule (such as biotin) to attach to a surface-bound linker (such as avidin).
[0288] In some embodiments, the present disclosure provides an anti-CD33 antibody of the present technology conjugated to a diagnostic agent. The diagnostic agent can include a radioactive or non-radioactive label, a contrast agent (such as for magnetic resonance imaging, computed tomography, or ultrasound), and the radioactive label can be a gamma, beta, alpha, Auger electron, or positron emitting isotope. The diagnostic agent is a molecule that is administered in conjunction with an antibody portion, i.e., an antibody or antibody fragment or subfragment, and can be used to diagnose or detect disease by locating cells containing the antigen.
[0289] Useful diagnostic agents include, but are not limited to, radioisotopes, dyes (such as using biotin-streptavidin complexes), contrast agents, fluorescent compounds or molecules, and enhancers (e.g., paramagnetic ions) for magnetic resonance imaging (MRI). U.S. Patent No. 6,331,175 describes MRI technology and the preparation of antibodies conjugated to MRI enhancers, and is incorporated by reference in its entirety. In some embodiments, diagnostic agents are selected from radioisotopes, enhancers for magnetic resonance imaging, and fluorescent compounds. In order to load radioactive metals or paramagnetic ions on antibody components, it may be necessary to react them with reagents having long tails, to which a variety of chelating groups for binding ions are attached. This tail can be a polymer, such as polylysine, polysaccharides or other derivatized or derivatizable chains, and the polymer has a side group that can be combined with a chelating group, and the chelating group is, for example, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), porphyrins, polyamines, crown ethers, bis-thiosemicarbazones, polyoximes, and similar groups known to be useful for this purpose. Chelates can be coupled to antibodies of the present technology using standard chemical methods. Chelates are typically linked to antibodies via a group that is capable of forming a bond with the molecule with minimal loss of immunoresponsiveness and minimal aggregation and / or internal cross-linking. Other methods and reagents for conjugating chelates to antibodies are disclosed in U.S. Pat. No. 4,824,659. Particularly useful metal-chelate combinations include 2-benzyl-DTPA and its monomethyl and cyclohexyl analogs for radioimaging with diagnostic isotopes. When compounded with non-radioactive metals such as manganese, iron, and gadolinium, the same chelate can be used for MRI when used with the CD33 antibodies of the present technology.
[0290] Macrocyclic chelates such as NOTA (1,4,7-triaza-cyclononane-N,N',N"-triacetic acid), DOTA, and TETA (p-bromoacetamido-benzyl-tetraethylaminetetraacetic acid) are used with a variety of metals and radioactive metals (e.g., radionuclides of gallium, yttrium, and copper), respectively. Such metal-chelate complexes can be stabilized by tailoring the ring size to the metal of interest. Other examples of DOTA chelates include (i) DOTA-Phe-Lys(HSG)-D-Tyr-Lys(HSG)-NH2; (ii) Ac-Lys(HSG)D-Tyr-Lys(HSG)-Lys(Tscg-Cys)-NH2; (iii) DOTA-D- Asp-D-Lys(HSG)-D-Asp-D-Lys(HSG)-NH2; (iv)DOTA-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (v)DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(H SG)-NH2; (vi)DOTA-D-Ala-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (vii)DOTA-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-NH2; (viii)Ac-D-Phe-D-L ys(DOTA)-D-Tyr-D-Lys(DOTA)-NH2; (ix)Ac-D-Phe-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-NH2; (x)Ac-D-Phe-D-Lys(Bz-DTPA)-D-Tyr-D-Lys(Bz- DTPA)-NH2; (xi)Ac-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(Tscg-Cys)-NH2; (xii)DOTA-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(Tscg-C ys)-NH2; (xiii) (Tscg-Cys)-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(DOTA)-NH2; (xiv)Tscg-D-Cys-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(H SG)-NH2; (xv) (Tscg-Cys)-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (xvi)Ac-D-Cys-D-Lys(DOTA)-D-Tyr-D-Ala-D-Lys(DOTA)-D-Cys-NH2;(xvii)Ac-D-Cys-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-NH2; (xviii)Ac-D-Lys(DTPA)-D-Tyr-D-Lys(D TPA)-D-Lys(Tscg-Cys)-NH2; and (xix)Ac-D-Lys(DOTA)-D-Tyr-D-Lys(DOTA)-D-Lys(Tscg-Cys)-NH2. ;
[0291] Also considered are the stable binding nuclides (such as those used in RAIT). 223 Other cyclic chelates of interest include macrocyclic polyethers.
[0292] B. Therapeutic Uses of Anti-CD33 Antibodies of the Present Technology
[0293] The immunoglobulin-related compositions (e.g., antibodies or antigen-binding fragments thereof) of the present technology can be used to treat CD33-related cancers and Alzheimer's disease. Such treatment can be used for patients identified as having pathologically high levels of CD33 (e.g., those diagnosed by the methods described herein) or patients diagnosed with diseases known to be associated with such pathological levels. In one aspect, the present disclosure provides a method for treating CD33-related cancers or Alzheimer's disease in a subject in need thereof, the method comprising administering to the subject an effective amount of an antibody (or antigen-binding fragment thereof) of the present technology. Examples of cancers that can be treated by the antibodies of the present technology include, but are not limited to, AML, biphenotypic leukemia, bi-lineage leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, or acute lymphoblastic leukemia.
[0294] The compositions of the present technology can be used in combination with other therapeutic agents that can be used to treat CD33-related cancers. For example, the antibodies of the present technology can be administered separately, sequentially or simultaneously with at least one additional therapeutic agent selected from the following: alkylating agents, platinum agents, taxanes, vinca agents, anti-estrogen drugs, aromatase inhibitors, ovarian inhibitors, VEGF / VEGFR inhibitors, EGF / EGFR inhibitors, PARP inhibitors, cell-inhibiting alkaloids, cytotoxic antibiotics, antimetabolites, endocrine / hormonal agents, bisphosphonate therapeutic agents, and targeted biological therapeutic agents (e.g., therapeutic peptides described in US 6306832, WO 2012007137, WO2005000889, WO 2010096603, etc.). In some embodiments, the at least one additional therapeutic agent is a chemotherapeutic agent. Specific chemotherapeutic agents include, but are not limited to, cyclophosphamide, fluorouracil (or 5-fluorouracil or 5-FU), methotrexate, edatrexate (10-ethyl-10-deaza-aminopterin), thiotepa, carboplatin, cisplatin, taxanes, paclitaxel, protein-bound paclitaxel, docetaxel, vinorelbine, tamoxifen, raloxifene, toremifene, fulvestrant, gemcitabine, irinotecan, ixabepilone, temozolomide, topotecan, vincristine, vinblastine, eribulin, mutamycin, capecitabine, a Nastrazole, exemestane, letrozole, leuprolide, abarelix, buserelin, goserelin, megestrol acetate, risedronate, pamidronate, ibandronate, alendronate, denosumab, zoledronate, trastuzumab, lapatinib, anthracyclines (e.g., daunorubicin and doxorubicin), bevacizumab, oxaliplatin, melphalan, etoposide, nitrogen mustard, bleomycin, microtubule poison, annonaceous acetone, or a combination thereof.
[0295] The compositions of the present technology can optionally be administered to a subject in need thereof in the form of a single bolus injection. Alternatively, the dosing regimen can include multiple administrations at different times after the tumor appears.
[0296] The method for treating Alzheimer's disease may also include sequentially, separately or simultaneously administering to the subject at least one additional therapy selected from the group consisting of donepezil, galantamine, memantine, rivastigmine, memantine extended release and donepezil, aducanumab, solanezumab, insulin, verubecestat, AADvac1, CSP-1103 and intepirdine.
[0297] Administration can be by any suitable route, including oral, intranasal, parenteral (intravenous, intramuscular, intraperitoneal or subcutaneous), rectal, intracranial, intratumoral, intrathecal or topical. Administration includes self-administration and administration by another person. It is also understood that the various treatments of medical conditions as described herein are intended to mean "substantially," which includes complete treatment but also less than complete treatment, and in which some biologically or medically relevant results are achieved.
[0298] In some embodiments, the antibodies of the present technology constitute pharmaceutical formulations, which can be administered to a subject in need thereof in one or more doses. The dosage regimen can be adjusted to provide a desired response (e.g., a therapeutic response).
[0299] Typically, the effective amount of the antibody composition of the present technology sufficient to achieve a therapeutic effect is within the range of about 0.000001 mg per kg of body weight per day to about 10,000 mg per kg of body weight per day. Typically, the dosage range is about 0.0001 mg per kg of body weight per day to about 100 mg per kg of body weight per day. For the administration of anti-CD33 antibodies, the dosage range is about 0.0001 to 100 mg / kg of subject weight per week, every two weeks or every three weeks, and more typically 0.01 to 5 mg / kg of subject weight. For example, the dosage can be 1 mg / kg of body weight or 10 mg / kg of body weight per week, every two weeks or every three weeks, or within the range of 1-10 mg / kg per week, every two weeks or every three weeks. In one embodiment, the single dose range of the antibody is 0.1-10,000 micrograms per kilogram of body weight. In one embodiment, the antibody concentration range in the carrier is 0.2 to 2000 micrograms per milliliter delivered. Exemplary treatment regimens require administration once every two weeks or once a month or once every 3 to 6 months. Anti-CD33 antibodies can be administered at multiple times. The intervals between single doses can be hourly, daily, weekly, monthly or annual. Intervals can also be irregular as indicated by measuring the blood level of the antibody in the subject. In some methods, the dose is adjusted to achieve the following serum antibody concentration in the subject: about 75 μg / mL to about 125 μg / mL, 100 μg / mL to about 150 μg / mL, about 125 μg / mL to about 175 μg / mL or about 150 μg / mL to about 200 μg / mL. Alternatively, anti-CD33 antibodies can be administered as sustained release formulations, in which case less frequent administration is required. The dose and frequency vary according to the half-life of the antibody in the subject. The dose and frequency of administration can vary depending on whether the treatment is preventive or therapeutic. In preventive applications, relatively low doses are administered at relatively infrequent intervals over a long period of time. In therapeutic applications, it is sometimes necessary to give relatively high doses at relatively short intervals until the progression of the disease is reduced or terminated, or until the subject shows partial or complete improvement in symptoms of the disease. Thereafter, the patient may be administered a prophylactic regimen.
[0300] In another aspect, the present disclosure provides a method for detecting a tumor in a subject in vivo, the method comprising (a) administering to the subject an effective amount of an antibody (or antigen-binding fragment thereof) of the present technology, wherein the antibody is configured to localize to a tumor expressing CD33 and is labeled with a radioactive isotope; and (b) detecting the presence of a tumor in the subject by detecting a level of radioactivity emitted by the antibody that is higher than a reference value. In some embodiments, the reference value is expressed as injected dose per gram (%ID / g). The reference value can be calculated by measuring the level of radioactivity present in non-tumor (normal) tissues and calculating the average radioactivity level ± standard deviation present in non-tumor (normal) tissues. In some embodiments, the ratio of radioactivity levels between tumor and normal tissue is about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, or 100:1.
[0301] In some embodiments, the subject is diagnosed as having or suspected of having cancer.The level of radioactivity emitted by the antibody can be detected using positron emission tomography or single photon emission computed tomography.
[0302] Additionally or alternatively, in some embodiments, the method further comprises administering to the subject an effective amount of an immunoconjugate comprising an antibody of the present technology conjugated to a radionuclide. In some embodiments, the radionuclide is an alpha particle emitting isotope, a beta particle emitting isotope, an Auger emitter, or any combination thereof. Examples of beta particle emitting isotopes include 86 Y. 90 Y. 89 Sr. 165 Dy, 186 Re, 188 Re, 177 Lu and 67 Cu. Examples of alpha-emitting isotopes include 213 Bi, 211 At 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn, 215 Po, 211 Bi, 221 Fr. 217 At and 255 Fm. Examples of Auger emitters include111 In, 67 Ga, 51 Cr, 58 Co. 99m Tc, 103m Rh, 195m Pt, 119 Sb, 161 Ho, 189m Os, 192 Ir, 201 Tl and 203 Pb. In some embodiments of the method, non-specific FcR-dependent binding in normal tissues is eliminated or reduced (e.g., via the N297A mutation in the Fc region, which results in deglycosylation). The therapeutic effectiveness of this immunoconjugate can be determined by calculating the area under the curve (AUC) tumor: AUC normal tissue ratio. In some embodiments, the AUC tumor: AUC normal tissue ratio of the immunoconjugate is about 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 15: 1, 20: 1, 25: 1, 30: 1, 35: 1, 40: 1, 45: 1, 50: 1, 55: 1, 60: 1, 65: 1, 70: 1, 75: 1, 80: 1, 85: 1, 90: 1, 95: 1 or 100: 1.
[0303] PRIT. In one aspect, the present disclosure provides a method for detecting a tumor in a subject in need thereof, the method comprising (a) administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and a bispecific antibody of the present technology that binds to the radiolabeled DOTA hapten and a CD33 antigen, wherein the complex is configured to localize to a solid tumor expressing the CD33 antigen recognized by the bispecific antibody of the complex; and (b) detecting the presence of a solid tumor in the subject by detecting a level of radioactivity emitted by the complex that is above a reference value. In some embodiments, the subject is a human.
[0304] In another aspect, the present disclosure provides a method for selecting a subject for pretargeted radioimmunotherapy, the method comprising (a) administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and a bispecific antibody of the present technology that binds to the radiolabeled DOTA hapten and the CD33 antigen, wherein the complex is configured to localize to a tumor expressing the CD33 antigen recognized by the bispecific antibody of the complex; (b) detecting the level of radioactivity emitted by the complex; and (c) selecting the subject for pretargeted radioimmunotherapy when the level of radioactivity emitted by the complex is higher than a reference value. In some embodiments, the subject is a human.
[0305] Examples of DOTA haptens include (i) DOTA-Phe-Lys(HSG)-D-Tyr-Lys(HSG)-NH2; (ii) Ac-Lys(HSG)D-Tyr-Lys(HSG)-Lys(Tscg-Cys)-NH2; (iii) DOTA-D-Asp-D-Lys(HSG)-D-Asp-D-Lys(HSG)-NH2; (iv) DOTA-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (v) DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (vi) DOTA-D-Ala-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (vii) DOTA-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-NH2; (viii) Ac-D-Phe-D-Lys(DOTA)-D-Tyr-D-Lys(DOTA)-NH2; (ix) Ac-D-Phe-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-NH2; (x) Ac-D-Phe-D-Lys(Bz-DTPA)-D-Tyr-D-Lys(Bz-DTPA)-NH2; (xi) Ac-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(Tscg-Cys)-NH2; (xii) DOTA-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(Tscg-Cys)-NH2; (xiii) (Tscg-Cys)-D-Phe-D-Lys(HSG)-D-Tyr-D-Lys(HSG)-D-Lys(DOTA)-NH2; (xiv) Tscg-D-Cys-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (xv) (Tscg-Cys)-D-Glu-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; (xvi) Ac-D-Cys-D-Lys(DOTA)-D-Tyr-D-Ala-D-Lys(DOTA)-D-Cys-NH2; (xvii) Ac-D-Cys-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-NH2; (xviii) Ac-D-Lys(DTPA)-D-Tyr-D-Lys(DTPA)-D-Lys(Tscg-Cys)-NH2;(xix) Ac-D-Lys(DOTA)-D-Tyr-D-Lys(DOTA)-D-Lys(Tscg-Cys)-NH2 and (xx) DOTA. The radioactive label can be an alpha-emitting isotope, a beta-emitting isotope, or an Auger emitter. Examples of radioactive labels include; 213 Bi, 211 At 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn, 215 Po, 211 Bi, 221 Fr. 217 At 255 Fm, 86 Y. 90 Y. 89 Sr. 165 Dy, 186 Re, 188 Re, 177 Lu, 67 Cu, 111 In, 67 Ga, 51 Cr, 58 Co. 99m Tc, 103m Rh, 195m Pt, 119 Sb, 161 Ho, 189m Os, 192 Ir, 201 Tl, 203 Pb, 68 Ga, 227 Th or 64 Cu.
[0306] In some embodiments of the methods disclosed herein, the level of radioactivity emitted by the complex is detected using positron emission tomography or single photon emission computed tomography. Additionally or alternatively, in some embodiments of the methods disclosed herein, the subject is diagnosed with, or suspected of having, Alzheimer's disease or a CD33-related cancer, such as AML, biphenotypic leukemia, bi-lineage leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, myeloid blast crisis of chronic myeloid leukemia, or acute lymphoblastic leukemia.
[0307] Additionally or alternatively, in some embodiments of the methods disclosed herein, the complex is administered intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intraorbitally, intradermally, intraperitoneally, transtracheally, subcutaneously, intraventricularly, orally, intratumorally, or intranasally. In certain embodiments, the complex is administered to the cerebrospinal fluid or blood of a subject.
[0308] In some embodiments of the methods disclosed herein, the radioactivity level emitted by the complex is detected between 2 and 120 hours after the complex is administered. In certain embodiments of the methods disclosed herein, the radioactivity level emitted by the complex is expressed as a percentage of injected dose per gram of tissue (% ID / g). The reference value can be calculated by measuring the radioactivity level present in non-tumor (normal) tissues, and calculating the average radioactivity level ± standard deviation present in non-tumor (normal) tissues. In some embodiments, the reference value is a standard uptake value (SUV). See Thie JA, J Nucl Med. 45 (9): 1431-4 (2004). In some embodiments, the ratio of radioactivity levels between tumor and normal tissue is about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, or 100:1.
[0309] In another aspect, the disclosure provides a method for increasing the sensitivity of a tumor to radiotherapy in a subject diagnosed with a CD33-related cancer, the method comprising (a) administering to the subject an effective amount of an anti-DOTA bispecific antibody of the present technology, wherein the anti-DOTA bispecific antibody is configured to localize to a tumor expressing a CD33 antigen target; and (b) administering to the subject an effective amount of a radiolabeled DOTA hapten, wherein the radiolabeled DOTA hapten is configured to bind to the anti-DOTA bispecific antibody. In some embodiments, the subject is a human.
[0310] The anti-DOTA bispecific antibody is administered under conditions and for a period of time (e.g., according to a dosing regimen) sufficient to allow it to saturate the tumor cells. In some embodiments, after administration of the anti-DOTA bispecific antibody, unbound anti-DOTA bispecific antibody is removed from the bloodstream. In some embodiments, the radiolabeled DOTA hapten is administered after a period of time sufficient to allow clearance of unbound anti-DOTA bispecific antibody.
[0311] The radiolabeled DOTA hapten can be administered any time between 1 minute to 4 or more days after administration of the anti-DOTA bispecific antibody. For example, in some embodiments, the radiolabeled DOTA hapten is administered 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 1.25 hours, 1.5 hours, 1.75 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, 6.5 hours, 7 hours, 7.5 hours, 8 hours, 8.5 hours, 9 hours, 9.5 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 48 hours, 72 hours, 96 hours, or any range therein, after administration of the anti-DOTA bispecific antibody. Alternatively, the radiolabeled DOTA hapten can be administered any time after 4 or more days after administration of the anti-DOTA bispecific antibody.
[0312] Additionally or alternatively, in some embodiments, the method further comprises administering to the subject an effective amount of a scavenger prior to administering the radiolabeled DOTA hapten. The scavenger may be any molecule (glucan or dendrimer or polymer) that can be conjugated to the C825 hapten. In some embodiments, the scavenger is no more than 2000 kD, 1500 kD, 1000 kD, 900 kD, 800 kD, 700 kD, 600 kD, 500 kD, 400 kD, 300 kD, 200 kD, 100 kD, 90 kD, 80 kD, 70 kD, 60 kD, 50 kD, 40 kD, 30 kD, 20 kD, 10 kD or 5 kD. In some embodiments, the scavenging agent is a 500 kD aminodextran-DOTA conjugate (eg, 500 kD dextran-DOTA-Bn(Y), 500 kD dextran-DOTA-Bn(Lu), or 500 kD dextran-DOTA-Bn(In), etc.).
[0313] In some embodiments, a scavenger and a radiolabeled DOTA hapten are administered without further administration of an anti-DOTA bispecific antibody of the present technology. For example, in some embodiments, an anti-DOTA bispecific antibody of the present technology is administered according to a regimen comprising at least one of the following cycles: (i) administration of an anti-DOTA bispecific antibody of the present technology (optionally, to saturate the relevant tumor cells); (ii) administration of a radiolabeled DOTA hapten and an optional scavenger; (iii) optional additional administration of a radiolabeled DOTA hapten and / or scavenger without additional administration of an anti-DOTA bispecific antibody. In some embodiments, the method may include multiple such cycles (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more cycles).
[0314] Additionally or alternatively, in some embodiments of the methods, the anti-DOTA bispecific antibody and / or the radiolabeled DOTA hapten is administered intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intraorbitally, intradermally, intraperitoneally, transtracheally, subcutaneously, intracerebroventricularly, intratumorally, orally, or intranasally.
[0315] In one aspect, the disclosure provides a method for increasing the sensitivity of a tumor to radiotherapy in a subject diagnosed with a CD33-related cancer, the method comprising administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and a bispecific antibody of the present technology that recognizes and binds to the radiolabeled DOTA hapten and a CD33 antigen target, wherein the complex is configured to localize to a tumor expressing the CD33 antigen target recognized by the bispecific antibody of the complex. The complex can be administered intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intraorbitally, intradermally, intraperitoneally, transtracheally, subcutaneously, intraventricularly, orally, intratumorally, or intranasally. In some embodiments, the subject is a human.
[0316] In another aspect, the present disclosure provides a method for treating cancer in a subject in need thereof, the method comprising (a) administering to the subject an effective amount of an anti-DOTA bispecific antibody of the present technology, wherein the anti-DOTA bispecific antibody is configured to localize to a tumor expressing a CD33 antigen target; and (b) administering to the subject an effective amount of a radiolabeled DOTA hapten, wherein the radiolabeled DOTA hapten is configured to bind to the anti-DOTA bispecific antibody. The anti-DOTA bispecific antibody is administered under certain conditions and for a certain period of time (e.g., according to a dosing regimen), and the conditions and time period are sufficient to allow it to saturate tumor cells. In some embodiments, after administration of the anti-DOTA bispecific antibody, unbound anti-DOTA bispecific antibodies are removed from the bloodstream. In some embodiments, the radiolabeled DOTA hapten is administered after a period of time sufficient to allow clearance of unbound anti-DOTA bispecific antibodies. In some embodiments, the subject is a human.
[0317] Thus, in some embodiments, the method further comprises administering to the subject an effective amount of a clearing agent prior to administering the radiolabeled DOTA hapten. The radiolabeled DOTA hapten can be administered any time between 1 minute to 4 or more days after administration of the anti-DOTA bispecific antibody. For example, in some embodiments, the radiolabeled DOTA hapten is administered 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 1 hour, 1.25 hours, 1.5 hours, 1.75 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, 6.5 hours, 7 hours, 7.5 hours, 8 hours, 8.5 hours, 9 hours, 9.5 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 48 hours, 72 hours, 96 hours, or any range therein, after administration of the anti-DOTA bispecific antibody. Alternatively, the radiolabeled DOTA hapten can be administered any time after 4 or more days after administration of the anti-DOTA bispecific antibody.
[0318] The scavenger can be a 500kD aminodextran-DOTA conjugate (e.g., 500kD dextran-DOTA-Bn(Y), 500kD dextran-DOTA-Bn(Lu), or 500kD dextran-DOTA-Bn(In), etc.). In some embodiments, the scavenger and the radiolabeled DOTA hapten are administered without further administration of the anti-DOTA bispecific antibody. For example, in some embodiments, the anti-DOTA bispecific antibody is administered according to a regimen comprising at least one of the following cycles: (i) administration of an anti-DOTA bispecific antibody of the present technology (optionally, to saturate the relevant tumor cells); (ii) administration of a radiolabeled DOTA hapten and an optional scavenger; (iii) optionally additionally administering a radiolabeled DOTA hapten and / or a scavenger without additionally administering the anti-DOTA bispecific antibody. In some embodiments, the method can include multiple such cycles (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more cycles).
[0319] Also provided herein is a method for treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and a bispecific antibody of the present technology that recognizes and binds to the radiolabeled DOTA hapten and a CD33 antigen target, wherein the complex is configured to localize to a tumor expressing the CD33 antigen target recognized by the bispecific antibody of the complex. The therapeutic effectiveness of such a complex can be determined by calculating the area under the curve (AUC) tumor: AUC normal tissue ratio. In some embodiments, the complex has an AUC tumor:AUC normal tissue ratio of about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, or 100:1.
[0320] Toxicity. Optimally, an effective amount (e.g., dose) of an anti-CD33 antibody described herein will provide a therapeutic benefit without causing substantial toxicity to a subject. The toxicity of an anti-CD33 antibody described herein can be determined by standard pharmaceutical procedures in cell culture or experimental animals, such as by measuring the LD 50 (dose lethal to 50% of the population) or LD 100The dose ratio between toxicity and therapeutic effect is the therapeutic index. The data obtained from these cell culture assays and animal studies can be used to formulate a dosage range that is non-toxic to humans. The dose of the anti-CD33 antibody described herein is within a range of circulating concentrations that includes an effective dose with little or no toxicity. The dose can vary within this range depending on the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage can be selected by an individual physician based on the subject's condition. See, e.g., Fingl et al., In: The Pharmacological Basis of Therapeutics, Chapter 1 (1975).
[0321] Formulation of pharmaceutical compositions. According to the methods of the present technology, anti-CD33 antibodies can be incorporated into pharmaceutical compositions suitable for administration. Pharmaceutical compositions typically comprise recombinant or substantially purified antibodies and a pharmaceutically acceptable carrier in a form suitable for administration to a subject. The pharmaceutically acceptable carrier depends in part on the specific composition being administered, as well as on the specific method for administering the composition. Thus, there are a variety of suitable formulations of pharmaceutical compositions for administering antibody compositions (see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 18th edition, 1990). Pharmaceutical compositions are typically formulated to be sterile, substantially isotonic, and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
[0322] The terms "pharmaceutically acceptable", "physiologically tolerable" and grammatical variants thereof, when they relate to compositions, carriers, diluents and agents, are used interchangeably and indicate that the material can be administered to or onto a subject without producing undesirable physiological effects to the extent that would prohibit the administration of the composition. For example, "pharmaceutically acceptable excipients" means excipients that can be used to prepare pharmaceutical compositions that are generally safe, non-toxic and desirable, and include excipients that are acceptable for veterinary and human pharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of aerosol compositions, gas. "Pharmaceutically acceptable salts and esters" means salts and esters that are pharmaceutically acceptable and have the desired pharmacological properties. Such salts include salts that can be formed when acidic protons present in the composition are capable of reacting with inorganic or organic bases. Suitable inorganic salts include those formed with alkali metals such as sodium and potassium, magnesium, calcium and aluminum. Suitable organic salts include those formed with organic bases, such as amine bases, such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Such salts also include acid addition salts formed with inorganic acids (e.g., hydrochloric acid and hydrobromic acid) and organic acids (e.g., acetic acid, citric acid, maleic acid, and alkanesulfonic acids and arenesulfonic acids such as methanesulfonic acid and benzenesulfonic acid). Pharmaceutically acceptable esters include esters formed with carboxyl, sulfonyloxy and phosphonooxy groups present in the anti-CD33 antibody, such as C 1-6 Alkyl esters. When two acidic groups are present, the pharmaceutically acceptable salt or ester may be a monoacid monosalt or ester or a disalt or ester; and similarly, when more than two acidic groups are present, some or all of such groups may be salified or esterified. The anti-CD33 antibodies named in this technology may exist in an unsalted or unesterified form, or in a salified and / or esterified form, and the naming of such anti-CD33 antibodies is intended to include the original (unsalted and unesterified) compound and its pharmaceutically acceptable salts and esters. In addition, certain embodiments of the present technology may exist in more than one stereoisomer form, and the naming of such anti-CD33 antibodies is intended to include all single stereoisomers and all mixtures of such stereoisomers (whether racemic or otherwise). It is not difficult for a person of ordinary skill in the art to determine the appropriate timing, sequence, and dosage for administering a particular drug and composition of the present technology.
[0323] Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles, such as fixed oils, may also be used. The use of such media and compounds for pharmaceutically active substances is well known in the art. Unless any conventional media or compounds are incompatible with the anti-CD33 antibody, their use in the composition is contemplated. Supplementary active compounds may also be incorporated into the composition.
[0324] The pharmaceutical compositions of the present technology are formulated to be compatible with their intended route of administration. The anti-CD33 antibody compositions of the present technology can be administered parenterally, topically, intravenously, orally, subcutaneously, intraarterially, intradermally, transdermally, rectally, intracranially, intrathecally, intraperitoneally, intranasally; or intramuscularly, or as an inhalant. The anti-CD33 antibodies can be administered in combination with other agents that are at least partially effective in treating various CD33-related cancers or Alzheimer's disease.
[0325] Solutions or suspensions for parenteral, intradermal or subcutaneous administration may include the following components: a sterile diluent such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetate, citrate or phosphate; and compounds for adjusting tonicity such as sodium chloride or dextrose. pH may be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be packaged in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[0326] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM (BASF, Parsippany, New Jersey) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that it is easy to inject. It must be stable under manufacturing and storage conditions and must be preserved against the contaminating effects of microorganisms (such as bacteria and fungi). The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. For example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant, appropriate fluidity can be maintained. Preventing the effects of microorganisms can be achieved by a variety of antibacterial and antifungal compounds (for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.). In many cases, it is desirable to include isotonic compounds in the composition, such as sugars, polyols (such as mannitol, sorbitol), sodium chloride. Extended absorption of injectable compositions can be achieved by including compounds that delay absorption in the composition, such as aluminum monostearate and gelatin.
[0327] Sterile injectable solutions can be prepared in the following manner: the anti-CD33 antibody of the present technology is incorporated in the desired amount into an appropriate solvent optionally having one or a combination of the ingredients listed above, followed by filtration sterilization. Typically, the dispersion is prepared by incorporating the anti-CD33 antibody into a sterile vehicle containing a basic dispersion medium and other ingredients required from those listed above. In the case of sterile powders for preparing sterile injectable solutions, the preparation method is vacuum drying and freeze drying, which produces a powder of the active ingredient and any additional required ingredients from a previously sterile filtered solution. The antibodies of the present technology can be administered in the form of a stored injection or implant formulation, which can be formulated in a manner that allows for sustained or pulsatile release of the active ingredient.
[0328] Oral compositions typically include an inert diluent or edible carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, anti-CD33 antibodies can be incorporated with excipients and used in the form of tablets, lozenges or capsules. Oral compositions can also be prepared using fluid carriers for use as mouthwashes, wherein the compound in the fluid carrier is applied orally and rinsed, and is spit out or swallowed. Pharmaceutically compatible binding compounds and / or auxiliary materials can be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds with similar properties: binders, such as microcrystalline cellulose, tragacanth or gelatin; excipients, such as starch or lactose, disintegrating compounds, such as alginic acid, Primogel or corn starch; lubricants, such as magnesium stearate or Sterotes; glidants, such as colloidal silica; sweetening compounds, such as sucrose or saccharin; or flavoring compounds, such as mint, methyl salicylate or orange flavor.
[0329] For administration by inhalation, the anti-CD33 antibody is delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.
[0330] Systemic administration can also be carried out by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants suitable for the barrier to be penetrated are used in the formulation. Such penetrants are generally known in the art and include (for example, for transmucosal administration) detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished by using nasal sprays or suppositories. For transdermal administration, the anti-CD33 antibody is formulated into an ointment, salves, gel, or cream as generally known in the art.
[0331] Anti-CD33 antibodies can also be prepared as pharmaceutical compositions for rectal delivery in the form of suppositories (eg, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas.
[0332] In one embodiment, the anti-CD33 antibody is prepared with a carrier that prevents rapid clearance of the anti-CD33 antibody from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be clear to those skilled in the art. The materials can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, such as those described in U.S. Patent No. 4,522,811.
[0333] C. Kit
[0334] The present technology provides a kit for detecting and / or treating CD33-related cancer or Alzheimer's disease, the kit comprising at least one immunoglobulin-related composition of the present technology (e.g., any antibody or antigen-binding fragment described herein) or a functional variant thereof (e.g., a substitution variant). Optionally, the above components of the kit of the present technology are packaged in a suitable container and labeled for diagnosis and / or treatment of CD33-related cancer or Alzheimer's disease. The above components can be stored in a unit container or a multi-dose container (e.g., a sealed ampoule, vial, bottle, syringe, and test tube) as an aqueous solution (preferably a sterile solution) or as a lyophilized (preferably sterile) preparation for reconstitution. The kit may also include a second container containing a diluent suitable for diluting the pharmaceutical composition to a larger volume. Suitable diluents include, but are not limited to, pharmaceutically acceptable excipients and saline solutions of the pharmaceutical composition. In addition, the kit may include instructions for diluting the pharmaceutical composition and / or instructions for administering the diluted or undiluted pharmaceutical composition. The container can be made of a variety of materials (such as glass or plastic) and can have a sterile access port (for example, the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). The kit can also include more containers containing pharmaceutically acceptable buffers, such as phosphate-buffered saline, Ringer's solution, and dextrose solution. It can also include other materials that are desirable from a commercial and user perspective, including other buffers, diluents, filters, needles, syringes, culture media for one or more suitable hosts. The kit can optionally include instructions that are typically included in the commercial packaging of a therapeutic or diagnostic product, the instructions containing information about, for example, the indications, usage, dosage, manufacture, administration, contraindications, and / or warnings for the use of such therapeutic or diagnostic products.
[0335] The kit can be used to detect the presence of immunoreactive CD33 protein in a biological sample, such as any body fluid, including but not limited to, for example, serum, plasma, lymph, cystic fluid, urine, feces, cerebrospinal fluid, ascites or blood, and includes a biopsy sample of body tissue. For example, the kit may include: one or more humanized, chimeric or bispecific anti-CD33 antibodies (or antigen-binding fragments thereof) of the present technology that can bind to CD33 protein in a biological sample; a device for determining the amount of CD33 protein in a sample; and a device for comparing the amount of immunoreactive CD33 protein in a sample with a standard. One or more anti-CD33 antibodies may be labeled. Kit components (e.g., reagents) may be packaged in a suitable container. The kit may also include instructions for using the kit to detect immunoreactive CD33 protein.
[0336] For antibody-based kits, the kit can include, for example, 1) a first antibody, such as a humanized, chimeric or bispecific CD33 antibody (or antigen-binding fragment thereof) of the present technology, attached to a solid support, which first antibody binds to a CD33 protein; and optionally; 2) a different second antibody that binds to a CD33 protein or the first antibody and is conjugated to a detectable label.
[0337] The kit may also contain, for example, a buffer, a preservative, or a protein stabilizer. The kit may also contain other components required for detecting the detectable label, such as an enzyme or a substrate. The kit may also contain a control sample or a series of control samples, which can be assayed and compared with the test sample. Each component of the kit can be encapsulated in a separate container, and all the different containers can be placed in a single package together with instructions for interpreting the results of the assay using the kit. The kit of the present technology may contain a written product on or in the kit container. The written product describes how to use the reagents contained in the kit, for example, for detecting CD33 protein in vitro or in vivo, or for treating CD33-related cancers in subjects in need. In certain embodiments, the reagents can be used according to the methods of the present technology.
[0338] Example
[0339] The present technology is further illustrated by the following examples, which should not be construed as limiting in any way. The following examples demonstrate the preparation, characterization, and use of illustrative anti-CD33 antibodies of the present technology. The following examples demonstrate the generation of chimeric, humanized, and bispecific antibodies of the present technology, as well as the characterization of their binding specificity and in vitro and in vivo biological activities.
[0340] Example 1: Structure of the anti-CD33 immunoglobulin-related compositions of the present disclosure
[0341] A bivalent modular platform was chosen to construct CD33-CD3 BsAb. Figure 1A As shown, the humanized anti-CD33 antibody of the present disclosure is prepared by attaching a single-chain Fv fragment (scFv) to the carboxyl terminus of the anti-CD33 antibody light chain, wherein the scFv binds to an antigen other than CD33. In some embodiments, the humanized anti-CD33 antibody of the present disclosure is constructed by attaching an anti-CD3 humanized OKT3 (huOKT3) single-chain Fv fragment (ScFv) to the carboxyl terminus of the My96 IgG1 light chain. The following considerations were taken into account in designing and constructing the humanized anti-CD33 antibodies of the present disclosure: (1) optimal size (100-200 kd) to maximize tumor uptake; (2) bivalency to the tumor target to maintain avidity; (3) a scaffold that assembles naturally like any IgG (heavy and light chains) in CHO cells and can be purified by standard protein A affinity chromatography; (4) a structural arrangement to make the anti-CD3 component functionally monovalent, thereby reducing nonspecific activation of T cells; and (5) a platform that has demonstrated tumor targeting efficiency in animal models.
[0342] Figure 13A-13J The amino acid sequences of the light and heavy chains of the murine My96 x C825 (anti-DOTA) BsAb in IgG-scFv format are shown. The light chain amino acid sequences are shown in SEQ ID NOs: 53, 55, 57, 59, 61, 63, 65, 67, 69, and 71; and the heavy chain amino acid sequences are shown in SEQ ID NOs: 54, 56, 58, 60, 62, 64, 66, 68, 70, and 72. Figure 14A-14HHH The amino acid sequences of the humanized My96 x C825 (anti-DOTA) BsAbs in single chain bispecific tandem fragment variable (scBsTaFv) format are shown (SEQ ID NOs: 73-132).
[0343] Example 2: Humanization of murine My96
[0344] The CDRs of the heavy and light chains of My96 were grafted onto the human IgG1 framework based on their homology to the human frameworks IGHV1-2*02IGHJ4*01 (for VH) and IGKV1-33*01-IGKJ2*01 (for VL), respectively. Nine versions of huMy96 were gene synthesized from three heavy and light chain designs, respectively, and expressed in DG44 cells. The amino acid sequences of the mouse and humanized My96 variable heavy chains are shown in SEQ ID NOs. 1, 5, 9 and 13 and Figure 6 The amino acid sequences of the mouse and humanized My96 variable light chains are shown in SEQ ID NOs. 17, 21, 25 and 29 and Figure 7 middle.
[0345] Generation of CD33-BsAb bispecific antibodies. Design of CD33-BsAb using IgG-scFv format ( Figure 1A CD33-BsAb was constructed by fusing humanized OKT3 scFv to the C-terminus of the light chain of a chimeric or humanized anti-CD33 antibody via a (G4S)3 linker, as previously described in: Xu H et al., Cancer Immunology Research 3:266-277 (2015) and Lopez-Albaitero A et al., OncoImmunology 6:e1267891 (2017). N297A and K322A mutations were introduced in the Fc region of the antibody to abolish FcR and complement binding activities, respectively (Shields RL et al., Journal of Biological Chemistry 276:6591-6604 (2001); Idusogie EE et al., Journal of Immunology 164:4178-4184 (2000)). The DNA construct was then transfected into Expi293F cells and stable clones were selected for high antibody production levels. For larger scale antibody purification, the selected stable clones were expanded in shake flasks. The bispecific antibodies were purified from the supernatant using one-step protein A affinity chromatography.
[0346] Fig. 8A and Figure 8B The amino acid sequence and nucleotide sequence of the light chain and heavy chain of chMy96 BsAb are shown, respectively. Figure 9A-9B , Figure 10A-10B , Figure 11A-11B and Figure 12A-12B The amino acid sequences of the light and heavy chains of the following four humanized CD33-BsAbs (hMy96-BsAbs) are shown, respectively: BC248, BC269, BC256, and BC257.
[0347] Example 3: Biochemical purification of anti-CD33 immunoglobulin-related compositions of the present disclosure
[0348] To determine the biochemical purity of the BsAb of the present disclosure, size exclusion chromatography-high performance liquid chromatography (SEC-HPLC) was used to resolve the purified BsAb. Proteins in the eluate were detected based on the absorbance of ultraviolet light at 280 nm. An exemplary SEC-HPLC chromatogram is shown in Figure 1B The BsAb peak was identified based on the retention time on SEC-HPLC. The biochemical purity was assessed based on the area of the BsAb peak. Figure 1B As shown, the BC269 BsAb was 95% pure.
[0349] Example 4: Stability of the anti-CD33 immunoglobulin-related compositions of the present disclosure
[0350] To characterize the humanized antibodies, culture supernatants were collected from shake flasks and purified using protein A affinity chromatography. The purified antibodies were analyzed for biochemical purity. The humanized antibodies were incubated at 40°C and aliquots were removed at designated times to assess purity using HPLC. Figure 2 The table below shows the stability values. Figure 2 As shown, eight of the nine humanized My96 IgG antibodies were >80% intact after 40 days at 40°C. The BsAbs were also purified and analyzed for biochemical purity. The BsAbs were incubated at 40°C and aliquots were analyzed at the indicated times to assess purity using HPLC. Figure 3 As shown, the BsAb also showed acceptable stability at 40 °C.
[0351] These results demonstrate that the immunoglobulin-related compositions of the present technology have pharmacologically acceptable purity and stability characteristics.
[0352] Example 5: Anti-CD33 immunoglobulin combinations of the present disclosure measured by surface plasmon resonance Comparative binding kinetics
[0353] To determine whether the humanized anti-CD33 My96 antibody binds to CD33 with an affinity equal to that of the chimeric form, surface plasmon resonance assays were performed using a Biacore T-200. Biacore T-200 biosensors, CM5 sensor chips, and related reagents were purchased from GE Healthcare. CD33 as an active surface and blanks as reference were immobilized onto a CM5 sensor chip at approximately 1000 RU (response units) using an amino coupling kit (GE Healthcare). CD33 antibodies and relevant control antibodies were diluted in HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% v / v surfactant P20) at different concentrations (31-500 nM) before analysis. Samples were injected onto the sensor surface at a flow rate of 30 μL / min within 1 min. After the association phase was completed, dissociation was monitored in HBS-EP buffer at the same flow rate for 3 min, or for cells with slow k offThe antibody was used to monitor dissociation for 30 minutes at 37°C. At the end of each cycle, the surface was regenerated using 10 mM NaOH at a flow rate of 50 μL / min for 30 seconds. The biosensor curve obtained after injection of the sample on the active surface was subtracted from the control curve obtained with the sample injected on the reference surface before kinetic analysis. The data were analyzed using Biacore T-200 evaluation software. As shown in the table below, the humanized anti-CD33 My96 antibody had a similar k on and k off Combine.
[0354] sample ka(1 / Ms) kd(1 / s) KD(M) chMy96 7.39E+05 2.38E-07 3.21E-13 My96-H1L1 4.47E+05 1.44E-07 3.21E-13 My96-H1L2 4.73E+05 1.03E-07 2.18E-13 My96-H1L3 5.63E+05 4.95E-07 8.80E-13 My96-H2L2 5.20E+05 1.42E-07 2.73E-13 My96-H2L3 6.41E+05 9.16E-08 1.43E-13 My96-H3L1 5.63E+05 3.63E-09 6.45E-15 My96-H3L2 5.43E+05 1.60E-07 2.94E-13 My96-H3L3 6.25E+05 2.03E-07 3.24E-13 My96-H2L1 6.23E+05 1.51E-06 2.42E-12
[0355] KD of humanized IgG My96
[0356] These results demonstrate that the immunoglobulin-related compositions of the present technology specifically bind to CD33 with high affinity. Therefore, the immunoglobulin-related compositions disclosed herein can be used in methods for detecting CD33 protein.
[0357] Example 6: hMy96 CD33-BsAb redirects T cells to kill CD33(+) AML cells
[0358] To evaluate whether CD33-BsAb can redirect T cells to kill leukemia cells, the standard 4-hour 51 The T cell cytotoxicity of BsAbs was tested in a Cr release assay using CD33(+) AML cells (MOLM). Figure 4 As shown, in the presence of humanized CD33-BsAb, the EC 50 Substantial killing of AML cell lines was observed (for MOLM13).
[0359] Example 7: In vivo therapeutic study using anti-CD33 immunoglobulin-related compositions
[0360] The prognosis of patients with FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutation (FLT3 / ITD) is usually poor. In pediatric AML, the negative consequences of these mutations are more prominent (Levis and Small, Leukemia 17:1738-52 (2003)). In order to evaluate whether CD33-BsAb BC248 can redirect T cells to AML with FLT3 / ITD mutation, NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg (CMV-IL3, CSF2, KITLG) 1Eav / MloySzJ (NSGS) (Jackson Laboratory, Bar Harbor, Maine) mice were used for in vivo experiments. Mice were randomly divided into 4 groups, and all received 1 million MOLM13 cells expressing the firefly luciferase gene: Group 1: activated T cells (ATC) only; Group 2: ATC plus BsAb BC248 (0.1 μg / dose); Group 3: ATC plus negative control BsAb (0.1 μg / dose); and Group 4: ATC plus BsAb BC248 (0.01 μg / dose). When leukemia was established, treatment was started on the 7th day. For three weeks, mice received weekly injections of 10 million ATC mixed with BsAb. BsAb was administered twice / week, once mixed with ATC and the other time alone. A total of five doses of BsA b were injected. In order to support T cell growth in vivo, 1000 IU of interleukin 2 was administered subcutaneously twice a week. Bioluminescence imaging was performed weekly to evaluate leukemia burden. As Figure 5A-Figure 5B As shown, administration of ATC in the presence of 100 or 10 ng / dose BsAb BC248 reduced the leukemia burden in mice. In contrast, negative control BsAb plus ATC at 100 ng / dose had no anti-tumor effect, which was similar to the ATC-only group.
[0361] The in vivo effect of BsAb BC269 was also tested in NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg (CMV-IL3, CSF2, KITLG) 1Eav / MloySzJ (NSGS) mice with MOLM cells. Mice were randomly divided into 4 groups, and all received 1,000,000 MOLM13 cells expressing firefly luciferase gene: Group 1: activated T cells (ATC) only; Group 2: ATC plus BsAb BC269 (0.1 μg / agent); Group 3: ATC plus control BsAb BC119 (0.1 μg / agent); and Group 4: ATC plus BsAb BC269 (0.01 μg / agent). When leukemia was established, treatment was started at the 7th day. For three weeks, mice were accepted to be injected weekly with 10,000,000 ATC mixed with BsAb. BsAb was administered twice / week, once mixed with ATC and the other time alone. A total of five doses of BsAb were injected. To support T cell growth in vivo, 1000 IU of interleukin 2 was administered subcutaneously twice a week. Bioluminescence imaging was performed weekly to evaluate leukemic burden. Figure 5C As shown, administration of ATC in the presence of 100 or 10 ng / dose of BsAb BC269 reduced the leukemia burden in mice. However, control BsAb plus ATC at 100 ng / dose had no anti-tumor effect, similar to the ATC-only group.
[0362] Therefore, the immunoglobulin-related compositions disclosed herein can be used in methods of treating CD33-related cancers in a subject in need thereof.
[0363] Example 8: Anti-CD33 Use of BsAb in PRIT
[0364] IgG-based CD33-C825 BsAb. CD33(+) leukemia cells are injected into animals subcutaneously, intraperitoneally, intravenously or via other routes. After tumor establishment (depending on tumor type and injection route), treatment will be initiated. Treatment consists of one or more cycles. Each cycle will include administration of the test BsAb (250 μg, intravenously), followed by an injection of a scavenger (DOTA dextran or DOTA dendrimer; dose is 5%-15% of the BsAb dose, see Cheal SM et al., Mol Cancer Ther 13:1803-12, 2014) 24 to 48 hours later. DOTA- 177 Lu (up to 1.5mCi) or DOTA- 225 Ac(1μCi). Usually, DOTA- 225 AC vs DOTA- 177 Lu is more effective and may require fewer cycles to eradicate the tumor.
[0365] Tetrameric BsAb. CD33(+) leukemia cells are injected into animals subcutaneously, intraperitoneally, intravenously or via other routes, and after tumor establishment (depending on tumor type and injection route), treatment will be initiated. Treatment consists of one or more cycles. Each cycle consists of the following: administration of BsAb (250 μg, intravenous), followed by intravenous injection of DOTA- 177 Lu (up to 1.5mCi) or DOTA- 225 Ac(1μCi). Usually, DOTA- 225 AC vs DOTA- 177 Lu is more effective and may require fewer cycles to eradicate the tumor.
[0366] These results demonstrate that the antibodies or antigen-binding fragments of the present technology can detect tumors and inhibit the progression of tumor growth and / or metastasis. Therefore, the immunoglobulin-related compositions disclosed herein can be used to detect and treat CD33-related cancers in subjects in need thereof.
[0367] Example 9: Anti-CD33 Use of BsAb in the treatment of Alzheimer's disease
[0368] Various rodent models for Alzheimer's disease (AD) have been developed (Nazem et al., J Neuroinflammation 17; 12: 74 (2015)). Since the My96 antibody binds to human CD33 and does not cross-react with mouse CD33, a knock-in mouse model of human CD33 (hCD33) will be generated. The hCD33 mice will then be crossed with the Alzheimer's disease transgenic mice of Nazem et al. (2015), and the offspring will be used to study the therapeutic effects of the CD33 antibodies or antigen-binding fragments of the present technology in vivo.
[0369] In one experiment, an anti-CD33 BsAb disclosed herein including a C825 anti-DOTA binding moiety was injected intracranially or into the cerebrospinal fluid, followed by intravenous injection of a radiolabeled metal-DOTA conjugate, e.g. 177 Lu-DOTA-Bn. In addition to behavioral analysis of mice, histopathological assessment of brain tissue over time was used for outcome measurement. It is expected that animals receiving anti-CD33 BsAbs of the present technology will show improvement in one or more symptoms of Alzheimer's disease (AD) compared to that observed in untreated controls. Therefore, the immunoglobulin-related compositions disclosed herein can be used to treat Alzheimer's disease in subjects in need thereof.
[0370] Equivalent content
[0371] The present technology is not limited to the specific embodiments described in the application, and the embodiments are intended to be a single description of the individual aspects of the present technology. It should be clear to those skilled in the art that many modifications and changes can be made to the present technology without departing from the spirit and scope of the present technology. It should be clear to those skilled in the art based on the foregoing description that, in addition to the methods and equipment listed herein, functionally equivalent methods and equipment within the scope of the present technology. Such modifications and changes are intended to fall within the scope of the present technology. It should be understood that the present technology is not limited to specific methods, reagents, compounds, compositions or biological systems, and they can certainly change. It should also be understood that the terms used herein are only used for the purpose of describing specific embodiments and are not intended to be restrictive.
[0372] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[0373] As will be understood by those skilled in the art, for any and all purposes, particularly with respect to providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily identified as fully describing the same range and enabling the same range to be decomposed into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be easily decomposed into a lower third, a middle third, and an upper third, etc. As will be understood by those skilled in the art, all such as "up to", "at least", "greater than", "less than", etc., words include the numbers and refer to the ranges that can be subsequently decomposed into sub-ranges as described above. Finally, as will be understood by those skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to a group having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to a group having 1, 2, 3, 4, or 5 cells, etc.
[0374] All patents, patent applications, provisional applications, and publications mentioned or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are consistent with the explicit teachings of this specification.
Claims
1. An anti-CD33 antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment is selected from Fab, F(ab')2, Fab', scF v and F v The antibody or antigen-binding fragment thereof comprises a heavy chain immunoglobulin variable domain (V H ) and light chain immunoglobulin variable domain (V L ),in (a) V H Comprising a V consisting of SYYIH (SEQ ID NO: 14) or SYYMH (SEQ ID NO: 6 or 10) H - CDR1; V consisting of VIYPGNDDISYAQKFQG (SEQ ID NO: 7 or 15) H -CDR2 sequence; and V consisting of EVRLRYFDV (SEQ ID NO: 8, 12 or 16) H -CDR3 sequence; and said V L Comprising a V consisting of KSSQSVFFSSSQKNYLA (SEQ ID NO: 22, 26 or 30) L -CDR1 sequence, V consisting of WAS TRES (SEQ ID NO: 23, 27 or 31) L - CDR2 sequence and V consisting of HQYLSSRT (SEQ ID NO: 24, 28 or 32) L - CDR3 sequence; or (b) V H Comprising a V consisting of SYYMH (SEQ ID NO: 6 or 10) H - CDR1; V consisting of VIYPGNDDISYNQKFQG (SEQ ID NO: 11) H -CDR2 sequence; and V consisting of EVRLRYFDV (SEQ ID NO: 8, 12 or 16) H -CDR3 sequence; and said V L Comprising a V consisting of KSSQSVFFSSSQKNYLA (SEQ ID NO: 22, 26 or 30) L -CDR1 sequence, V consisting of WASTRES (SEQ ID NO: 23, 27 or 31) L - CDR2 sequence and V consisting of HQYLSSRT (SEQ ID NO: 24, 28 or 32) L -CDR3 sequence.
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein: (a) V H Contains the amino acid sequence of SEQ ID NO: 5, and the V L comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25, and SEQ ID NO:29; or (b) V H Contains the amino acid sequence of SEQ ID NO: 9, and the V L comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25, and SEQ ID NO:29; or (c) V H Contains the amino acid sequence of SEQ ID NO: 13, and the V L Comprising an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:
29.
3. The antibody or antigen-binding fragment of claim 1 or 2, further comprising an Fc domain of an isotype selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM, IgD and IgE.
4. The antibody of claim 3, comprising an IgG1 constant region comprising one or more amino acid substitutions selected from N297A and K322A.
5. The antibody of claim 3, comprising an IgG4 constant region comprising an S228P mutation.
6. The antibody or antigen-binding fragment of any one of claims 1-5, wherein the antibody or antigen-binding fragment binds to the IgV domain of CD33.
7. The antibody according to any one of claims 1 to 6, wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a bispecific antibody.
8. An anti-CD33 antibody, comprising a heavy chain (HC) amino acid sequence and a light chain (LC) amino acid sequence selected from the following: SEQ ID NO:35 and SEQ ID NO:33; SEQ ID NO:39 and SEQ ID NO:37; SEQ ID NO:43 and SEQ ID NO:41; SEQ ID NO:47 and SEQ ID NO:45; SEQ ID NO:51 and SEQ ID NO:49; SEQ ID NO:54 and SEQ ID NO:53; SEQ ID NO:56 and SEQ ID NO:55; SEQ ID NO:58 and SEQ ID NO:57; SEQ ID NO:60 and SEQ ID NO:59; SEQ ID NO:62 and SEQ ID NO:61; SEQ ID NO:64 and SEQ ID NO:63; SEQ ID NO:66 and SEQ ID NO:65; SEQ ID NO:68 and SEQ ID NO:67; SEQ ID NO:70 and SEQ ID NO:69; and SEQ ID NO:72 and SEQ ID NO:
71.
9. The antibody according to claim 8, wherein the antibody is a chimeric antibody, a humanized antibody or a bispecific antibody.
10. The antibody according to any one of claims 8-9, wherein the antibody binds to the IgV domain of CD33.
11. The antibody of any one of claims 8-10, wherein the antibody comprises an IgG1 constant region comprising one or more amino acid substitutions selected from N297A and K322A.
12. The antibody of any one of claims 8-10, wherein the antibody comprises an IgG4 constant region comprising an S228P mutation.
13. A bispecific antibody or antigen-binding fragment, wherein the antibody or antigen-binding fragment is an amino acid sequence selected from any one of SEQ ID NOs: 73-132, wherein the bispecific antibody or antigen-binding fragment binds to CD33, wherein the antigen-binding fragment is scBsTaFv.
14. A recombinant nucleic acid encoding the antibody or antigen-binding fragment according to any one of claims 1-13.
15. The recombinant nucleic acid according to claim 14, having a sequence selected from the group consisting of: SEQ ID NOs: 38 and 40, SEQ ID NOs: 42 and 44, SEQ ID NOs: 46 and 48, SEQ ID NOs: 50 and 52.
16. A host cell or vector comprising the recombinant nucleic acid according to claim 14 or claim 15.
17. A composition comprising an antibody or antigen-binding fragment according to any one of claims 1-13 and a pharmaceutically acceptable carrier, wherein the antibody or antigen-binding fragment is optionally conjugated to an agent selected from the group consisting of an isotope, a dye, a chromogen, a contrast agent, a toxin, a radionuclide, a metal, a liposome, a nanoparticle, or any combination thereof.
18. A composition comprising the antibody or antigen-binding fragment according to any one of claims 1 to 13 and a pharmaceutically acceptable carrier, wherein the antibody or antigen-binding fragment is optionally conjugated to an agent selected from a drug.
19. The composition of claim 18, wherein the drug is selected from RNA, DNA, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors.
20. The antibody of any one of claims 1-12, wherein the antibody lacks α-1,6-fucose modification.
21. The bispecific antibody of claim 7 or 9, wherein the bispecific antibody binds to T cells, B cells, myeloid cells, plasma cells, or mast cells.
22. The bispecific antibody or antigen-binding fragment of any one of claims 7, 9 and 13, wherein the bispecific antibody or antigen-binding fragment binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCRγ / δ, NKp46, KIR or a small molecule DOTA hapten.
23. Use of an anti-CD33 antibody in the preparation of a medicament for treating AML in a subject in need thereof, wherein the antibody comprises an HC amino acid sequence and an LC amino acid sequence respectively selected from the following: SEQ ID NO:35 and SEQ ID NO:33; SEQ ID NO:39 and SEQ ID NO:37; SEQ ID NO:43 and SEQ ID NO:41; SEQ ID NO:47 and SEQ ID NO:45; SEQ ID NO:51 and SEQ ID NO:49; SEQ ID NO:54 and SEQ ID NO:53; SEQ ID NO:56 and SEQ ID NO:55; SEQ ID NO:58 and SEQ ID NO:57; SEQ ID NO:60 and SEQ ID NO:59; SEQ ID NO:62 and SEQ ID NO:61; SEQ ID NO:64 and SEQ ID NO:63; SEQ ID NO:66 and SEQ ID NO:65; SEQ ID NO:68 and SEQ ID NO:67; SEQ ID NO:70 and SEQ ID NO:69; and SEQ ID NO:72 and SEQ ID NO:
71.
24. Use of a bispecific antibody or antigen-binding fragment in the preparation of a medicament for treating AML in a subject in need thereof, wherein the bispecific antibody or antigen-binding fragment is an amino acid sequence selected from any one of SEQ ID NOs: 73-132, wherein the bispecific antibody or antigen-binding fragment binds to CD33.
25. The use according to any one of claims 23-24, wherein the antibody or antigen-binding fragment is formulated for separate, sequential or simultaneous administration with an additional therapeutic agent.
26. The use according to claim 25, wherein the additional therapeutic agent is one or more of the following: an alkylating agent, a platinum agent, a taxane, a vinca agent, an anti-estrogen, an aromatase inhibitor, an ovarian inhibitor, a VEGF / VEGFR inhibitor, an EGF / EGFR inhibitor, a PARP inhibitor, a cytostatic alkaloid, a cytotoxic antibiotic, an antimetabolite, an endocrine / hormonal agent.
27. The use according to claim 25, wherein the additional therapeutic agent is one or more of the following: an alkylating agent, a platinum agent, a taxane, a vinca agent, an anti-estrogen drug, an aromatase inhibitor, an ovarian inhibitor, a VEGF / VEGFR inhibitor, an EGF / EGFR inhibitor, a PARP inhibitor, a cytostatic alkaloid, a cytotoxic antibiotic, an endocrine / hormonal agent, a bisphosphonate therapeutic agent.
28. A kit comprising the antibody or antigen-binding fragment according to any one of claims 1-13 and instructions for use.
29. The kit of claim 28, wherein the antibody or antigen-binding fragment of any one of claims 1-13 is coupled to at least one detectable label selected from a radioactive label, a fluorescent label, and a chromogenic label.
30. The kit according to claim 28 or 29, further comprising a secondary antibody that specifically binds to the antibody according to any one of claims 1-13.
31. The bispecific antibody or antigen-binding fragment of any one of claims 7, 9 and 13, wherein the bispecific antibody binds to a radiolabeled DOTA hapten and a CD33 antigen.
32. Use of a complex comprising a radiolabeled DOTA hapten and the bispecific antibody or antigen-binding fragment according to claim 31 in the preparation of a medicament for selecting a subject for pre-targeted radioimmunotherapy, comprising: (a) administering to the subject an effective amount of a complex comprising a radiolabeled DOTA hapten and the bispecific antibody or antigen-binding fragment that binds to the radiolabeled DOTA hapten and a CD33 antigen, wherein the complex is configured to localize to an AML tumor expressing the CD33 antigen recognized by the bispecific antibody or antigen-binding fragment of the complex; (b) detecting the level of radioactivity emitted by the complex; and (c) selecting the subject for pretargeted radioimmunotherapy when the level of radioactivity emitted by the complex is higher than a reference value.
33. Use of a complex comprising a radiolabeled DOTA hapten and the bispecific antibody or antigen-binding fragment of claim 31 in the preparation of a medicament for increasing the sensitivity of a tumor to radiation therapy in a subject diagnosed with AML, wherein the complex is configured to localize to AML tumors expressing CD33.
34. Use of a complex comprising a radiolabeled DOTA hapten and the bispecific antibody or antigen-binding fragment of claim 31 in the preparation of a medicament for treating AML in a subject in need thereof, wherein the complex is configured to localize to AML tumors expressing CD33.
35. Use of the bispecific antibody or antigen-binding fragment according to claim 31 in the preparation of a medicament for increasing the sensitivity of a tumor to radiotherapy in a subject diagnosed with AML, comprising: (a) administering an effective amount of the bispecific antibody or antigen-binding fragment, wherein the bispecific antibody or antigen-binding fragment is configured to localize to AML tumors expressing CD33; and (b) administering to the subject an effective amount of a radiolabeled DOTA hapten, wherein the radiolabeled DOTA hapten is configured to bind to the bispecific antibody or antigen-binding fragment.
36. Use of the bispecific antibody or antigen-binding fragment of claim 31 in the preparation of a medicament for treating AML in a subject in need thereof, wherein the bispecific antibody binds to a radiolabeled DOTA hapten and a CD33 antigen, wherein the bispecific antibody or antigen-binding fragment is configured to localize to a tumor expressing CD33; and Wherein the radiolabeled DOTA hapten is configured to bind to the bispecific antibody or antigen-binding fragment.
37. The use according to claim 35 or 36, further comprising administering a clearing agent to the subject prior to administering the radiolabeled DOTA hapten.
38. The use according to any one of claims 32-37, wherein the subject is a human.
39. The use according to any one of claims 32-34, wherein the complex is formulated for intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intradermal, intraperitoneal, transtracheal, subcutaneous, intracerebroventricular, oral, intratumoral or intranasal administration.
40. The use according to any one of claims 32-39, wherein the radiolabeled DOTA hapten comprises an alpha particle emitting isotope, a beta particle emitting isotope, or an Auger emitter.
41. The use according to any one of claims 32 to 40, wherein the radiolabeled DOTA hapten comprises 213 Bi, 211 At 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn, 215 Po, 211 Bi, 221 Fr. 217 At 255 Fm, 86 Y. 90 Y. 89 Sr. 165 Dy, 186 Re, 188 Re, 177 Lu, 67 Cu, 111 In, 67 Ga, 51 Cr, 58 Co. 99m Tc, 103m Rh, 195m Pt, 119 Sb, 161 Ho, 189m Os, 192 Ir, 201 Tl, 203 Pb, 68 Ga, 227 Th or 64 Cu.
42. An anti-CD33 bispecific antigen-binding fragment, comprising a first polypeptide chain, wherein: The first polypeptide chain comprises, in the N-terminal to C-terminal direction: i. a heavy chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; ii. a flexible peptide linker comprising the amino acid sequence (GGGGS)6; iii. the light chain variable domain of the first immunoglobulin; iv. a flexible peptide linker comprising the amino acid sequence (GGGGS) 4; v. a heavy chain variable domain of a second immunoglobulin that is capable of specifically binding to a second epitope; vi. A flexible peptide linker comprising the amino acid sequence (GGGGS)6; vii. the light chain variable domain of the second immunoglobulin; viii. a flexible peptide linker sequence comprising the amino acid sequence TPLGDTTHT; and ix. Self-assembly and decomposition (SADA) polypeptide; wherein the heavy chain variable domain of the first immunoglobulin is selected from: SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 13; and the light chain variable domain of the first immunoglobulin is selected from: SEQ ID NO: 21, SEQ ID NO: 25 and SEQ ID NO: 29, wherein the antigen binding fragment is scBsTaFv.
43. An anti-CD33 bispecific antigen-binding fragment, comprising a first polypeptide chain, wherein: The first polypeptide chain comprises, in the N-terminal to C-terminal direction: i. a light chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; ii. a flexible peptide linker comprising the amino acid sequence (GGGGS)6; iii. the heavy chain variable domain of the first immunoglobulin; iv. a flexible peptide linker comprising the amino acid sequence (GGGGS) 4; v. a heavy chain variable domain of a second immunoglobulin that is capable of specifically binding to a second epitope; vi. A flexible peptide linker comprising the amino acid sequence (GGGGS)6; vii. the light chain variable domain of the second immunoglobulin; viii. a flexible peptide linker sequence comprising the amino acid sequence TPLGDTTHT; and ix. Self-assembly and decomposition (SADA) polypeptide; wherein the heavy chain variable domain of the first immunoglobulin is selected from: SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 13; and the light chain variable domain of the first immunoglobulin is selected from: SEQ ID NO: 21, SEQ ID NO: 25 and SEQ ID NO: 29, wherein the antigen binding fragment is scBsTaFv.
44. The antigen-binding fragment of claim 42 or 43, wherein the SADA polypeptide comprises a tetramerization, pentamerization or hexamerization domain.
45. The antigen-binding fragment of claim 44, wherein the SADA polypeptide comprises a tetramerization domain of any one of p53, p63, p73, hnRNPC, SNA-23, Stefin B, KCNQ4, or CBFA2T1.
46. The antigen-binding fragment according to any one of claims 42-45, wherein the antigen-binding fragment is an amino acid sequence selected from SEQ ID NO: 73-132.
47. An anti-CD33 bispecific antibody, comprising a first polypeptide chain, a second polypeptide chain, a third polypeptide chain, and a fourth polypeptide chain, wherein the first polypeptide chain and the second polypeptide chain are covalently bonded to each other, the second polypeptide chain and the third polypeptide chain are covalently bonded to each other, and the third polypeptide chain and the fourth polypeptide chain are covalently bonded to each other, and wherein: a. Each of the first polypeptide chain and the fourth polypeptide chain comprises, in the N-terminal to C-terminal direction: i. a light chain variable domain of a first immunoglobulin that is capable of specifically binding to a first epitope; ii. the light chain constant domain of the first immunoglobulin; iii. a flexible peptide linker comprising the amino acid sequence (GGGGS) 3; and iv. a light chain variable domain of a second immunoglobulin connected to the complementary heavy chain variable domain of the second immunoglobulin or a heavy chain variable domain of a second immunoglobulin connected to the complementary light chain variable domain of the second immunoglobulin, wherein the light chain variable domain and the heavy chain variable domain of the second immunoglobulin are capable of specifically binding to a second epitope and are connected together to form a single-chain variable fragment via a flexible peptide linker comprising the amino acid sequence (GGGGS)6; and b. Each of the second polypeptide chain and the third polypeptide chain comprises, in the N-terminal to C-terminal direction: i. the heavy chain variable domain of the first immunoglobulin capable of specifically binding to the first epitope; ii. the heavy chain constant domain of the first immunoglobulin; and wherein the heavy chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:9 and SEQ ID NO:13; and the light chain variable domain of the first immunoglobulin is selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:25 and SEQ ID NO:
29.
48. The bispecific antibody of claim 47, wherein the second immunoglobulin binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCRγ / δ, NKp46, KIR, or a small molecule DOTA hapten.
